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Abstract 
GRP78 is a known cyto-protective gene which is induced in microenvironments 
typical of tumours with low glucose and hypoxia. Furthermore up-regulation of GRP78 
has been linked to chemo- and radioresistance as well as poor survival outcome.  
This study is the first to confirm that GRP78 is up-regulated in tumours of the 
oropharynx, larynx and hypopharynx compared with matched histologically normal 
tissue (p(Χ2)<0.001). Up-regulation of GRP78 may be important for tumour development 
and therefore we have investigated the consequences of inhibition of GRP78 in cells 
derived from laryngeal squamous cell carcinomas (LSCC).  
EGF-SubA is a novel drug consisting of EGF covalently attached to the A 
subunit of an E.coli derived AB5 toxin which can cleave GRP78. EGF-SubA was able to 
induce EGFR-dependent cytotoxicity in a panel of seven laryngeal SCC cells with an 
IC50 range of between 4-100pM. EGF-SubA treatment induced G1 cell cycle arrest as 
well as apoptosis. Therefore apoptosis may be the mechanism by which EGF-SubA 
causes cell death. 
In vitro studies demonstrated that EGF-SubA enhances the effects of clinically 
relevant genotoxic agents. Two Gy survival fractions (SF2) were significantly reduced 
with EGF-SubA pre-treatment (p<0.03). In addition EGF-SubA in combination with the 
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primary head and neck cancer chemo-therapeutic agent cisplatin, resulted in IC50 drug 
combination indexes (CI) as low as 0.542, which is suggestive of a synergistic effect. 
The potency of EGF-SubA appears to be substantially dependent on EGFR 
membrane expression since cells expressing higher EGFR levels were associated with 
increased sensitivity to EGF-SubA where Spearman’s rank correlation coefficient = 
0.919 (p=0.003). Furthermore pre-incubation of LSCC cells with sub-toxic doses of 
cetuximab, a therapeutic monoclonal antibody to EGFR, completely rescued cells from 
the cytotoxic effects of EGF-SubA (p(t test)≤0.005). This is an important proof of 
principal for a proposed combined toxin-protectant therapeutic strategy that would 
permit topical use of EGF-SubA peri- or post-operatively after tumour resection in order 
to kill any remaining tumour cells, or as an oral rinse in patients who present with pre-
malignant lesions of the oral cavity, with any potential systemic toxicity being abrogated 
by cetuximab.  
In summary this study has found that GRP78 is up-regulated in head and neck 
cancers suggesting that this protein may be important for tumour development and 
survival. Thus inhibition of GRP78 through EGF-SubA may offer a novel approach to 
cancer therapy. In addition to suppressing the growth of LSCC cell, EGF-SubA was 
found to enhance the effects of relevant genotoxic agents in vitro of cisplatin and 
radiation. Further work is now warranted in order to assess the efficacy and toxicity of 
EGF-SubA, in vivo, before phase I clinical trials can commence.  
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1 Introduction 
Expression of protein chaperone GRP78 is known to be up-regulated under conditions 
typical of tumour microenvironments specifically hypoxia and low glucose, possibly 
acting as a cyto-protective agent under these conditions(1). GRP78 expression has been 
shown to be up-regulated in a wide variety of cancers including lung, breast and 
colorectal cancers (1). 
 
Currently there are no published data regarding GRP78 levels in laryngeal tumours, 
which is the most common of the head and neck sub-sites, or in tumours of the 
oropharynx or hypopharynx (2). Therefore one of the initial objectives of this research 
project was to establish whether GRP78 was also up-regulated in these tumours. 
 
Previous studies have shown that up-regulation of GRP78 may contribute to chemo- and 
radioresistance (3, 4). EGF-SubA is a novel cytotoxic drug that promotes proteolytic 
cleavage of GRP78 (5) and encompasses a enzymatically active moiety which is a 
bacterial endotoxin (SubA) covalently bound to EGF to permit targeting of EGFR-
expressing cells. We therefore determined whether targeting of GRP78 via EGF-SubA 
could enhance the effects of clinically relevant genotoxic agents which are currently 
used in the treatment of head and neck cancers.  
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Backer and colleagues have suggested that the potency of EGF-SubA may be dependent 
on EGFR expression and therefore this may allow for the selective targeting of head and 
neck tumours which are known to over express EGFR (5, 6).   
 
Subtilase A (SubA) is a bacterial toxin, with proteolytic activity, derived from a specific 
strain of E. coli known as Shiga toxigenic E. Coli (STEC) (7). These strains of E. Coli 
are known to cause life threatening outbreaks of haemolytic uraemic syndrome (HUS) 
such as in Australia in 1998 (7) as well as gastrointestinal disease. Therefore we wanted 
to determine whether cetuximab, a monoclonal antibody (mAb) against EGFR, could 
inhibit the cytotoxicity of EGF-SubA. This could allow for a combined toxin-protectant 
approach where topical application of EGF-SubA peri- or post-operatively after tumour 
resection could be used, with any potential systemic toxicity of EGF-SubA being 
prevented by cetuximab.  
 
In this literature review an overview of head and neck cancer epidemiology, diagnosis 
and current management will be discussed. This will be followed by a description of the 
signalling pathways of EGFR, as well as a review of studies which have analysed 
expression levels of EGFR in head and neck cancers. Finally the function of GRP78 as a 
protein chaperone will be discussed as well as a review of current studies that have 
associated up-regulation of GRP78 with chemo and radioresistance (1, 8). 
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1.1 Head and neck cancer  
 
1.1.1 Epidemiology, signs and symptoms, diagnosis and current 
treatment 
Head and neck cancer constitutes cancer of the upper aerodigestive tract which 
incorporates regions of the nasal cavity, oral cavity, larynx, and pharynx. Squamous cell 
carcinoma of the head and neck (SCCHN) is the 6
th
 most common cancer in the world 
(9). In 2002 the World Health Organization (WHO) estimated a worldwide incidence of 
600,000 new cases and 300,000 deaths each year. Although in national databases oral 
cavity is typically listed as the most prevalent of the head and neck cancers it consists of 
several different sub-sites such as the tongue, floor of the mouth, palate and gums as 
well as the oropharynx. The most prevalent single sub-site is in fact the larynx (10) with 
approximately 160,000 new cases worldwide each year (2). Similarly within the South 
East of England of the 8490 newly diagnosed patients with head and neck cancer, 
between 2000-2004, 2543 (30%) patients had laryngeal cancer (10). The two major risk 
factors for developing SCCHN are tobacco and alcohol (11). In addition there are site 
specific risk factors as shown in Table 1.1.1. 
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Table 1.1.1 Tumour region and associated risk factors. 
Table reproduced from reference (12). 
 
Ethanol is oxidised in the liver by alcohol dehydrogenase (ADH) to acetaldehyde, which 
is a known carcinogen, and then to acetate via aldehyde dehydrogenase (ALDH) (13). If 
alcohol consumption is high cytochrome P450 2E1 can also oxidise ethanol into 
acetaldehyde and another carcinogen known as reactive oxygen species (ROS). 
Acetaldehyde and ROS can induce DNA lesions which if not repaired result in 
carcinogenesis. 
 
 Polymorphisms in genes involved in alcohol metabolism as well as the amount of 
alcohol consumed can alter the risk of cancer development. For example ADH1B has a 
polymorphism that enhances alcohol-oxidising capability known as mutant allele 
This text box is where the original thesis contained the table showing ‘tumour region 
and associated risk factors’ which was reproduced from reference (12). 
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ADH1B*2. Asians who are moderate or heavy drinkers who are heterozygous or 
homozygous for ADH1B*2 are statistically less likely to develop head and neck cancers 
compared to those Asians who have wild-type ADH1B genotype with a reduced odds 
ratio of 0.57 (95% CI 0.36-0.91) (13). Furthermore inactive ALDH2 encoded by the 
ALDH2*1/2*2 genotype results in increased accumulation of acetaldehyde and is a 
strong risk factor for head and neck cancers (14). 
 
Acetaldehyde is able to form DNA adducts which may escape cellular repair 
mechanisms causing miscoding resulting in gene mutations in critical genes such as 
oncogenes and tumour suppressor genes (14). Ethanol may directly stimulate 
carcinogenesis by preventing DNA methylation. Methylation is important for 
suppressing gene transcription. S-Adenosyl-L-methionine (SAM) promotes the transfer 
of methyl groups however ethanol inhibits synthesis of SAM. Suppression of SAM 
results in hypomethylation of certain oncogenes, but not of tumour suppressor gene p53. 
This results in up-regulation of oncogenes and down-regulation of p53 (14).  
  
Cigarette smoke contains over 60 known carcinogens (14). These carcinogens are 
oxygenated by cytochrome P450. However in their intermediate states they are reactive 
with DNA leading to DNA adducts resulting in mutations and genomic instability. DNA 
adducts associated with cigarette smoke frequently produce G-to-T transversions (14). 
Furthermore in vitro tests with cigarette carcinogens have induced p53 mutations in a 
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similar spectrum to that found in lung cancer cells (14).p16 protein inhibits CDK 4 and 6 
binding to cyclin D thus preventing pRB phosphorylation and cell cycle progression 
from G1 into S phase (14). Inactivation of p16
INK4a
 gene, via smoking induced 
methylation, is another common feature in lung cancer. 
 
 Individual susceptibility to cigarette induced cancer is in part dependent on how well 
potential carcinogenic effects are counteracted. Carcinogenic metabolites may be 
detoxified by various enzymes such as glutathione-S-transferase and uridine diphosphate 
(UDP)-glucuronosyl transferases (14). In addition DNA adducts may be eliminated 
through DNA repair mechanisms such as nucleotide excision repair (14). 
 
A recent rise in oropharyngeal cancer patients have been reported in patients under fifty 
with no known history of alcohol or smoking. These cancers have been attributed to 
human papilloma virus (HPV). HPV produces two oncoproteins encoded by E6 and E7 
genes (15). E6 can bind onto both p53 and ubiquitin-protein ligase E6 associated protein 
(E6AP) (16). It is reported that the interaction of E6 between these two proteins 
subsequently initiates ubiquitin mediated degradation of p53 (16). Normally p53 induces 
either cell cycle arrest to allow for DNA repair or apoptosis. However E6 expressing 
cells are deficient in p53 protein resulting in genetic instability (17, 18). p16 is a cyclin 
dependent kinase inhibitor which prevents pRB phosphorylation thus inhibiting cell 
cycle progression from G1 to S (19). E7 causes functional inactivation of pRB leading to 
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unregulated proliferation ‘independent of growth factor signalling’ (19). Functional loss 
of pRB is an early event in SCCHN which is followed by up-regulation of p16. Thus up-
regulation of p16, which can be detected through immunohistochemistry, is used as one 
of the markers for HPV infection (17). 
 
A meta-analysis by Hobbs and colleagues in 2006, found a strong association between 
HPV16 and tonsillar cancer (odds ratio (OR): 15.1, 95% CI: 6.8–33.7), a moderate 
association with oropharyngeal tumours (OR: 4.3, 95% CI: 2.1–8.9) and weak 
association for oral cancers (OR: 2.0, 95% CI: 1.2–3.4) , and laryngeal tumours (OR: 
2.0, 95% CI: 1.0–4.2) (20). SCCHN patients with HPV are more responsive to chemo- 
and radiation therapy(p ≤ 0.05) compared with HPV negative patients (19). In addition 
HPV positive patients tend to have a better survival outcome. For example 2 year 
survival rates of patients with either laryngeal or oropharyngeal grade III or IV tumours 
were 95% and 62 % (p=0.005) in HPV positive versus HPV negative patients, 
respectively (21).  
 
Literature review 
 
8 
 
Patients present with a variety of symptoms depending upon the site of their tumour. For 
example laryngeal cancers typically present with hoarseness whilst patients with 
pharyngeal cancers may present with dysphagia and sore throat (2).  
 
Table 1.1.2  provides information on the red flag signs and symptoms of head neck 
cancer that should warrant urgent two week referral to specialists in Otolaryngology / 
Head and Neck Surgery. 
 
 
 
 
 
 
Table 1.1.2 Red flag symptoms and signs of head and neck cancer.  
Patients should be referred if they have any one of the above signs or symptoms 
occurring for more than three weeks. Table reproduced from reference (2). 
 
Diagnosis of head and neck cancers, in patients presenting with a palpable neck mass, is 
confirmed through histological examination of fine needle aspiration cytology (FNAC) 
This text box is where the original thesis contained the table showing ‘red flag 
symptoms and signs of head and neck cancer’ which was reproduced from reference 
(2). 
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(22). This involves a hollow needle being inserted into the suspected tumour in order to 
extract cells which will later be visualised by a histopathologist. 
 
Further staging of the extent of tumour load is achieved by radiological imaging (MR or 
CT scanning of the head and neck and CT scanning of the thorax and upper abdomen) 
and an examination under anaesthetic. More recently, Positron emission tomography 
(PET scan) can be combined with 18F-fluorodeoxyglucose (18F-FDG), which is taken 
up selectively by tumours due to their high glycolytic rates(as observed by Otto 
Warburg), in order to identify the tumour location, size and to monitor treatment 
efficacy (2).  
 
Following investigation tumours are staged according to the TNM staging system (22) 
Early stage SCCHN tumours are treated with either surgery or radiotherapy (23). The 
objective of head and neck cancer treatment is to increase locoregional control and 
survival and to preserve important functions such as swallowing, speech and respiration. 
Most T1 and T2 tumours of the tongue and oral cavity are treated with surgical resection 
(24). Exposure to radiotherapy in this area may lead to osteoradionecrosis of the 
mandible and hence surgery is the preferred choice in tumours of this region (24).  
 
In sites of the larynx, oropharynx and hypopharynx radiotherapy is the preferred option 
as traditional open surgical intervention often results in swallowing and speech 
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impairment (24).  A recent development is the use of transoral laser microsurgery which 
permits resection of laryngeal, hypopharyngeal and orophayngeal tumours without 
significant impairment in function. Furthermore cure rates have been found to be similar 
to that of radiotherapy and to traditional open methods of surgery (24, 25). The recent 
trend towards treating stage 1 and 2 tumours with surgery as opposed to radiotherapy 
may permit the application of topical anti-cancer medication after tumour resection in 
order to remove any remaining tumour cells around the excised margin.    
 
Both surgery and radiotherapy present with their own complications. Apart from general 
surgical complications such as infection, head and neck surgery may result in cranial 
nerve damage (VII, X, XII), spinal accessory nerve damage leading to shoulder 
dysfunction, impaired swallowing and speech, salivary fistulas, and end stomas from 
laryngectomy. Complications from radiation include dry mouth due to radiation of the 
salivary glands (xerostomia), inflammation of the mucosa, and dermatitis. Consequently 
patients often require enteral nutrition delivered via percutaneous gastrostomy or 
nasogastic feeding tube (23). 
 
In late stage tumours (grade III and IV) treatment regimes include, induction 
(neoadjuvant) chemotherapy (ICT) followed by concurrent chemotherapy and 
radiotherapy (CRT); ICT followed by surgery; CRT alone; surgery followed by post-
operative (adjuvant) radiotherapy (PORT) or CRT. Postoperative radiotherapy is 
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considered when there is high chance of recurrence such as when surgical resection 
margins are small or when two or more lymph nodes are involved (26).   Traditionally, 
the main drugs used in chemotherapy strategies for SCCHN are cisplatin and 5-FU (22).  
 
1.1.2 Recent advancements in the treatment of head and neck cancer 
Current survival rates have reached a plateau as at present only 51% of oral cavity and 
61% of laryngeal cancer patients survive past five years since initial diagnosis (23). 
Therefore there is still a need to develop biomarkers of outcome and/or treatment 
response as well as methods to allow early detection. In addition, new treatments which 
improve survival rates and reduce treatment related toxicity are urgently needed. 
 
Over recent years intensity modulated radiotherapy (IMRT) has been increasingly used 
in the treatment of patients with SCCHN. The technique using data from CT scans, 
allows the delivery of radiation energy in doses which conform to the 3D shape of the 
tumour, thereby allowing a much reduced dose to adjacent normal tissue so minimising 
the collateral damage of external beam RT. IMRT has been shown to preserve the 
function of salivary glands, optic nerves, the cochlea, pharyngeal constrictor muscles, 
the brain stem and spinal cord (27). The use of IMRT is now rapidly gaining popularity 
in the UK (22). One randomized control trial – the PASSPORT trial - compared parotid 
sparing IMRT to standard radiotherapy and found a 36% (p=0.004) reduction in the 
incidence of xerostomia (27). A separate study by Chen and colleagues in 2009, found 
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no differences in survival rates or loco- regional control rates between conventional 
radiotherapy and IMRT and therefore IMRT may provide a means of lowering radiation 
related morbidity whilst maintaining radiation treatment efficacy (28).  
 
A better understanding of cancer at the molecular level has allowed for the development 
of drugs which can specifically target proteins responsible for promoting cancer. Of 
particular relevance in SCCHN has been the Epidermal Growth Factor Receptor 
(EGFR), which has been at the centre of targeted therapy strategies to date. However, 
other targets, such as the Unfolded Protein Response and inhibition of HSP90 are the 
subject of ongoing active research programmes designed to explore their exploitation in 
the management of SCCHN. 
 
 Signals derived from EGFR pathway stimulate cell growth and survival. 
Overexpression and prolonged activation of EGFR is found in many cancers including 
head and neck, cervical, bladder, brain, breast, lung stomach, ovary and prostate and is 
associated with poor clinical outcome (29). In these instances EGFR becomes an oncogene. 
Several new treatments have been developed in order counteract EGFR oncogenic 
signalling.   
 
Cetuximab is a monoclonal antibody which competitively binds to EGF receptor 
blocking EGF induced signalling. (23). In 2008 cetuximab was recommended for locally 
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advanced head and neck squamous cell carcinoma in combination with radiotherapy 
once concurrent platinum based therapy had failed (30). Tyrosine kinase inhibitors 
(TKIs) are ATP competitive inhibitors that prevent trans or autophosphorylation of the 
tyrosine residues on EGFR therefore blocking signal transduction through these means 
(31) Current TKI such as lapatinib have undergone phase I trials with 
chemoradiotherapy for head and neck cancer and are currently undergoing randomised 
phase II and III evaluation (32). Both cetuximab and TKI will be discussed further in 
sections 1.2.3 and 1.2.3respectively.  
 
DNA damage response (DDR) which involves coordinating DNA repair and cell cycle 
arrest may lead to resistance to genotoxic insults caused by a wide variety of 
chemotherapeutic agents such as cisplatin and radiation (33). Hence interest has recently 
grown in inhibiting the DDR mechanism. For example poly (ADP-ribose) polymerase 
(PARP) is responsible for repair of single strand breaks (SSB) in DNA. PARP inhibitors 
may lead to further double strand breaks (DSB) however these can be repaired by 
BRCA1/2 which are responsible for coordinating repair of DSB (34). Therefore the use 
of PARP inhibitors may be more useful in cancers with BRCA1/2 mutations thus 
leading to irreparable DSB and subsequent apoptosis (34). Since radiation treatment 
induces DNA damage PARP is being explored as a possible radiosensitising agent. Pre 
clinical data suggests that PARP inhibitors may potentiate the effects of radiation, which 
is know to cause SSB and DSB, in a variety of tumours including head and neck cancer 
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(32). Another protein called Checkpoint kinase 1 (Chk1) is activated upon SSB. As part 
of the DNA damage response, Chk1 can phosphorylate downstream effectors which are 
involved in cell cycle arrest, DNA replication checkpoints, as well as proteins involved 
in DNA repair. Currently both PARP and Chk1 inhibitors are involved in phase I clinical 
trials (33).  
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1.2 EGFR 
1.2.1 EGFR pathway 
 
EGFR is part of the HER/ErbB family of receptor tyrosine kinase proteins (HER/RTK). 
The family includes EGFR( also known as ErbB1/HER1), ErbB-2/HER2, ErbB-
3/HER3, and ErbB-4/HER4 (35).  
 
There are three parts to the EGFR structure as seen in Figure 1.2.1 
Figure 1.2.1. Outside of the cell lies the ectodomain which acts as the receptor site for 
ligand binding, this is connected to the cytoplasmic tyrosine kinase domain by the 
transmembrane domain which passes through the plasma membrane. (36) 
 
Figure 1.2.1 The EGF receptor 
Figure reproduced from reference (36). 
 
There is a high degree of homology between the tyrosine kinase domains of the HER 
RTK family members. In contrast, the extracellular domains are less conserved and bind 
to different ligands. For example only EGFR will bind EGF. Currently there is no 
known natural ligand for HER2. Ligand binding induces receptor dimerization between 
This text box is where the original thesis contained the diagram showing ‘the EGF 
receptor’ which was reproduced from reference (36).   
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two receptors of the HER RTK family. Dimerization can occur between two identical 
receptors (homo-dimerization) or betweens two different receptors (hetero-dimerization) 
(35). Following dimerisation, a process of transphosphorylation then occurs, where the 
tyrosine kinase domain of one EGFR phosphorylates a variable number of tyrosine 
residues of the cytoplasmic C terminus of adjacent EGFR molecules as shown in   
Figure 1.2.2 (36). 
 
 
 
 
 
 
Figure 1.2.2 EGF receptor dimerization after ligand binding.  
In the presence of EGF, EGF receptors dimerize and transphosphorylate tyrosine 
domains. Figure reproduced from (36). 
  
 Various cytoplasmic proteins are then able to bind to specific phosphotyrosine residues. 
The phosphotyrosine residue to which a given protein binds is governed by the 
specificity of the SH2 domain of the binding protein. (37).  
 
This text box is where the original thesis contained the diagram showing ‘EGF 
receptor dimerization after ligand binding’ which was reproduced from reference 
(36). 
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In addition to the binding of cytoplasmic protein binding, other plasma membrane 
associated proteins are also able to bind to the phosphotyrosine residues; which once 
again depends on the specificity of the SH2 domain of the binding protein. 
 
Figure 1.2.3 demonstrates an example of this process. Here EGFR has been activated by 
EGF. Several phosphotyrosine residues are subsequently formed. The protein Grb2 
contains an SH2 domain which facilitates its binding to the RTK phosphotyrosine 
residues. In addition, Grb2 possesses an SH3 domain which allows binding of Sos. This 
binding complex ensures that Sos is now in close proximity to the membrane bound Ras, 
with the result that Sos can activate the Ras signalling pathway. (37). Sos is known as a 
guanine exchange factor (GEF) which is able to substitute Ras GDP for Ras GTP. Ras 
signalling is turned off by intrinsic GTPase activity which hydrolyses GTP to GDP. This 
GTPase activity is enhanced in the presence of GTPase activating proteins (GAPs) (36).  
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Figure 1.2.3 Intermolecular links between EGFR and RAS.  
Phosphorylation of EGFR tyrosine domains allows binding between the SH2 domain of 
Grb2 and the cytoplasmic phosphotyrosine residues of EGFR. Simultaneously the SH3 
domain of Grb2 facilitates binding of Sos. Sos is now juxtaposed to membrane bound 
protein Ras which it then activates by phosphorylating Ras bound GDP. Figure 
reproduced from reference (37).  
 
The two main signalling pathways that are influenced by EGFR binding are:  
1. Ras→Raf→Mek→Erk pathway  
2. Ras→PI3K→PIP3→Akt/PKB pathway (38) 
 
Ras→Raf→Mek→Erk pathway  
This text box is where the original thesis contained the diagram showing 
‘intermolecular links between EGFR and RAS’ which was reproduced from 
reference (37). 
Literature review 
 
19 
 
Following activation, Ras binds Raf kinase via a domain called an effector loop, 
resulting in activation of Raf (37). In turn, activated Raf kinase phosphorylates and 
therefore activates MEK. MEK proceeds to phosphorylate extracellular signal-regulated 
kinases 1 and 2 (ERK 1 and 2) (37). Following activation ERK moves into the nucleus 
where it in turn, phosphorylates and activates multiple transcription factors (TFs) such as 
Ets, Elk-1 and SAP-1 (37). A summary of this pathway is given in Figure 1.2.4. 
 
These TFs in turn coordinate the expression of particular genes (39). By unknown 
mechanisms TFs facilitate the access of set genes to RNA polymerase(39). Thereby 
determining which genes are transcribed and ultimately which proteins are produced 
(39). Proteins produced under the stimulus of the Ras →Raf→Mek→Erk pathway, such 
as cyclin D1, are needed to drive the cell forward during the G1 phase of the cell cycle 
(37).  
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Figure 1.2.4 Summary of the Ras →Raf→Mek→Erk pathway.  
This pathway leads to activation of ERK kinase which in turn activates transcription 
factors, via phosphorylation, such as Ets, Elk-1, and SAP-1. Ets can then activate the 
expression of genes which regulate growth such as cyclin D1. Erk can also directly 
activate Mnk1 kinase. Mnk1 kinase then phosphorylates and subsequently activates 
eurokaryotic initiating factor eIF4E which is essential in order for protein translation. 
Figure reproduced from reference (37). 
 
pRb regulates cell cycle progression from late G1 to S phase (40). When pRb is not 
phosphorylated it exerts a restraining effect on transcription factor E2F (40). However, 
when hyperphosphorylated, pRb detaches from E2F which in turn promotes the 
transcription of downstream S phase genes leading to cell cycle progression from late 
G1 into S phase. (40). 
 
This text box is where the original thesis contained the diagram showing the 
‘summary of the Ras to Erk pathway’ which was reproduced from reference (37) 
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Cyclin D1 gene transcription is initiated through the EGFR→Ras→Raf→Mek→Erk 
pathway. In G1 of the cell cycle, cyclin D combines with cyclin dependent kinases 4 and 
6 (CDK4/6) (40). Cyclin D-CDK4/6 complexes initiate phosphorylation of pRb. At this 
point pRb is only hypophosphorylated and is not deactivated. Phosphorylation of pRb is 
completed by the action of cyclin E-CDK2 complexes, which results in 
hyperphosphorylation of pRb and subsequent release of E2F (40). Activated E2Fs can 
then trigger increased transcription of cyclin E genes. Thus this cycle becomes self 
perpetuating with more cyclin E-CDK2 complexes formed, causing more pRb to 
become hyperphosphorylated and more activated E2Fs.  
 
Figure 1.2.5 shows that growth factor leads to eventual hyperphosphorylation of pRb. 
Once the restriction point has been passed, the cell will continue through the cell cycle 
without the need for further growth factor stimulus.  
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Figure 1.2.5 Control of the G1 restriction point and positive feedback loops. 
EGFR signalling leads to increased levels of cyclin D expression. pRB is then 
phosphorylated by cyclin E/CDK2 and cyclin D/CDK4 complexes. Hyperphosphorylated 
pRB then releases transcription factor E2F which is required for the transcription of 
proteins in order for the cell to enter S phase. Figure reproduced from reference  (40).  
 
 
 
 
This text box is where the original thesis contained the diagram showing the 
‘control of the G1 restriction point and positive feedback loops’ which was 
reproduced from reference (40). 
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Ras→PI3K→PIP3→Akt/PKB pathway 
 Ras, once activated through EGFR, can also activate the catalytic domain of 
phosphatidylinositol 3 kinase (PI3K) (37). PI3K is able to phosphorylate 
phosphatidylinositol-diphosphate (PIP2) thereby forming phosphatidylinositol-
triphosphate (PIP3) (37).  
 
The PH (pleckstrin homology) domain of Akt/PKB is able to bind PIP3 facilitating its 
biphosphorylation by PDK1 and PDK2 (37). Phosphorylated (active)Akt/PKB then 
proceeds to phosphorylate a variety of substrates such as GSK-3β (which regulates cell 
proliferation) and Bad (which regulates cell survival) (37). Figure 1.2.6 shows the 
activation of the Ras→PI3K→PIP3→Akt/PKB pathway. 
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Figure 1.2.6 Activation of the Akt/PKB pathway 
Ras activates kinase PI3K which then phosphorylate PIP2 to PIP3. An Akt/PKB kinase 
molecule is then able to dock onto PIP3. This is followed by Akt/PKB complex being 
phosphorylated by kinases PDK1 and 2. PIP3 is then dephosphorylated via phosphatase 
PTEN. Figure reproduced from reference (37). 
  
Similar to pRb, p27
Kip1
 and p21
Cip1
 promote cell cycle arrest if damaged DNA remains 
unrepaired (40). Ordinarily, p27
Kip1
 and p21
Cip1
 inhibit the activity of cyclin CDK 
complexes in the nucleus. Akt/PKB is able to phosphorylate these two molecules 
causing their translocation out of the nucleus so that their inhibitory effects on cyclin 
CDK complexes are lost (40). 
 
This text box is where the original thesis contained the diagram showing ‘activation 
of the Akt/PKB pathway’ which was reproduced from reference (37). 
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Akt/PKB can also suppress apoptosis by inhibiting pro-apoptotic proteins such as Bad 
and activating anti-apoptotic proteins such as Mdm2 (37).  
 
As outlined in Figure 1.2.6, phosphorylation of PIP2 by PI3K can be reversed by the 
phosphatase PTEN (37). In many human tumours e.g. breast carcinoma or colon cancer 
inactivation of PTEN is a common occurrence and leads to unregulated cell cycle 
progression (37).  
 
1.2.2 EGFR and tumorigenesis 
 
EGFR over expression and prolonged activation of its signalling pathway are 
characteristic of many solid tumours including that of the head and neck, cervical, 
bladder, brain, breast, lung stomach, ovary and prostate (29). In these instances EGFR 
becomes an oncogene. A summary of studies investigating the expression of EGFR in 
HNSCC is shown in Table 1.2.1. 
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Study Main findings 
Grandis and 
colleagues, 1993 
(41) 
EGFR mRNA levels were elevated by an average of 69 fold in 92% of 
SCCHN tumours compared to mRNA levels in healthy normal mucosa.  
Chung and 
colleagues, 2006 
(42) 
58% of HNSCC tissue samples showed EGFR gene amplification as 
determined by FISH. 
Ryott and 
colleagues, 2008 
(43) 
EGFR protein expression was found to be high in 72% in tumours of 
the oral tongue squamous cell carcinoma. Furthermore 54% of these 
tumours had a high EGFR gene copy numbers (≥ four gene copy 
numbers). 
Sarkis and 
colleagues, 2010 
(44) 
EGFR expression was found in all epithelial layers on oral squamous 
cell carcinoma specimens where as in normal oral epithelia, EGFR 
could only be detected in the basal cell layer. 
Table 1.2.1 Summary of studies indicating that EGFR is over expressed in HNSCC. 
 
 Ryott and colleagues in 2008 showed that EGFR protein was over expressed in 72% of oral 
tongue squamous cell carcinoma (OTSCC) and that EGFR gene amplification was 
correlated with EGFR over-expression, (p=0.004) (43).  Figure 1.2.7 shows low and high 
expression of EGFR protein as detected by IHC and normal and amplified levels of EGFR 
gene as detected by FISH in OTSCC. 
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Figure 1.2.7  Levels of EGFR protein and gene copy number as determined by IHC 
and FISH respectively in OTSCC. 
(A) EGFR IHC weak staining. (B) EGFR strong staining. (C) EGFR FISH analysis 
showing normal disomy copy of genes. (D) EGFR gene amplification. Figure 
reproduced from reference (43). 
 
As well as gene amplification, EGFR protein may be overexpressed in tumours due to 
reduced rate of ubiquitin mediated proteasomal degradation. Shortly after EGF binding 
to wild-type EGFR, EGFR is endocytosed, internalized, ubiquitinated and then 
undergoes proteasomal degradation (45). This process allows for the termination of 
growth signal and provides a refractory period before the next growth signal is 
generated. In cells expressing endogenous levels of EGFR (<200,000 receptor molecules 
per cell), receptor half life is typically between 6-10h, whereas in cells over expressing 
This text box is where the original thesis contained the diagram showing ‘levels of 
EGFR protein and gene copy number as determined by IHC and FISH respectively 
in OTSCC’ which was reproduced from reference (43). 
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EGFR, such as in the epidermoid carcinoma cell line A-431, EGFR half life can exceed 
24h (46). 
 
Degradation of EGFR once internalised, is rapid. Following EGFR 
transphosphorylation, members of the Cbl family of proteins, which contain ring finger 
E3 ubiquitin ligases, are able to tag EGFR with ubiquitin thereby directing its 
proteasomal degradation (46). Cbl proteins contain a tyrosine kinase binding domain 
(TKB) that can bind directly to Tyr1045 of EGFR. In this way EGFR, once 
phosphorylated, is quickly degraded via Cbl. 
 
EGFR tyrosine kinase domain mutations such as L858R/T790M can impair Cbl-EGFR 
association and significantly slow endocytosis and degradation compared to cells 
expressing wild type EGFR (47). Cells expressing these mutant receptors have shown 
persistently longer mitogenic and antiapoptotic signalling compared to wild type cells 
(47).  
 
In addition to mutations of the tyrosine kinase domain, EGFRvIII mutants lack the 
ectodomain (ligand binding portion) of EGFR (29) and are constitutively active, 
independent of EGF (29). EGFRvIII mutations are commonly found in gliomas, non 
small cell lung cancer and SCCHN. (29). Furthermore, a study by Sok and colleagues in 
2006, found 42% of SCCHN tumours expressing EGFRvIII (48). In addition, EGFRvIII 
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transfected cells showed reduced rates of apoptosis when treated with cisplatin and 
decreased growth inhibition with cetuximab treatment when compared to parental cells 
(48).  
 
Normally growth factors exert their effects via paracrine stimulation (36). However, it 
has been observed that SCCHN cells may be able to self induce EGFR receptor 
activation via secretion of such ligands as TGF-α (transforming growth factor) (29). i.e. 
autocrine stimulation.  
 
Increased EGFR gene copy number, over-expression (or reduced degradation) of EGFR 
and autocrine TGF-α stimulation, have all been correlated with poor survival outcome 
and increased metastatic potential (29, 49, 50). Grandis and colleagues found 2 year 
survival rates for SCCHN patients to be 31% for patients with tumours expressing high 
EGFR levels compared with 90% for those with tumours expressing low EGFR 
levels.(p=0.001) (50). In the same study they also observed that the 2 year overall 
survival for patients with tumours secreting high levels of TGF-α as compared to those 
with tumours secreting low levels was 50% and 89% (p=0.001) respectively (50). 
 
Several studies have suggested that EGFR signalling pathway may be important in 
causing resistance to radiotherapy treatment. A correlative study was performed, by Ang 
and colleagues, which examined EGFR levels in patients with advanced head and neck 
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cancer who had undergone radiotherapy (51). Patients who had tumours expressing 
relatively low levels of EGFR had significantly greater overall survival, disease free 
survival, and local regional control rates (51) Thereby inferring that tumours expressing 
relatively higher levels of EGFR expression are more radioresistant. Similarly, studies 
involving patients with glioblastoma multiforme or cervical cancer, also demonstrated 
that EGFR over-expression was a significant predictor for poor response to radiation 
(52, 53).  
 
1.2.3 Inhibiting EGFR with cetuximab  
 
In 2008 the role of cetuximab in the management of SCCHN was reviewed by the 
national Institute for Clinical Excellence (NICE). Following this review, the use of 
cetuximab was permitted for locally advanced head and neck squamous cell carcinoma 
in combination with radiotherapy in patients for whom concurrent platinum based 
therapy is unsuitable (30).  
 
Cetuximab is a monoclonal IgG antibody (mAb) which binds to EGFR with a greater 
affinity than either EGF or TGF-α (54). Binding inhibits the activation of EGFR tyrosine 
kinases and thus prevents Ras associated downstream signalling pathways that are 
associated with cell proliferation, prevention of apoptosis, cellular repair and survival as 
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described in section 1.2.1 (54). Binding of Cetuximab to EGFR promotes receptor 
internalization but unlike the binding of EGF does not induce proteasomal degradation 
of EGFR (55).  
 
As mentioned in section 1.2.1 cyclin/CDK complexes, which are formed upon activation 
of the EGFR pathway, are needed for the phosphorylation of pRB in order for cells to 
enter the S phase of the cell cycle. Oral squamous cell carcinoma cells were shown to 
have decreased expression of CDK2 and CDK4 proteins resulting in an associated 
accumulation of cells in G1 and a corresponding decrease in cells in S phase when 
treated with cetuximab (56). The authors also demonstrated an increase in expression of 
G1 cyclin dependent kinase activity inhibitors p15 and p21 (56). To corroborate this, 
another study found accumulation of the hypophosphorylated pRb protein when 
squamous carcinoma cells were treated with 30nM of cetuximab for two days as shown 
in Figure 1.2.8 (57).  
 
 As well as G1 arrest, cetuximab is known to induce apoptosis (a summary of the 
apoptosis pathway is provided in section 1.3.4) by increasing the cellular levels of Bax 
(a proapoptotic protein) and reducing the levels of Bcl-2 (an anti apoptotic protein), as 
shown in Figure 1.2.8 . Cetuximab has been shown to down regulate the expression of 
nuclear factor κB (NF-κB) in pancreatic cell line MDA Panc-28 (58). NF-κB is essential 
Literature review 
 
32 
 
for the transcription of antiapoptotic protein Bcl-xl – which is an additional mechanism 
by which cetuximab facilitates apoptosis  
 
Cetuximab may also be involved in the inhibition of angiogenesis. Several studies have 
shown that upon treatment with cetuximab there were reductions in pro-angiogenic 
factors such as vascular epidermal growth factor (VEGF) and IL-8 with corresponding 
decreases in micro-vascular density as compared to controls (59, 60).  
 
 
 
 
 
 
 
Figure 1.2.8 Treatment of SCC-13Y cells with 30nM cetuximab (C225) 
SCC-13Y with cetuximab shows that cetuximab modifies cell cycle by increasing p27 
expressing and subsequent expression of hypophosphorylated pRB; cetuximab also 
increases proapoptotic protein levels of Bax. Figure reproduced from reference (57). 
 
This text box is where the original thesis contained the diagram showing 
‘treatemtn of SCC-13Y cells with 30nM cetuximab (C225)’ which was 
reproduced from reference (57). 
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As mentioned in section 1.2.2 up-regulation of EGFR in tumours corresponds to 
radioresistance. A study by Liang and colleagues demonstrated that there was increased 
radioresistance in clones over expressing EGFR compared to parental lines and that 
radioresistance was reduced upon the addition of cetuximab (61). The study by Huang 
found a 2 fold increase in apoptosis, as assessed by the magnitude of the sub-G1 peak, in 
SCC-13Y cells treated with 6 Gray radiation alone and a 5-6 fold increase in apoptosis 
when the same cells were treated with 30nM of cetuximab combined with radiation as 
compared to non irradiated controls (57).  
 
A study by Dittman and colleagues tried to determine the possible mechanism behind 
cetuximab induced radiosensitisation (62). DNA dependent protein kinase (DNA-PK) is 
a protein which is found in the nucleus and aids the repair of double strand breaks which 
occur commonly after ionizing radiation. After radiation the study found large 
accumulation of EGFR/DNA-PK complexes in the nucleus. When cells were pre-treated 
with cetuximab there was a significant reduction in EGFR/DNA-PK complexes, a 
decrease in DNA-PK activity and an increase in residual DNA damage. (62). In addition 
to this proposed mechanism, it is known that cetuximab causes an increase in the 
proportion of cells in G1 arrest where cells are known to be more radiosensitive (54).  
 
In contrast to HER2 over-expression, which predicts response to monoclonal antibody 
trastuzumab (herceptin) against HER2 in breast cancer patients, levels of EGFR have not 
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correlated with the outcome to cetuximab treatment (63). Clinical studies in metastatic 
colorectal cancer have shown no correlation between EGFR expression levels and 
sensitivity to cetuximab (64). Therefore further molecular markers are required to 
predict the treatment outcome of cetuximab. 
  
Several gene mutations, which fall within the downstream signalling pathway of EGFR, 
are emerging as indicators of poor response to cetuximab therapy. Once wild-type Ras 
has been stimulated by EGFR, activated Ras GTP is converted into its inactivated form, 
Ras GDP, by its own GTPase. KRAS mutations which occur in 40% of colorectal 
carcinomas have a non functional GTPase site resulting in constitutive signalling and 
independence from EGFR control (65). Several studies have indicated that KRAS 
mutations are correlated with poor response to cetuximab in colorectal cancer (65-67). 
Loss of PTEN and mutant EGFR VIII have also been linked to cetuximab resistance, 
with one study showing that all patients (n=11) with loss of PTEN, did not receive any 
additional benefit from cetuximab (68).  
 
Currently the National Comprehensive Cancer Network (NCCN) Clinical Practice 
Guidelines in Oncology Version 3 2008 recommends KRAS genotyping in patients 
presenting with colorectal carcinoma before the use of EGFR inhibitors (69). 
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RAS mutations in SCCHN are rare and therefore, similar predictive biomarkers remain 
elusive. 
 
Apart from inherent resistance to cetuximab, evidence suggests that tumours which 
initially responded to cetuximab treatment later developed resistance (70). As already 
explained, EGFR is a member of the HER family of receptor tyrosine kinases which 
consists of EGFR, HER2, HER3 and HER4. HER family members share several 
downstream signalling cascades such as the MAPK and PI3K/AKT pathways, which can 
be initiated upon homo or hetero-dimerization between HER members and therefore one 
theory is that acquired resistance to cetuximab may be in part due the ability of cells to 
activate growth signals through other HER RTK members independently thereby 
bypassing the effect of EGFR blockade (70).  
 
Wheeler and colleagues established cetuximab resistant cell lines following long term 
exposure to cetuximab. . These include, cell lines derived from non small cell lung 
cancer (NSCLC; H226) and SCCHN (UMSCC-1). To further clarify the role of the HER 
family in cetuximab resistant lines, cells in which HER2 was blocked using monoclonal 
antibody 2C4 or transfected with siRNA against HER3 were treated with and without 
cetuximab. In both cases loss of either HER2 or HER3 activity resulted in rescue of 
cetuximab resistance and a consequent reduction of cell proliferation(70). Hence 
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targeted combination therapy against several members of the HER family may be more 
efficacious than targeting EGFR alone.  
 
1.2.4 Inhibiting the EGFR pathway with tyrosine kinase inhibitors 
 
Tyrosine kinase inhibitors (TKIs) prevent trans or autophosphorylation of the tyrosine 
residues of receptor tyrosine kinase (RTK) family members (31). Whilst monoclonal 
antibodies (mAbs) such as cetuximab are typically specific to one receptor, TKIs may 
cross react by inhibiting the phosphorylation of tyrosine residues present on other RTK 
species. (31). Despite this, preferential activity towards one or more RTK species is 
possible allowing some specificity of action. For example, gefitinib and erlotinib are 
specific to EGFR whilst lapatinib preferentially inhibits EGFR and HER-2 (31).  
 
Both cetuximab and EGFR targeted TKI gefitinib share similar cytotoxic properties. Both 
drugs cause G1 arrest, induce proapoptotic protein Bax and reduce expression of 
antiapoptotic protein Bcl-2, as well as inhibiting the production of VEGF (56, 71, 72). In 
addition TKIs have been shown to enhance the cytotoxic effects of radiation (57, 73, 74). 
Similarly, PTEN and Ras mutation have also been linked to TKI resistance (75).  
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1.3 GRP78 
1.3.1 Basic functions of the endoplasmic reticulum and the role of 
chaperones in protein folding 
 
Proteins which are destined to be secreted out of the cell such as immunoglobulins, or 
which will be incorporated into lysosomes or onto the plasma membrane, require post 
translational modification in order to become functionally active and are therefore 
selectively targeted to enter the endoplasmic reticulum (ER) (76).  
 
Chaperones are proteins which facilitate the folding of newly synthesised proteins both 
in the cytosol and ER. Chaperones do not provide any additional information on how a 
protein should fold, as this is already pre-determined by the amino acid sequence. 
However chaperones act as scaffolds, binding to partially folded intermediates and 
providing structural support to ensure that proteins are folded correctly. Thus they 
prevent premature folding before all of the nascent peptide chain has been released from 
the ribosome and thereby avoid the formation of protein aggregates (77). Most 
chaperones are part of a homologous family known as heat shock proteins: HSP40, 
HSP60, HSP70, HSP90, HSP100. HSPs are not only involved in folding of proteins but 
also in: the ubiquitin proteasome system, endoplasmic reticulum associated degradation 
(ERAD), Unfolded Protein Response (UPR), apoptosis and autophagy (78).  
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Proteins can enter the ER either during the process of translation (known as 
cotranslational translocation) or after completion of translation (known as post-
translational translocation) as shown in Figure 1.3.1. In cotranslational translocation a 20 
amino acid sequence from an elongating polypeptide chain, known as the signal 
sequence, is recognized and bound by signal recognition particle (SRP) (79). At this 
point further translation is stopped and the ribosome along with the polypeptide chain 
move towards the ER. The SRP binds to a receptor on the ER membrane where it is then 
removed from the signal sequence. The ribosome attaches to a pore in the ER membrane 
known as a Sec61 protein translocation complex and the polypeptide chain is then able 
to enter the ER. Translocation then resumes and the ribosome feeds the remainder of the 
polypeptide chain into the ER (79). 
 
In post-translational translocation the completed unfolded polypeptide chain is supported 
in the cytosol by chaperones. It is targeted by its signal sequence towards Sec 61and 
Sec62/63 complexes(79). At this point cytosolic chaperones are released and the peptide 
passes though the ER pore. GRP78 (also known as Bip) is a chaperone which consists of 
two functional domains: an N-terminal ATPase domain and a C terminal peptide binding 
domain (80). Sec 63 is able to catalyse the ATP hydrolysis by GRP78/BiP allowing the 
chaperone to attach onto hydrophobic parts of the polypeptide chain. When more of the 
polypeptide chain enters the ER another GRP78/Bip molecule, within the ER lumen, can 
attach on to it. This attachment prevents retrograde movement of the polypeptide chain 
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back out into the cytosol. Once the polypeptide chain is completely within the ER 
lumen, GRP78/Bip can release the polypeptide chain upon exchange of ADP for ATP 
(79). 
 
(1) Recently translated polypeptide chain is supported by cytosolic chaperones and 
moves towards the Sec complexes. (2) Cytosolic chaperones dissociate as the 
polypeptide chain comes into contact with Sec complexes. The J domain of Sec63 causes 
ATP hydrolysis of GRP78/BiP. GRP78/Bip can now adhere to the polypeptide chain. (3) 
As more of the polypeptide chain moves into the ER more GRP78/BiP chaperones are 
able to adhere, thus securing the peptide inside the ER. (4) As all of the peptide is now 
in the ER GRP78/BiP can now dissociate from nascent peptides. Figure reproduced 
from reference (79).  
 
Figure 1.3.1 Post-translational translocation 
This text box is where the original thesis contained the diagram showing ‘post-
translational translocation’ which was reproduced from reference (79). 
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After entry into the ER a series of enzymatic post translational modifications of the 
polypeptide chain occurs. The oxidative environment in the ER and protein disulphide 
isomerase (PDI) enzymes help catalyse disulphide bond formation between cysteine 
residues. These bonds form the protein’s three dimensional structure (76).  
 
In addition, within the ER, proteins are often cleaved in a process called proteolysis by 
peptidases. For example insulin is formed in two stages. First the signal sequence is 
removed from preproinsulin to make prosinsulin (81). Further proteolysis removes a 
connecting amino acid sequence which becomes unnecessary once disulphide bonds 
have formed, thus producing insulin (81).  
 
Similarly, lipids may also attach to proteins allowing them to anchor to hydrophobic 
portions of the cell membrane. Proteins may also undergo glycosylation (attachment of 
carbohydrates) (81). Once proteins have folded correctly and undergone other post 
translational modifications their hydrophobic areas are no longer exposed and therefore 
GRP78 can no longer attach to them. 
 
Proteins which are destined to stay in the ER, such as GRP78, are tagged with a 
targeting sequence (KDEL or KKXX). Proteins (tagged and untagged) are transported 
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out of the ER in a non selective manner to the Golgi apparatus. Tagged proteins are then 
recognized by receptors in the Golgi apparatus and transported back to the ER (76).  
 
1.3.2 The roles of GRP78, PERK, ATF6, and IRE1 in the Unfolded 
Protein Response 
 
Accumulation of unfolded or incorrectly folded proteins may occur in the ER under 
certain physiological conditions and can be induced experimentally. Protein folding and 
maintenance of the ER environment is an energy intensive process. Glucose and ATP in 
the ER are needed for: binding and unbinding of chaperones, maintenance of Ca
2+
 levels 
in the ER (which is required for both chaperone function and protein folding), 
preserving redox homeostasis, for glycosylation, and for ER assisted degradation 
(ERAD) (82). Furthermore molecular oxygen is essential as an electron acceptor during 
the formation of disulphide bonds. 
 
 The tumour microenvironment is often subject to low oxygen and low glucose levels 
due to the poor microvasculature and such conditions can lead to increased levels of 
unfolded proteins in the ER (83). An increased unfolded protein load in the ER may also 
appear during synthesis of large amounts of secretary proteins such as when B 
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lymphoblasts begin secreting antibodies upon antigen stimulation or when pancreatic 
cells secrete insulin (84).  
  
In order to counteract an increase in unfolded or incorrectly folded proteins a mechanism 
known as the Unfolded Protein Response (UPR) becomes activated. The UPR results in 
the attenuation of protein translation, and degradation of misfolded protein by a system 
known as endoplasmic reticulum associated degradation ERAD, thus reducing the 
protein load in the ER (85). The UPR also induces genes which are involved in the 
formation of correctly folded proteins such as GRP78 thus increasing the folding 
capacity of the ER (84). If homeostasis is not resumed then the over stimulation of the 
UPR, that can ensue, may lead to apoptosis (85).  
 
GRP78 normally binds to and inhibits two ER transmembrane kinase signalling 
molecules: pancreatic kinase like ER kinase (PERK) and inositol-requiring enzyme 1 
(Ire1). As well as these two molecules GRP78 also binds and inhibits to a UPR-specific 
transcription factor known as activating transcription factor 6 (ATF6) (83). During the 
accumulation of unfolded proteins, GRP78 preferentially attaches to hydrophobic parts 
of unfolded proteins thus dissociating from PERK, Ire1 and ATF6. The disassociation of 
GRP78 from these three molecules enables their activation. (83). 
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PERK 
Upon GRP78 disassociation, PERK is able to dimerize and transphosphorylate its 
cytosolic kinase domain (83). This kinase domain then phosphorylates eukaryotic 
translation initiation factor-2  (eIF2 ). eIF2 proteins in the GTP state attach to initiator 
tRNA and bring initiator tRNA towards ribosomes therefore aiding in the start of 
translation of mRNA (86). Hydrolysis of eIF2-GTP complex results in eIF2-GDP 
formation and eIF2B (guanine nucleotide exchange factor) must catalyse the removal of 
GDP for GTP in order for eIF2 to attach to another tRNA and participate once again in 
translation initiation (86). eIF2α in the phosphorylated state is able to competitively 
inhibit the function of eIF2B thus reducing translation initiation (86). The inhibition of 
eIF2B by eIF2α is in equilibrium so there will always be at least some protein translation 
even if there are high levels of phosphorylated eIF2α (86). Increased levels of 
phosphorylated eIF2  impedes the translation of most mRNA, therefore reducing the 
cellular protein load. A direct consequence of translation attenuation is G1 cell-cycle 
arrest due to the loss of cyclin D1 protein (83). 
 
It has been reported by Paton and colleagues that GRP78 is the only known substrate of 
E. Coli derived toxin Subtilase (SubA) (7). SubA has proteolytic activity resulting in 
GRP78 (72 kDa) being cleaved specifically at two leucine residue at positions 416 and 
417. This results in two fragments of GRP78 of 28 kDa and 48 kDa (7). A study by 
Wolfson and colleagues in 2008 (87) measured protein synthesis levels by the [
3
H]-
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Leucine incorporation method in PERK wild-type MEFS and PERK knock out MEFs. 
When SubA was applied, GRP78 (72kDa) was cleaved into 28kDa and 44kDa moieties 
in both PERK wild-type MEFs and PERK knock out MEFs, as shown in Figure 1.3.2A. 
Cleavage of GRP78 lead to the disassociation of GRP78 from PERK, IRE1 and ATF6 
and the subsequent activation of the UPR. Upon activation of the UPR there was 
phosphorylation of eIF2  in the PERK wild-type MEFs but not in the PERK knock out 
MEFs as shown in Figure 1.3.2B. Figure 1.3.2C shows a subsequent decrease in the 
amount of protein synthesis in PERK wild-type MEFs compared to the PERK knock out 
MEFs after the application of SubA.  
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Figure 1.3.2 Effects of SubA on GRP78, phosphorylation of eIF2α, and protein 
synthesis in PERK wild-type MEFs and PERK knock out cells. 
A: Western blot of GRP78 showing cleavage of GRP78 after the application of SubA in 
both wild-type and PERK knock out cells. B: Western blots of eIF2  and its 
phosphorylated form in wild-type cells (+) and PERK knockout cells (-) after SubA 
application. C: Percentage protein synthesis as compared to cells prior to the 
application of SubA in wild-type and PERK knock out cells. Figures reproduced from 
reference(87). 
This text box is where the 
original thesis contained the 
diagram showing the ‘effects of 
SubA on GRP78, 
phosphorylation of eIF2α, and 
protein synthesis in PERK 
wild-type MEFs and PERK 
knock out cells’ which was 
reproduced from reference (87). 
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Paradoxically, a decrease in eIF2 activity favours the translation of activating 
transcription factor 4 (ATF4) (88). Most mRNA have a cap-structure, consisting of 7-
methylguanosine residue, which is linked to the 5’ end of the first nucleotide in mRNA 
sequence (86). This cap-structure is recognised by initiation factor eIF-4F and eIF-4F 
guides the ribosome towards the start codon of  mRNA thus initiating translation. Under 
high levels of phosphorylated eIF2α translation of those mRNA which contain the cap-
structure, decreases. Some mRNA such as that of ATF4 do not contain the cap-structure 
and are said to be cap-independent mRNA. Although these cap-independent mRNA, are 
constitutively expressed they are not efficiently translated until there are high levels of 
phosphorylated eIF2α during for example when the Unfolded Protein Response is 
activated (86). 
 
 ATF4 protein expression in turn, induces transcription factor C/EBP homologous 
protein (CHOP) (89). A study by Marciniak and colleagues in 2009 (89), demonstrated 
that CHOP promotes the reactivation of protein synthesis as well as increasing the 
activity of enzymes involved in protein folding (89). Increased levels of CHOP lead to 
the expression of target gene GADD34. GADD34 contains an eIF2α phosphatase 
complex which results in eIF2  being dephosphorylated and inactivated thus restarting 
the translation process. Marciniak and colleagues in 2009 (89), demonstrated that there 
was increased protein level production in CHOP wild-type mice compared to CHOP 
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knock-out mice when the mice were given thapsigargin. Thapsigargin is a drug which 
produces ER stress by depleting calcium resources within the endoplasmic reticulum 
(90). Marciniak and colleagues also showed that CHOP plays a role in increasing levels 
ERO1  expression. ERO1  is a protein which oxidises protein disulfide isomerases 
(PDIs). This then allows PDIs to create disulfide bonds in newly forming proteins in the 
ER (89). The mechanism of disulphide bond formation is summarised in Figure 1.3.3. 
 
 
 
 
 
 
 
 
Figure 1.3.3: Mechanism of disulphide bond formation in proteins by oxidative 
reaction.  
ERO1 oxidizes protein disulphide isomerase (PDI) which can then initiate disulphide 
bonds formation (S-S) on ER proteins. ERO1, once activated by FAD, transfers 
electrons to molecular oxygen. Figure reproduced from reference (91).  
 
This text box is where the original thesis contained the diagram showing the 
‘mechanism of disulphide bond formation in proteins by oxidative reaction’ which 
was reproduced from reference (91). 
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ATF 6 
ATF6 is a transcription factor which is also released by GRP78 disassociation upon 
accumulation of unfolded proteins. Upon release, ATF6 enters the Golgi apparatus 
where it undergoes partial proteolysis by Site 1 and Site 2 proteases (S1P, S2P). A 
smaller part of ATF6, at 50kDa, is now free to enter the nucleus where it induces other 
genes (87). ATF6 increases levels of: GRP78, protein disulphide isomerases, ER 
degradation enhancing  mannosidase like protein 1 (EDEM1) and transcriptional 
factors such as CHOP and X-box-binding protein (XBP1) (87). The rise in chaperones 
as well as proteins which are involved in disulphide bond formation enhances the 
folding capacity of the ER.  
 
IRE 1 
Finally the third UPR protein to be released by GRP78 is IRE1. IRE1 is unusual as it 
acts as both a serine/threonine kinase and an endoribonuclease (92). After induction of 
the XBP1 gene by ATF6, XBP1 mRNA is then spliced by the endoribonuclease part of 
IRE1 (93). Spliced XBP1 acts as a transcriptional activator that elicits up-regulation of a 
group of proteins responsible for degrading misfolded proteins. This response is known 
as the endoplasmic reticulum activated degradation (ERAD) and leads to an overall 
reduction in misfolded proteins (92). Misfolded proteins are selected by molecular 
chaperones and targeted for retrotranslocation out of the ER via the Sec61 translocon 
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complex (94). Currently it is unknown how chaperones are able to distinguish between 
misfolded and nascent unfolded proteins, in order to target misfolded proteins for 
degradation. Once outside the ER, misfolded proteins are then ubiquitinated via 
ubiquitin ligase (94). These targeted proteins then undergo degradation by the 
proteasome (94). Cells that are deficient in IRE1 or XBP1 are defective at degrading 
misfolded proteins (93).  
Figure 1.3.4 provides a summary of the UPR.  
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Figure 1.3.4: Summary of GRP78/Bip and its role in the UPR 
GRP78 otherwise known as Bip disassociates from IRE1, ATF6 and PERK upon binding 
to either misfolded or unfolded proteins which contain exposed hydrophobic sites. 
Activated PERK leads to attenuation of protein translation through phosphorylation of 
eIF2α. Phosphorylation of eIF2α also gives rise to CHOP. CHOP expression results in 
the reinitiation of protein translation and an increase in proteins which catalyse 
disulphide bond formation. ATF6 undergoes proteolysis and then enters the nucleus 
leading to the transcription of chaperones such as GRP78 as well as PDI, CHOP and 
mXBP1. IRE1 acts as an endoribonuclease removing introns from mXBP1. XBP1 then 
upregulating proteins which are involved in ER assisted degradation (ERAD). Figure 
reproduced from reference (82)  
 
This text box is where the original thesis contained the diagram showing a 
‘summary of GRP78/Bip and its role in the UPR’ which was reproduced from 
reference (82). 
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1.3.3 Induction of GRP78 in the tissue microenvironment and its role 
in tumorigenesis 
 
Due to the poor microvasculature, tumours are often subject to conditions of hypoxia 
and nutritional deprivation. For example normal breast tissue contains typically 10 kPa 
of oxygen compared to 4 kPa in breast cancer tissue (83). Similarly normal tissue 
contains glucose levels of 5 mM whilst in many tumours this can range from anywhere 
between 0-2 mM (83).  
 
Hypoxia and low glucose conditions cause cellular stress and leads to up-regulation of 
GRP78 as shown by Kakinuma and colleagues in 2008(95). Another study by Sorensen 
and colleagues 2009 used proteomic techniques to compare protein levels in head and 
neck cancer cell line FaDuDD under normoxic (21% O2 for 24h) and hypoxic (1% O2 for 
24h) conditions(96). The study identified over 11 different proteins which were up-
regulated under hypoxia. These included GRP78 , protein disulfide isomerase A, as well 
as glycolytic enzyme glyceraldehydes 3 phosphate dehydrogenase (GAPDH) (96). 
 
GRP78 has been found to be elevated in many tumours such as those of lung, breast, 
stomach, prostate, colon and liver (1). Up-regulation of GRP78 may be important for 
tumours to survive and grow in their microenvironment of low oxygen and low glucose. 
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Below several studies which have investigated the role of GRP78 in tumorigenesis are 
summarised.  
 
A study by Fu and colleagues in 2008 reported that homozygous deletion of GRP78 in 
the prostate gland of mice lead to suppression of prostate tumour development and 
growth (97). All mice in the study had inactive phosphatase and tensin gene (PTEN). 
Inactivation of PTEN is a common occurrence in prostate cancers and leads to excessive 
stimulation and phosphorylation of the PI3K/AKT pathway and subsequent enhanced 
cell growth and proliferation (see section 1.2.1 for a review of the EGFR signalling 
pathway). All mice with PTEN inactivation developed tumours within 12-20 weeks of 
birth. Whilst none of the eight mice with both PTEN inactivation and GRP78 double 
allele knockout developed any tumours or precancerous lesions (97).  
 
A study by Dong and colleagues in 2009 (98), compared mammary tumour development 
in GRP78 homozygous +/+ mice to and GRP78 heterozygous +/- mice. All mice 
expressed the polyoma middle T oncogene (PyT) (98). Tumours were first detectable 
around 8-10 weeks in the homozygous group but in the heterozygous group tumours 
were detectable between 10-12 weeks. Furthermore tumour size was reduced by 60% in 
the heterozygous group as compared to the homozygous group. Hence even partial 
reduction in GRP78 may be sufficient to impede tumour growth and size (98). 
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In order to understand whether GRP78 may contribute to human gastric invasion and 
metastasis GRP78 expression was analysed, by Zhang and colleagues, in patients with 
N0, N1 and N2/N3 (more than six nodal metastasis) tumours (99). The study found 
strong association between increased nodal status and high GRP78 expression 
(p=0.0037). Furthermore upon transfection of gastric cancer cells with siRNA against 
GRP78, in vitro, there was significant inhibition of invasion compared to controls as 
determined by Matrigel invasion assay (p<0.001). These studies indicate that up-
regulation of GRP78 may also increase the metastatic potential of tumours (99). 
 
EGF-SubA is a novel drug developed by SibTech® consisting of epidermal growth 
factor covalently bound to SubA. As mentioned previously SubA is able cleave GRP78 
(72 kDa) into 44 kDa and 28 kDa fragments. In the study by Backer and colleagues, 
human breast and prostate tumours bearing mice underwent a seven day course of 
intraperitoneal injections of EGF-SubA, resulting in significant reductions in growth in 
both tumour models. Critically Backer and colleagues observed the treatment was ‘well 
tolerated in mice without clinical signs of toxicity’ (5). As loss of GRP78 has been 
shown to suppress tumour development, targeting this protein for example by EGF-
SubA may offer a novel way in treating tumours. 
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1.3.4 Overview of apoptosis 
 
If there is prolonged activation of the UPR, and the issue of unfolded proteins remains 
unresolved, the UPR mechanism can initiate apoptosis. Before discussing the role of the 
UPR in apoptosis it is important to review the basic mechanisms involved in apoptosis.  
 
Apoptosis is the active process of cell death. It is executed by a group of proteases 
collectively known as caspases (100). Effector caspases (such as caspase 3 and 7) are 
able to cleave more than 100 different proteins which contributes to the emergence of 
morphological features which are characteristic of apoptosis. These include cleavage of 
the inhibitor of caspase-activated DNase (ICAD) which leads to activation of CAD and 
subsequent DNA defragmentation (101). Also proteolysis of several cytoskeletal 
proteins such as actin results in loss of cell shape (101). Similarly, proteolysis of 
membrane proteins gives rise to membrane blebbing. The resulting distortion of the cell 
membrane leads to exposure of phosphatidylserine (PS). PS is recognized by phagocytic 
cells which then engulf these PS expressing cells (100).  
 
Caspases are synthesised as inactive precursors which require cleavage for activation. 
Before effector caspases can digest cellular target proteins these caspases need to be 
activated by the initiator caspases(such as key initiator caspase 9) (100). Caspase 9 is 
activated by forming a multisubunit complex between Apaf-1 and a protein released by 
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mitochondria known as cytochrome c (100) This complex collectively is known as an 
apoptosome.  
 
Cytochrome c release is governed by activation of proapoptotic multidomain proteins 
Bax and Bak. In healthy cells Bax and Bak are inhibited by interactions with anti 
apoptotic proteins Bcl-2 and Bcl-xL (100). Cell death signals can activate a group of 
proteins known as proapoptotic ‘BH3 only proteins’, which includes: Bid, Bad, Noxa, 
Puma and Bim. Upon activation BH3 only proteins can interact with anti apoptotic 
proteins and cause the release and subsequent activation of Bax and Bak (100). 
 
Caspases are also regulated by a set of proteins known as inhibitors of apoptosis (IAP) 
which inhibit caspases by binding to them directly or by targeting them for ubiqitinated 
degradation (100). 
 
In response to DNA damage, the tumour suppressor and transcription factor p53 is up-
regulated. Initially ATM and Chk2 protein kinases phosphorylate and stabilize p53 
(100). p53 can either induce G1 cell cycle arrest via transcription of Cdk2 inhibitor p21 
or cause cell death via transcription of Puma and Noxa (100).  
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Growth factor signals such as those generated by the epidermal growth factor (EGF) can 
promote cell survival by activating signal pathways such as PI3 kinase/Akt or 
Ras/Raf/MEK/ERK (100). Once activated these pathways can phosphorylate and 
inactivate Bad thereby inhibiting apoptosis (100). 
 
Caspase 3 can also be activated through a mitochondrial independent pathway known as 
the extrinsic apoptosis pathway. The extrinsic pathway is initiated through the 
stimulation of death receptors such as CD95 and tumour necrosis factor related 
apoptosis inducing ligand (TRAIL) (101). Once these receptors are activated through 
their appropriate ligands, they activate caspase 8 which can then directly control the 
activity of caspase 3. The extrinsic pathway can be inhibited by FLIP which blocks 
caspase 8 activation (101). Activated caspase 8 can also enhance the intrinsic pathway 
by cleaving and stimulating Bid (102).  
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1.3.5 GRP78 leads to suppression of apoptosis 
 
Several studies as described below have identified GRP78 as a protein which inhibits 
apoptosis.  
 
As mentioned previously ATF6 up-regulates GRP78 during ER stress (87). Before 
ATF6 can enter the nucleus and act as a transcription factor it must be split into a 
smaller fraction by Site 1 protease (S1P). AEBSF is a protease inhibitor which can block 
S1P and prevent the up-regulation of GRP78 (103).  
 
A study by Shu and colleagues in 2008(103), initiated the ER stress response with 
thapsigargin and analysed the levels of BAD phosphorylation at Ser75 with and without 
AEBSF. Ser75 is ordinarily phosphorylated by Raf 1. Phosphorylation of BAD at Ser75 
prevents BAD from causing the release of cytochrome c and initiating apoptosis. The 
study found that the amount of BAD phosphorylation was less, as shown by western 
blot, when thapsigargin was combined with AEBSF rather than with just thapsigargin 
alone (103).  
 
The study also found a decrease in mitochondrial membrane potential and an increase in 
cytochrome c release when thapsigargin was combined with AEBSF, as opposed to 
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when thapsigargin was used on its own. The study further analysed the contents of a 
subcellular fraction of mitochondria and found the presence of both GRP78 and Raf 1 by 
western blot. The study concluded that there may be an interaction between GRP78 and 
Raf 1that increases phosphorylation of BAD thus inhibiting BAD from initiating 
apoptosis (103). 
 
As mentioned previously, the study by Reddy and colleagues in 2003(104), found 
through coimmunoprecipitaion that there may be some interaction between procaspase 7 
(35kDa) and GRP78 (104). Confocal microscopy further located both GRP78 and 
procaspase 7 around the peri nuclear/ER region of the cell. They went on to treat 
Chinese hamster ovarian (CHO) cells with the topoisomerase inhibitor etoposide. 
Following treatment, CHO cells that over expressed GRP78 had reduced levels of 
activated caspase 7 levels (32kDa) when compared to parental CHO cells. Hence GRP78 
may be able to suppress caspase 7 activity, via an ATP domain which is able to bind 
procaspase 7 and prevent caspase 7 activation and subsequent apoptosis (104). When 
GRP78 was manipulated so that cells expressed a mutant form of GRP78 without the 
ATP domain there was no interaction between procaspase 7 and GRP78, as determined 
by immunoprecipitation using anti-caspase 7 antibody. Furthermore, Annexin V 
labelling and clonogenic survival assay showed increased cell death and reduced cell 
survival in the mutant GRP78 cell population compared to cells with normal 
GRP78(104).  
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1.3.6 UPR and apoptosis. 
 
Primarily the UPR is a prosurvival response; however in the event of prolonged ER 
stress the UPR initiates the apoptosis cascade. As discussed in section 1.2 CHOP is 
induced during the activation of both PERK and ATF6 (92). CHOP causes the up-
regulation of Bim which is one of the proapoptotic BH3 only proteins (92). CHOP can 
also induce DR5 which is a TRAIL receptor thus promoting p53 independent apoptosis 
(102). Not surprisingly activation of caspase 3 can occur during ER stress even in Apaf-
1
-/-
 cells (84).  
 
Activation of IRE1 also increases levels of JNK. JNK mediated phosphorylation inhibits 
the anti-apoptotic activity of BCl-2 whilst activating Bim and inducing BAX (83). A 
study by Urano and colleagues in 2000(105), showed that following ER stress, IRE1 
wild-type fibroblasts increased JNK levels by two fold, whilst JNK expression was 
impaired in IRE1 knock out fibroblasts(105). 
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1.3.7 GRP78 and chemo-therapy resistance 
 
A review of the current published data suggests that over expression of GRP78 in 
tumours may reduce the effectiveness of chemo-therapeutic agents. Cisplatin is the main 
chemotherapeutic agent used in the treatment of head and neck cancer (106). Cisplatin is 
able to bind to DNA leading to DNA-DNA inter and more commonly intra-strand 
crosslinks. Formation of such DNA adducts lead to the suppression of RNA 
transcription, inhibition of cell division and apoptosis (107). 
 
Lee and colleagues in 2008, transfected glioma cells with GRP78. Subsequent increases 
in GRP78 expression in these transfected cells resulted in decreased caspase 7 activation 
and rendered cells resistant to cisplatin induced apoptosis. Upon siRNA treatment 
against GRP78, decreased cell growth was observed as well as increased sensitisation to 
both cisplatin and radiation (108).  
 
As explained above, GRP78 is known to inhibit apoptosis through direct interaction with 
BIK and procaspase 7 (104) (109). Jiang and colleagues in 2009, found that siRNA 
knockdown of GRP78 increased caspase 4 and 7 activity induced by cisplatin whilst 
over expression of GRP78 suppressed caspase 4 and 7 activity in melanoma cells(110).  
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A study by Langer and colleagues in 2008, compared protein expression in patients who 
responded well to cisplatin/5-FU chemo-therapy to those who were resistant to chemo-
therapy (111). All together 34 patients with locally advanced oesophageal 
adenocarcinomas were treated with neoadjuvant chemo-therapy prior to surgery. 
Responders to chemo-therapy had a median disease free survival of 16.4 months 
compared to 8.4 months for nonresponders (p=0.0015). Proteomic analysis of primary 
tumour tissue was used to analyse differences in protein expression of the tumours 
between responders and non responders and it was found that cellular stress proteins 
HSP27, HSP60, GRP78 and GRP94 were all up-regulated in the nonresponder group 
(p<0.001) (111). 
 
A study by Scriven and colleagues in 2009 found increased resistance to 5-FU under low 
glucose conditions in T47D breast cancer cells (112). Cells were grown in normal and 
low glucose (2 mM) media. Cells grown in low glucose concentration had elevated 
levels of GRP78 and were significantly more resistant to 5-FU (p=0.05) (112). 
Moreover, Pyrko and colleagues in 2007 found increased sensitivity to 5-FU in 
knockdown GRP78 glioma cells (113). Furthermore, GRP78 knockdown resulted in 
reduced cell proliferation, induction of CHOP and increased activated caspase 7 in 
temozolomide treated cells (113).  
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A study by Wang and colleagues in 2008(114) wanted to determine whether modifying 
levels of GRP78 could alter the potency of chemo-therapeutic agent V-16 on lung cancer 
cells NCI-H446 (114). V-16 is a topoisomerase inhibitor which prevents unravelling of 
DNA and subsequent DNA copying, and hence targets cells in S phase. 
 
 The study involved the up-regulation of GRP78 using the GRP78 inducer A23187 (a 
calcium ionophore which facilitates the transport of calcium ions into the ER) and 
reducing GRP78 levels using BAPTA-AM (a calcium chelator which reduces calcium 
levels in the ER).Cells were either treated with V-16 for 6h and then left to grow in fresh 
media without drug for a further 48h before analysis, or pre-incubated with either 
A23187 or BAPTA-AM for 24h followed by V-16. When V-16 was used alone 27.8% 
±1.48% of cells underwent apoptosis, as measured by flow cytometry. When the cells 
were treated with V-16 and A23187 the percentage of cells undergoing apoptosis was 
significantly reduced at 7% ±1%. With V-16 and GRP78 inhibitor BAPTA-AM the 
percentage of apoptotic cells was significantly increased relative to the controls at 56.5% 
±2.13% (P < 0.05) (114).  
 
Cell cycle profile analysis was also performed and it demonstrated that there was a 
significant decrease in the number of cells in S phase following treatment with A23187 
and a corresponding significant increase in the number of cells in S phase with BAPTA-
AM cells (114). Hence GRP78 inducers may decrease sensitivity whilst GRP78 
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inhibitors may increase to chemo-therapeutic agents whose predominant activity occurs 
during S phase of the cell cycle.  
 
In another study by Pyrko and colleagues in 2007(113), GRP78 was both down 
regulated using siRNA against GRP78 and up-regulated following transfection with 
lentivirus expressing human GRP78, in glioma cells U251 (113). Temozolomide is 
currently a first line chemo-therapeutic agent for patients with malignant gliomas and 
works by inducing DNA damage and subsequent apoptosis. Upon treatment with 
temozolomide there were significant decreases in colony survival in cells in which 
GRP78 had been knocked-down and significant increases in colony survival in cells in 
which GRP78 expression had been up-regulated as compared to parental cells (113).  
 
BIK is a proapoptotic protein which is up-regulated when breast cancer cells are 
deprived of oestrogen (109). Many anti-breast cancer agents work by reducing levels of 
oestrogen available to cancer cells. Tamoxifen is an antiestrogen and fulvestrant is an 
oestrogen receptor antagonist. BIK is located in the ER and is able to target BAX 
indirectly which results in release of cytochrome c. However a study by Fu and 
colleagues in 2007(109), demonstrated by coimmunoprecipitation that GRP78 is able to 
interact with BIK and prevent it from inducing apoptosis. Oestrogen dependent cells 
MCF-7/BUS were grown in oestrogen starved growth media which lead to the induction 
of BIK. (109). BIK is an upstream regulator of BAX. MCF-7/BUS cell which had been 
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transfected with adenovirus expressing GRP78, resulting in over expression of GRP78, 
were also cultured in low oestrogen growth media, In this case, BAX activation was 
reduced in comparison with parental cells. Furthermore cell transfected with siRNA 
against GRP78 increased levels of apoptosis in oestrogen starved cells. Hence up-
regulation of GRP78 may induce resistance to anti-breast cancer agents whose mode of 
action is to suppress the levels of available oestrogen.  
 
1.3.8 GRP78 and radioresistance 
 
Hypoxic head and neck tumours are highly radioresistant. Oxygen is needed to ensure 
maximum biological damage from ionizing radiation. A hypoxic environment of less 
than 3-4 mmHg oxygen leads to hypoxic cells requiring approximately three times as 
much radiation as normoxic cells in order to achieve the same levels of cytotoxicity 
(115). Tumour oxygen levels can therefore act as a predictive marker(116). The 
‘Eppendorf electrode’ is widely used in the research setting for detecting oxygen levels 
in tumours. In the laboratory setting carbonic anhydrase 9 (CA9) proteins can be 
detected by immunohistochemistry. CA9 is a gene which is transcribed by hypoxia 
inducible transcription factor (HIF- ) under hypoxic conditions (116).  
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A study by Schrijvers and colleagues in 2008(117), classified patient treated with 
radiotherapy for grade I or II laryngeal tumours into those with high expression of either 
HIF-  or CA9 or those with low expression(117). Of the 92 patient samples analysed, 
59 patients had a hypoxic expression pattern. Out of this subset of patients 32% (19/59) 
developed recurrence. In the 40 patients classified as having normoxic tumours only 6% 
(2/32) of patients developed recurrence (117). Similar studies found a significant 
decrease in local regional control and overall survival in head and neck patients with 
hypoxic tumours (classed as O2 concentration of ≤ 2.5 mmHg) treated with radiation 
therapy (118).  
 
Recent clinical trails have attempted to modify the hypoxic environment in order to 
improve radiosensitivity. A large Danish clinical trial (DAHANCA) randomly assigned 
414 patients with advanced cancer of the supraglottic larynx or pharynx to either 
radiation and placebo or nimorazole (115). Nimorazole is a hypoxic cell radiosensitizer 
which mimics oxygen by increasing the concentration of DNA damaging free radicals, 
but is not metabolized by cells (115). The trial found significant improvements in both 
local regional tumour control (p=0.002) and disease specific survival (p=0.01) in 
patients with high levels of hypoxia as determined by plasma concentrations of 
osteopontin (a hypoxia marker) but no significant improvements in patients with 
apparently normoxic tumours (115). Similarly phase II trials are currently taking place 
which are assessing the potential of ARCON therapy which combines accelerated 
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radiation therapy with carbogen breathing (95% O2 and 5% CO2) and nicotinamide 
(119). Nicotinamide prevents the acute closure of blood vessels thus reducing incidences 
of transient hypoxia (119).  
 
Hypoxic tumours may be more radioresistant not only due to the lack of oxygen but also 
due to the induction of certain genes under hypoxia such as GRP78 (119).  
 
Several studies have recently associated GRP78 as a radio resistant phenotype. Feng and 
colleagues in 2010 found GRP78 to be a potential prognostic biomarker with up-
regulation of GRP78 in tumours corresponding to radioresistance in patients with 
nasopharyngeal carcinoma (3). Lee and colleagues in 2008, found that silencing of 
GRP78 via transfection with siRNA significantly enhanced the sensitivity of 
glioblastoma cells to radiation (108). 
 
A study by Lin and colleagues in 2010 analysed the expression of proteins between 
parental and radioresistant cell lines in head and neck cancer (8). This included cells 
from poorly differentiated tongue squamous cell carcinoma (SAS cell line) and gingival 
epidermoid carcinoma (OECM1 cell line) (8). These parental cell lines were treated with 
ionising radiation at sequential 2 Gy intervals. After each treatment, surviving cells were 
sub-cultured and further exposed to 2 Gy fractions of ionising radiation. This sequence 
was continued until surviving cells had been subject to a total of 60 Gy. Protein 
Literature review 
 
67 
 
expression was then compared between parental and radioresistant cell lines. Amongst 
the proteins that were identified as being up-regulated in the radioresistant lines were 
three protein chaperones: Gp96, Grp78 and HSP60. Grp78 was up-regulated on average 
by 2.7 fold (8). 
 
1.3.9  Targeted inhibition of GRP78 
 
GRP78 acts as a protein chaperone, a gatekeeper to the Unfolded Protein Response, and 
as an anti apoptotic agent by preventing caspase activity.  
 
It is linked to tumorigenesis and is known to be over expressed in a wide variety of 
cancers such as lung, breast and colorectal cancer. Up-regulation of GRP78 appears to 
be an adaptive response of tumour cells, enabling these cells to tolerate their typical 
microenvironment of hypoxia and low glucose availability. Furthermore GRP78 over-
expression is implicated in chemo- and radio-resistance and therefore inhibition of 
GRP78 may aid in the treatment of cancer.  
 
Subtilase A (SubA) is a bacterial toxin, with proteolytic activity, derived from a specific 
strain of E. coli known as Shiga toxigenic E. Coli (STEC) (7). These strains of E. Coli 
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are known to cause life threatening outbreaks of haemolytic uraemic syndrome (HUS) 
such as in Australia in 1998 (7) as well as gastrointestinal disease. 
 
Paton and colleagues identified only GRP78 (a 72kDa protein) to be cleaved by SubA 
(7). 2D gel electrophoresis showed four spots that were specific to when cells were 
treated with SubA. Upon matrix assisted laser desorption/ionization-mass spectrometry 
(MALDI-MS) one of these four spots was identified as GRP78. Furthermore only 
GRP78 showed ‘significant size discrepancy’ from ~27kDa on the gel compared to 72 
kDa on the database. GRP78, which consists of 654 highly conserved amino acids, is 
cleaved, by SubA between two leucine residues at position 416-417. In addition, Paton 
and colleagues demonstrated that a single amino acid substitution at L416 ensured that 
SubA was no longer able to cleave GRP78 into two fragments (7) Although HSP72 
shares 7 out of 11 amino acid positions with GRP78, HSP72 does not contain the two 
leucine cleavage site. As expected Paton and colleagues did not find HSP72 to be 
cleaved by SubA (7). The protease site of SubA is located at Serine272. Paton et al, 
mutated SubA at this and this inactive mutant (SubAA272) was no longer able to cleave 
GRP78. 
 
EGF-SubA is a novel drug developed by SibTech® consisting of epidermal growth 
factor covalently bound to SubA. SubA, as previously discussed, is able to cleave 
GRP78 (72kDa) into two parts of weight 28kDa and 44kDa which leads to the activation 
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of the Unfolded Protein Response (UPR). Epidermal growth factor (EGF) is the 
naturally occurring ligand of the RTK transmembrane protein epidermal growth factor 
receptor (EGFR). Hence EGF-SubA has the ability to target deliver SubA to EGFR 
expressing cells. Should the same cells be over-expressing GRP78, it is conceivable that 
SubA mediated, GRP78 cleavage could result in cell death – a strategy that may be 
exploitable in the treatment of EGFR expressing tumours which also harbour high levels 
of GRP78.  
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2 Aims of this study 
Protein chaperone GRP78, a key component of the Unfolded Protein Response which is 
induced as part of a survival response under certain conditions of stress common in 
cancer (hypoxia/hypoglycaemia), has been shown to be up-regulated in a wide variety of 
cancers(1, 4). The up-regulation of GRP78 has been associated with both poor survival 
outcome as well as increased resistance to current cancer therapies (1, 8, 97, 120). Thus 
we will examine GRP78 expression in head and neck cancers. In addition to this we will 
investigate the impact of a novel compound EGF-SubA, which promotes proteolysis of 
GRP78. EGF-SubA will be tested upon a panel of laryngeal squamous cell carcinoma 
(LSCC) cells, in vitro, alone and in combination with clinically relevant agents.  
 
Although GRP78 is reported as being up-regulated in nasopharyngeal squamous cell 
carcinoma there are currently no published data regarding GRP78 levels in patients with 
laryngeal squamous cell carcinoma (LSCC) which constitute the most prevalent sub-
group of head and neck patients or in patients with either oropharyngeal or 
hypopharyngeal SCC (3). 
 
 Therefore we first determined whether GRP78 expression was up-regulated 
in SCC of oropharynx, larynx and hypopharynx via immunohistochemical 
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analysis of a tissue micro array of 190 patients. To establish whether GRP78 
is a potential prognostic biomarker in head and neck cancer, GRP78 protein 
expression was correlated with patient survival data. 
 
An increasing body of evidence suggests that up-regulation of GRP78 in tumours may 
lead to chemo- and radioresistance (1, 8, 97, 120). EGF-SubA is a novel cytotoxic drug 
that encompasses a bacterial endotoxin (SubA) covalently bound to EGF to permit 
targeting of EGFR-expressing cells and an enzymatically active moiety SubA which 
promotes proteolytic cleavage of GRP78 (5). 
 
 Therefore we explored whether EGF-SubA could enhance sensitivity in vitro 
to treatment modalities currently used in the treatment of head and neck 
cancer, in a panel of LSCC cell lines. Clonogenic assays were used to 
determine whether EGF-SubA could enhance the effects of ionising 
radiation. An MTT assay was used to measure any potential 
antagonistic/synergistic effects between cisplatin and EGF-SubA on cell 
viability/growth. In addition, flow cytometry-based Annexin V/PI assays 
were performed in order to determine the effects of combinations of these 
two drugs on apoptosis. 
 
Aims of this study 
 
72 
 
It has been reported that EGF-SubA cytotoxicity is dependent upon EGFR density and 
therefore EGF-SubA may, potentially, be more toxic to tumour cells of the head and 
neck which are known to over-express EGFR, compared to healthy tissue (5).  
 
 EGFR membrane expression will be compared to EGF-SubA sensitivity in 
our panel of cell lines in order to establish if there is a correlation between 
these two factors. LSCC membrane expression will be investigated via 
florescence generated from anti EGFR antibody conjugated PE and flow 
cytometric analysis.  
 
 Lastly we wanted to determine whether cetuximab, a monoclonal antibody 
(mAb) against EGFR, can inhibit the cytotoxicity of EGF-SubA (54). This 
could allow for a combined toxin-protectant approach where topical 
application of EGF-SubA peri- or post-operatively after tumour resection 
could be used, or as an oral rinse in patients who present with pre-malignant 
lesions of the oral cavity, with any potential systemic toxicity of EGF-SubA 
being abrogated by systemic administration of cetuximab.  
Performing the above experiments should allow for a greater understanding of the 
potential cytotoxic effects of EGF-SubA upon laryngeal squamous cell carcinoma cells, 
in vitro. Furthermore the role of GRP78 as a potential prognostic tumour biomarker will 
also be clarified.
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3 Materials and methods 
 
3.1 Materials and reagents 
Materials and reagents were provided by the following suppliers: 
 
Sigma Aldrich: ammonium per sulphate (APS), bovine serum albumin (BSA), 
bromodeoxyuridine (BrdU), depex polystyrene (DPX), dimethyl sulfoxide (DMSO), 
Dulbecco’s modified eagle medium (DMEM), foetal bovine serum (FBS), L-glutamine 
solution, MTT, non essential amino acids (NEAA), penicillin, phenyl methane sulfonyl 
fluoride (PMSF), Phosphate buffered saline (PBS), propidium iodide (PI), RNAse A, 
RPMI 1640 medium, Spermine, Trypsin-EDTA. 
 
Roche Applied Science: aprotinin, leupeptin, pepstatin, soybean trypsin inhibitor. 
 
Biorad: Bradford protein assay reagent, blotting grade non-fat dry milk powder. 
 
New England Biolabs: broad range protein marker. 
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Western Lightening Chemiluminescence: enhanced luminal reagent, oxidizing 
reagent. 
 
Southern Biotech: annexin V conjugated FITC. 
    
Amersham Biosciences: hybond ECL nitrocellulose membrane. 
 
Beckman coulter: isoton solution. 
 
Reagena: reastain quick diff fix, reastain quick diff red, reastain quick diff blue. 
 
Fisher: x-ray film (180mmx240mm) 
 
Vector laboratories: R.T.U vectastain ABC reagent, DAB substrate kit 
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3.2 Drugs 
EGF-SubA. Dissolved in 20nM Tris, 0.3M NaCl pH 9.0 (filter sterilized). Kept as stock 
at 7.5μM at -80oC. Stable at 4oC for one week. Manufactured and generously donated by 
SibTech Inc. ® USA. 
 
Cetuximab. MW 145781.6. Dissolved in PBS. Kept as stock at 5mg/ml (34.3μM) at 
4
o
C (do not freeze). Supplied by Erbitux®. Generously donated by Clatterbridge Centre 
for Oncology NHS Trust.  
 
Trastuzumab. MW 145531.5. Dissolved in PBS. Kept as stock at 21mg/ml (144μM) at 
4
o
C (do not freeze). Supplied by Erbitux®. Generously donated by Clatterbridge Centre 
for Oncology NHS Trust.  
 
AT13387 (HSP90 inhibitor). Dissolved in DMSO. Kept as stock at 10 mM at -80
o
C. 
Stable at room temperature for a week. Supplied and generously donated by Astex 
Therapeutics Ltd. UK.  
 
Cisplatin. MW 300.5. Dissolved in PBS. Kept as stock at 1mg/ml (3.3mM) at room 
temperature and in the dark. Generously donated by Clatterbridge Centre for Oncology 
NHS Trust.  
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Staurosporine. MW 466.53. Dissolved in DMSO. Kept as stock at 1mM at 4
o
C. 
Supplied by LC Laboratories USA. 
 
3.3 Antibodies 
3.3.1 Primary antibodies for western blot 
PARP, rabbit polyclonal antibody, final dilution of 3 g/ml, Abcam (ab6079) 
GRP78 (N-20), goat polyclonal antibody, final dilution of 3 g/ml, Santa Cruz 
Biotechnology (sc-1050) 
GRP78 (H-129), rabbit polyclonal antibody, final dilution 3 μg/ml, Santa Cruz 
Biotechnology (sc-13968) 
Tubulin (DM1A0), mouse monoclonal antibody, final dilution 1:10,000, Santa Cruz 
Biotechnology (sc-32293) 
Actin (C-2), mouse monoclonal antibody, final dilution 3 g/ml, Santa Cruz 
Biotechnology (sc-8432) 
EGFR (1005), rabbit polyclonal antibody, final dilution 3 g/ml, Santa Cruz 
Biotechnology (sc-03) 
HSP72 (SPA-810), mouse monoclonal, final dilution 50 ng/ml, Stressgen 
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3.3.2 Secondary antibodies for western blot 
Anti mouse IgG, horse radish peroxidase linked whole antibody, final dilution 1:2,500, 
Amersham 
Anti rabbit IgG, horse radish peroxidase linked whole antibody, final dilution 1:5,000, 
Amersham 
Anti goat IgG, horse radish peroxidase linked whole antibody, final dilution 1:5,000, 
Zymed 
 
3.3.3 Antibodies used for flow cytometry 
Anti EGFR (ICR10) conjugated PE, rat monoclonal antibody, 10 l of antibody added 
to 1 ml of cell suspension containing one million cells, Abcam (ab27764-50) 
Anti BrdU, mouse monoclonal, 20µl added to cell suspension of 100ul containing one 
million cells, BD Biosciences (BD347580) 
Donkey- anti mouse antibody conjugated FITC, 2.7µl added to cell suspension of 80 
µl containing one million cells. 
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3.4 Cell culture 
3.4.1 Cell lines 
University of Michigan squamous cell carcinoma cell lines (UM-SCC) of head and neck 
origin were kindly provided by Professor T. Carey at the University of Michigan 
Medical School, USA. With the exception of UM-SCC 1 which is of oral cavity origin 
and has mutant p53 status, the rest of the UM-SCC cell lines are of laryngeal origin. 
UM-SCC 17A and UM-SCC 17AS have p53 wild-type status. UM-SCC 10A and UM-
SCC 5 both have a single p53 mutation and retain a wild-type allele (heterozygous 
G245C and heterozygous V157F respectively). UM-SCC 11B and UM-SCC 81B have 
no wild-type p53 alleles (mutant C242S and H193R respectively). UM-SCC 12 is p53 
null (homozygous Q104X). 
 
Prostate cancer cells (PC3) were kindly provided by Mrs Carol Beasley, Department of 
Pathology, Liverpool University, UK.  
 
Mouse embryonic fibroblasts (MEF) used were both null in p53 and MDM2.  
 
Mouse hepatoma cells (Hepa 1c1c7) were kindly supplied by the Department of 
Physiology, Liverpool University UK. 
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3.4.2 Cell medium and growth environment 
All cell lines were grown in a humidified cell incubator at 37
o
C with 5% CO2. 
 
All UM-SCC, MEF and Hepa 1c1c7 cells were grown in DMEM, supplemented with 
10% (v/v) FBS, 2mM L-glutamine solution, 100 units/ml penicillin with 0.1mg/ml 
streptomycin solution and 100μM NEAA. 
 
PC3 cells were grown in RPMI 1640, supplemented with 10% (v/v) FBS, 100 units/ml 
penicillin with 0.1mg/ml streptomycin solution and 100μM NEAA. 
 
3.4.3 Cell culture techniques 
At all times aseptic technique was observed in order to avoid contamination. Tissue 
culture work was carried out in a class II laminar flow tissue culture cabinet. 
 
Cells were grown typically in 175cm
2 
tissue culture flasks with 25ml of media solution. 
Cells were split upon reaching 70-90% confluence. Media was removed and cells were 
washed once with 5ml of PBS. PBS was removed and 5ml of trypsin-EDTA was added. 
Adherent cells were then placed in the incubator until they had detached as observed by 
light microscopy. An equal volume of media as compared to trypsin was added. Cells 
were then pipetted up and down in order break up any clumps of cells. Cells were then 
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split according to the cell type. Slow growing cell lines were split typically in a ratio of 
1:5 whilst fast growing cell lines were split 1:10. 
 
3.4.4 Cryopreservation and recovery of cryopreserved cell stocks 
Cells with high confluence were passaged as described above with the remaining cells 
used to make up cryopreserved cell stocks as follows. First cells were centrifuged at 300 
× RCF, at 4
o
C for 5 minutes. The supernatant was removed and the pellet of cells was 
then resuspended in 1ml of freezing media consisting of 90% (v/v) FBS and 10% (v/v) 
DMSO and placed in a cryo-vial. The cells were kept in a -80
o
C freezer for 24h in a 
polystyrene box before being placed into a liquid nitrogen storage tank.  
 
When needed, cells from liquid nitrogen stocks were thawed immediately at 37
o
C and 
typically placed into a 75cm
2
 tissue culture flask along with 20ml of media. 
 
3.4.5  Cell grown under hypoxic or low glucose conditions 
 
On occasions UM-SCC cells were grown in low oxygen and low glucose conditions in 
order to mimic the typical tumour microenvironment. 
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For cells grown in normal glucose concentrations of 4 g/l, the standard Sigma DMEM 
media was used (which already contained a glucose concentration of 4 g/l), and 
supplemented with 10% (v/v) FBS, 2 mM L-glutamine solution, 100 units/ml penicillin 
with 0.1 mg/ml streptomycin solution and 100 μM NEAA. For the low glucose 
concentrations a second glucose free media manufactured by GIBCO called ‘DMEM 
(1x) liquid, no glucose’ was used in combination with Sigma DMEM. GIBCO DMEM 
was also supplemented with the above reagents apart from L-glutamine as it already 
contained this amino acid. Sigma DMEM was subsequently serially diluted in glucose 
free GIBCO DMEM in order to establish glucose concentrations of 0.4 g/l and 0.04 g/l. 
 
Cells grown in normoxic conditions were simply placed in the humidified cell incubator 
which contained 5% CO2 and 95% air. Cells that were to be grown in either 2% or 0% 
O2 levels were placed in air tight chambers (Billups Rothenberg inc Modular Incubator 
Chamber, Patent number 535 2414 box 977 del Mar California 92014). A petri dish 
containing distilled water was also put inside the air tight chamber in order to humidify 
the atmosphere. Chambers were initially flushed with a mixture of 5% CO2 and 95% 
nitrogen and then oxygen content was adjusted with the aid of an oxygen meter 
(Greisinger humidity meter GOX 100). The air tight chambers were then placed into the 
incubator.  
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3.5 Western blotting 
3.5.1 Reagents and buffers for western blotting 
 
SLIP Buffer (100ml) 
50 ml of 0.1 M HEPES (pH 7.5) 
10ml of glycerol 
0.1ml of Triton X-100 
15ml of 150mM NaCl 
0.05 g of BSA 
Solution made up to 100ml with distilled water 
SLIP Buffer was kept for seven days and stored at 4
o
C. 
 
PBS/Tween (4 litres) 
44.8g Na2HPO4.2H20 
9.67g NaH2PO4.2H20 
17.52g NaCl 
4ml of Tween 20 
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Tris-Glycine Electrophoresis Running Buffer (500ml/tank) 
25 mM Tris 
250 mM glycine 
0.1% (w/v) SDS 
 
Tris-Glycine Electrophoresis Transfer Buffer (1L/tank) 
25 mM Tris 
192 mM glycine 
20% (v/v) methanol 
 
4x Sample Buffer (10ml) 
0.25 M Tris (pH 6.8)  
8% (w/v) SDS 
40% (v/v) glycerol 
4mg/ml bromophenol blue 
1% (v/v) β-mercaptoethanol 
Diluted with distilled water to make 2x and 1x samples. Stored at -20
o
C. 
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SDS Polyacrylamide Separating Gel (10ml) 
 6% 7.5% 10% 12% 
H2O 5.8ml 5.42ml 4.8ml 4.3ml 
40% Acrylamide mix 1.5ml 1.87ml 2.5ml  3ml 
1.5 M Tris (pH 8.8) 2.5ml 2.5ml 2.5ml 2.5ml 
10% SDS 0.1ml 0.1ml 0.1ml 0.1ml 
10% APS 0.1ml 0.1ml 0.1ml 0.1ml 
TEMED 0.008ml 0.008ml 0.008ml 0.008ml 
Table 3.5.1SDS polyacrylamide separating gel formulation 
 
SDS Polyacrylamide Stacking Gel (10ml) 
7.225ml H20 
1.275ml of 40% (w/v) acrylamide mix 
1.25ml of 1 M Tris (pH 6.8) 
0.1ml of 10% (w/v) SDS 
0.1ml of 10% (w/v) APS 
0.010ml of TEMED 
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Ponceau Staining Solution (10X stock) 
2g Ponceau S 
30g sulphosalicyclic acid 
30g trichloroacetic acid 
H20 added to make a final volume of 100ml 
 
3.5.2 Cell pellets and protein extraction 
Cells were harvested via trypsinisation as described in section 3.4.3. Cells were then 
centrifuged for five minutes at a speed of 1000 × RPM. The supernatant was removed 
and the cells were resuspended in 1ml of PBS. The cells were then centrifuged again for 
five minutes at 1000 × RPM. The supernatant was removed and the pellet was stored at -
80
o
C for at least an hour before beginning protein extraction. 
 
SLIP buffer was placed on ice and combined with the following protease inhibitors: 
soybean trypsin inhibitor 100ug/ml, aprotinin 2 g/ml, leupeptin 0.5 g/ml, pepstatin A 
1 g/ml and phenylmethylsulfonyl fluoride (PMSF) 1mM. Proteases inhibitors prevent 
endogenous proteases from proteolysis of proteins of interest. Triton X-100 which is 
present in SLIP buffer permeabilises the cell membrane in order to release proteins. 
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Cell pellets were resuspended and broken up in 10-50 l of the above solution and left on 
ice for ten minutes. The samples were then centrifuged at 14000 × RCF for ten minutes 
at 4
o
C. The supernatants from each sample was then separated from their pellets and 
kept on ice. 
 
3.5.3 Calibration of protein samples 
Bradford reagent contains a dye called coomassie. When this dye binds to protein it 
produces a shift in absorbance from 465 nm to 595 nm. Hence this dye can be used as a 
colorimetric method for total protein quantisation. 
  
Initially a series of protein standards were prepared as follows. Bovine serum albumin 
(BSA) was serially diluted in the existing SLIP buffer, containing the protease 
inhibitors, at the following dilutions: 20, 10, 5, 2.5, 1.25, 0.625, 0.3125 and 0 mg/ml. 
Bradford protein assay reagent was then diluted 1:5 parts with distilled water. 2 l of 
each of the above concentrations were then placed into separate eppendorfs containing 1 
ml of the diluted Bradford reagent. These nine samples were vortexed and then placed in 
a spectrophotometer in order to establish a standard protein concentration curve. A 
coefficient of variable of less than 5% was deemed an acceptable level of calibration.  
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2 l of each of the cellular supernatants were added to 1 ml of diluted Bradford reagent 
and placed in the spectrophotometer. The volume of supernatant containing 50µg of 
protein was then calculated. Equal volumes of 2x sample buffer (section 3.5.1) was then 
added to the supernatant. 1x sample buffer was then added in appropriate volumes so 
that the final protein concentrations would be 50µg per 20 l. 
 
Sample buffer contains detergent SDS and reducing agent mercaptoethanol. When 
protein samples are heated SDS is able to disrupt secondary, tertiary, and quaternary 
structures of proteins producing a linear polypeptide chain which is coated in negatively 
charged SDS in a ratio of 1.4g of SDS for every 1g of protein (121). Mercaptoethanol is 
further able to denature the proteins by removing disulphide bonds(121). Proteins now 
become linear and have a negative charge which is proportional to their weight. During 
electrophoresis proteins are separated solely on the basis of how much negative charge 
they carry due to SDS and not on their original shape.  
 
 
Samples can be either stored at -80
o
C or heated at 100
o
C for 5 minutes to denature the 
proteins and then centrifuged at 14,000 × RCF for 5 minutes at 4
o
C, prior to being 
loaded onto the polyacrylamide gel.  
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3.5.4 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
The percentage polyacrylamide separating gel (Table 3.5.1) was chosen depending upon 
the molecular weight of the protein to be analysed. High molecular weight proteins such 
as epidermal growth factor receptor (EGFR) at 135kda required a low percentage gel of 
around 7.5% whilst low molecular weight proteins such as cyclin D at 35kda required a 
high percentage gel of around 12%.  
 
Glass plates of 0.75 mm were cleaned with 70% ethanol and placed in their stands. 
Distilled water was added in between the two plates, for five minutes, to check for 
leakage and then removed. The appropriate percentage polyacrylamide separating gel 
(Table 3.5.1) was then added until a level of 1.5 cm below the top of the glass plates was 
left. The top of the gel was then covered with water and left to set for 30 minutes. Water 
was then removed and stacking gel (section 3.5.1) was then added with a 0.75 mm 10 
well comb. This was left to set for a further 30 minutes.  
 
The plates along with the gel were then placed in a Mini Protean III electrophoresis 
chamber. 500ml of electrophoresis running buffer (section 3.5.1) was then added to 
completely fill the central chamber and half of the outside chamber. 15µl of broad range 
protein marker was added to the first well. 20 l of sample was then loaded into each of 
the other wells. 20 l of 1x buffer was placed in any remaining wells. The chamber was 
then subject to 200 v until the loaded samples had reached the bottom of the gel. 
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Hybond ECL nitrocellulose membrane, two pieces of 3mm Whatman® chromatography 
paper and two sponges where pre-soaked in transfer buffer (section 3.5.1). Stacking gel 
was discarded and the separating gel was placed in between the nitrocellulose membrane 
and chromatography paper. Two sponges were added on the outside and the whole entity 
was placed in a cassette. The cassette was placed in the chamber in such a way that the 
membrane faced the positive electrode whilst the gel faced the negative electrode. The 
negatively charged proteins on the gel would then run in the direction of the 
nitrocellulose membrane towards the cathode. Transfer buffer (section 3.5.1) was added 
to the chamber along with an ice pack in order to ensure cooling during transfer. The 
chamber was left at 100 v for one hour. 
 
3.5.5 Ponceau S Staining 
After protein transfer the membrane was removed and stained with Ponceau S (section 
3.5.1) to determine whether protein transfer was even. The membrane was cut 
horizontally at appropriate bands depending upon the molecular weight of the proteins to 
be studied and then washed in PBS Tween (section 3.5.1) to remove Ponceau S staining. 
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3.5.6 Incubation of antibodies 
The membrane was then incubated in PBS Tween with 5% blotting grade non fat dry 
milk powder for one hour, with agitation, in order to block antibodies from binding to 
non specific protein binding sites on the membrane itself. 
 
Primary antibodies (section 3.3.3) were diluted, according to their manufactures’ 
guidelines, in PBS Tween (section 3.5.1). The membrane was then incubated with 
agitation in its primary antibody for one hour followed by washing in PBS Tween for 
three cycles of ten minutes. Horse radish conjugated secondary antibodies (section 3.3.2) 
were diluted in PBS Tween and 5% milk powder. Membranes were then incubated and 
agitated for an hour with these secondary antibodies (section 3.3.2). This was then 
followed by three washes with PBS Tween. 
 
Anti bodies against human proteins are created by injecting antigens into animals such 
as rabbits and mice. During the primary response, when a foreign antigen is initially 
introduced, IgM antibodies are the first to appear. These lymphocytes do not produce 
memory cells. Later levels of IgG start to rise as lymphocytes start to produce both 
memory cells and plasma cells.  
 
When the foreign antibody appears the second time round, during a second injection, 
there is an immediate increase in IgG levels, as memory B cells differentiate into plasma 
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cells and produce IgG antibodies. It is these IgG antibodies which are commercially 
harvested. 
 
Polyclonal antibodies contain a mixture of antibodies which target different epitopes of 
the same antigen. The mixture of antibodies vary in specificity (whether the anti body 
recognizes other proteins) and affinity (how well the antibody attaches to the antigen) to 
one another. 
 
Monoclonal antibodies are a homogenous population of antibodies which recognize a 
single epitope. The antibodies are generated from a single B cell clone. The specific 
plasma cell is taken and fused with an immortal cell (myeloma cell line/fusion partner). 
This is known as a hybridoma. This fusion allows for the production of specific 
antibodies and indefinite growth in culture (122).  
 
Monoclonal antibodies produce cleaner bands on a western blot as there is less 
possibility of cross reactivity with other proteins, as there is just one antibody acting 
against one epitope. However the ability of polyclonal antibodies to recognize several 
epitopes increases the chance that at least some of the antibodies will bind to the protein 
of interest especially after possible deleterious effects that sample processing may have 
upon the protein (122).  
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3.5.7 Developing 
In order to visualize the proteins of interest, after probing with appropriate primary and 
horse radish conjugated secondary antibodies, the membrane was incubated for 60 
seconds with chemiluminescence ECL reagent. This consisted of equal volumes of 
Enhanced Luminol Reagent and Oxidising Reagent. Horse radish peroxidase is able to 
catalyse the oxidation of luminol into a chemical which emits light. The location and the 
amount of horseradish peroxidase corresponds to the position and quantity of protein, 
and subsequently to the location and amount of light emitted. The luminescence signal 
can be detected via the Kodak IM4000 image station or on X-ray film, at different 
exposure times ranging from 10 seconds to 30minutes.  
 
3.5.8 Detecting phosphorylated proteins via western blot 
In order to be able to prevent phosphatase enzymes from dephosphorylating 
phosphorylated proteins such as phospho-EGFR, the following phosphatase inhibitors 
were added to SLIP buffer (section3.5.1): 5 mM sodium fluoride, 1 mM sodium 
orthovandate and 10 mM sodium pyrophosphate. SLIP buffer containing phosphatase 
inhibitors was pre-cooled on ice. Media was removed and the six well tissue culture 
dishes were placed on ice. Approximately 150 μl of SLIP buffer containing phosphatase 
inhibitors was placed into one well. Cells were detached using a cell scraper and the cell 
suspension with SLIP buffer was transferred to the remaining wells. Lysates were then 
processed for SDS-PAGE and western blot analysis 
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3.6 Annexin V apoptosis detection 
3.6.1 General principles of flow cytometry 
A flow cytometer passes a laser through individual cells which are flowing in single file. 
The machine is then able to detect scattered light and fluorescence emissions from these 
cells. Light emitted in the forward direction from the laser and out of the cell is collected 
by the forward scatter channel (FSC) and light emitted at 90
o 
is collected by the side 
scatter channel (SSC).  
FSC intensity is related to cell size and can be used to distinguish between cell debris 
and live cells. SSC is associated with cellular granularity.  
 
Single cells from the same cell line will have similar FS and SS values to each other. In 
order to analyse the data generated from this group of cells and to exclude data from 
either cell debris or clumps of cells FS versus SS dot plots are generated and a gate is 
drawn around the central population of cells. 
  
Detection of fluorochromes by flow cytometry can be used as surrogate indicators for 
the presence and quantity of various receptors such EGFR via anti EGFR antibody 
conjugated to fluorochrome PE. Fluorochromes such as PI can bind to DNA and be used 
in cell cycle analysis. Other fluorochromes can be used for the detection of apoptosis as 
will be discussed later. 
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Fluorochromes are compounds which absorb light energy from the laser beam and 
release this energy in the form of both heat and light energy (fluorescence). The light 
emitted is always of a longer wave length (lower energy) to that absorbed from the laser 
and hence the emitted light is of a different colour. The difference between the energy 
absorbed from the laser and the energy emitted, in the form of fluorescence, is known as 
Stoke’s Shift. For example Argon-ion laser can excite FITC at 488 nm, which is close to 
FITC’s maximal absorbance of 490 nm (or the wave length at which the maximum 
amount of photons are absorbed). In turn FITC emits a fluorescence at a range of 475-
700 nm with maximum emission of photons at 525 nm. With the aid of optical filters 
various photodetectors (labelled as fl1, fl2, fl3) can then be used to detect appropriate 
range of wavelengths. 
 
3.6.2 Reagents and buffers used in Annexin V apoptosis detection 
 Annexin V conjugated FITC solution (5µl per sample) 
 Propidium iodide (PI) was dissolved at a concentration of 100 g/ml in 10 mM 
potassium phosphate (pH 7.4), 150 mM NaCl. (10µl per sample) 
 10x binding buffer consisting of: 0.1 M Hepes/NaOH (pH 7.4), 1.4 M NaCl, 25 
mM CaCl2. For 1X working solution 1 part 10x was diluted in 9 parts distilled 
water. 
 BSA(10mg/ml) in PBS (ice cold) 
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3.6.3 Protocol for Annexin V apoptosis detection 
Apoptosis is structurally characterized by chromatin condensation, reduction in cell 
volume(reduced FSC signal), and DNA defragmentation via endonucleases (123). 
During early stages of apoptosis there is loss of phospholipid membrane symmetry 
which leads to exposure of protein phosphatidyl serine (PS) from the inside to the 
outside of the cell membrane. PS expression at the cell surface causes identification and 
removal of apoptosing cells by macrophages in vivo (123). Annexin V can bind to PS in 
the presence of calcium and therefore Annexin V conjugated to fluorochrome FITC can 
be used to indicate early stages of apoptosis. During late apoptosis there is loss in 
membrane integrity and PI can now enter cells.  
 
A population of unfixed cells can be stained simultaneously with both PI (red 
fluorescence) and FITC (green fluorescence) conjugated Annexin V, and analysed by 
flow cytometry. Four subset populations of cells will appear on a dot plot graph of 
Annexin V versus PI. Cells which remain unstained are healthy cells. Cells which stain 
with just Annexin V are undergoing early apoptosis. Cells which stain with just PI are 
necrotic cells and cells which stain with both Annexin V and PI are cells which have 
entered late apoptosis. These four subsets can be divided using a quadrant and the 
percentage of cells in each quadrant can be calculated. 
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In order to first calibrate the position of the four quadrants, for each of the cell lines, a 
known healthy population of cells had to be compared to a known apoptotic population 
of cells. 
 
Staurosporine is a tyrosine kinase inhibitor which is a known potent inducer of 
apoptosis. Staurosporine was dissolved in its drug vehicle control DMSO and mixed 
with growth media at a concentration of 2 M. Staurosporine was applied to cells for 
24h. This group of cells would therefore help identify the areas of apoptosis in the 
quadrant. A control group of cells was grown for 24h with growth media mixed with 
appropriate volumes of DMSO. This group of cells would help to identify the location of 
healthy cells.  
 
Cells were harvested using trypsin as described previously (section 3.4.3) however the 
media that the cells were grown in was also collected in order to obtain dead cells that 
may have detached from the surface. It was important not to over trypsinise cells as this 
may also lead to damage to the cell membrane. A light microscope was used to 
determine when 80 to 90% of cells had detached from the surface of the well. 
Immediately trypsin was neutralised by adding equal amounts of growth media. 
 
Cellular concentrations per ml were determined by Beckman coulter counter and the 
volume of cells in solution was adjusted so that there would be one million cells per 
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sample. Cells were spun down at approximately 173 × RCF for five minutes at 4
o
C. 
Supernatant was removed and cells were resuspended and washed twice in a solution of 
ice cold PBS with 1% BSA. Samples were kept on ice.  
 
Cells were centrifuged at approximately 173 × RCF for five minutes at 4
o
C. The 
supernatant was removed and the one million cells were resuspended in 1ml of ice cold 
1x binding buffer (section 3.6.2). Samples were kept on ice and moved to the flow 
cytometer. Initially Beckman Coulter Epics XL flow cytometer was used and data was 
analysed using WIN MDI software (Windows multiple document interface for flow 
cytometry). However at the start of 2010 the use of a newer machine became available 
called BD FACSCalibur flow cytometer and the data was analysed on CellQuest Pro 
Software.  
 
The flow cytometry parameters were as follows: FL1 log to detect FITC Annexin V 
staining, FL2 log to detect PI, FS linear, SS linear, and 20,000 events.  
 
Sample were stained with 5 l of FITC Annexin V solution and 10 l of PI solution and 
left on ice and in the dark for exactly ten minutes before being tested. It is critical that 
sample are tested at exactly ten minutes as any further delay leads to photo bleaching as 
eventually all cells, if left long enough, will absorb PI. 
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3.7 Cell cycle analysis 
3.7.1 Reagents and buffers used in cell cycle analysis 
 70% ethanol (ice cold) 
 RNAse A 10mg/ml in 0.01M sodium acetate 
 1M Tris (pH 7.4) 
 PBS Tween (section 3.5.1) 
 BSA (10mg/ml) in PBS 
3.7.2 Protocol for cell cycle analysis 
In cells fixed with 70% ethanol, propidium iodide is able to pass through the membrane 
and attach to the DNA content. The more the DNA content of a cell the higher the 
fluorescent signal will be. In G1 the human cell has 23 chromosomes. S phase is the 
beginning of new DNA synthesis. So cells in S phase will have a higher fluorescent 
signal then cells in G1. Cells in G2 phase will contain 46 chromosomes thus these cells 
will give out the greatest amount of fluorescence.  
 
A late stage of apoptosis is DNA degradation. When cells are fixed with 70% ethanol 
and then subsequently rehydrated some degraded fragments of DNA are able to leach 
out. This lowers the DNA content of the cell and the fluorescence given out by these 
apoptotic cells are less than those given out by cells in G1phase. Hence these cells are 
indicated by a ‘sub-G1’ peak.  
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In order to identify and distinguish the sub-G1 peak from the G1 peak a group of cells 
treated with staurosporine 2µM (a known potent inducer of apoptosis) for 24 hours, was 
used and compared to an untreated healthy population of cells as described in section 
3.6.3. 
 
All cells, adherent and non adherent, were harvested as explained in section 3.6.3. Each 
sample contained a million cells as determined by Beckman coulter counter. Cells were 
than centrifuged at approximately 173 × RCF for five minutes at 4
o
C. Supernatant was 
removed and cells were resuspended and washed twice in a solution of ice cold PBS 
with 1% BSA. Samples were kept on ice.  
The supernatant was removed. 70% ice cold ethanol was added drop wise to the pellet, 
whilst slowly vortexing, until a total volume of 3 ml of 70% ethanol had been added. 
Vortexing helps break clumps of cells whilst the ethanol makes the cell membrane 
permeable to PI. Samples were left on ice for thirty minutes.  
 
Samples were centrifuged at approximately 173 × RCF, for five minutes at 4
o
C. 
Supernatant was removed and cells were washed twice and centrifuged in ice cold PBS 
Tween (section3.5.1) to remove residual ethanol. 
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As well as DNA, PI is able to bind none specifically to RNA. Therefore specific staining 
of DNA requires RNAse treatment. 
 
A solution of RNAse was prepared as follows. RNAse was dissolved at a concentration 
of 10mg/ml in 0.01M sodium acetate (pH 5.2). The solution was boiled for 15 minutes at 
100
o
C to inactivate DNase contaminants. The solution was cooled and nine parts of this 
solution was added to one part 1 M tris HCl (Ph 7.4). RNAse solution was aliquoted and 
stored at minus 20
o
C. 
 
Samples were centrifuges at approximately 173 × RCF, for five minutes at 4
o
C. 
Supernatant was removed and cells were mixed with the 100µl of the above RNAse 
solution. Samples were left on ice for five minutes. 
 
A stock of propidium iodide solution of 1mg/ml dissolved in PBS was kept at 4
o
C. For 
each sample 50 l of this stock solution was added to 850 l of PBS and then added to 
the samples already containing the RNAse. Samples were left in the dark for thirty 
minutes before being analysed by flow cytometer (section 3.6.3). 
 
Occasionally two cells in the G1 phase may adhere together and pass through the laser 
beam simultaneously. Subsequently these two aggregated cells will produce a similar 
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nuclear fluorescent signal as a single cell in G2/M phase. This could lead to an over 
estimation of the G2 population and hence a technique called doublet discrimination 
needs to be applied.  
 
The emitted fluorescent light signal produces three electronic signals: pulse 
area/integral, pulse width, and pulse height. Height is the maximum fluorescence, width 
is the cell transit time, and area is the total fluorescence produced (124). Usually only 
height signal is recorded for flow cytometry. However for doublet discrimination pulse 
height is plotted against pulse width in order to distinguish between single cells and 
aggregates. Single cells in G0/1 or G2/M will have similar transit times (pulse width) 
whilst aggregated cells have a longer transit time and can easily be gated out (124). 
Aggregates can be clearly seen to the left of the dot plot in Figure 3.7.1. The region of 
single cells is then gated and only data produced form this area is analysed. 
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Figure 3.7.1: Doublet discrimination. 
 Where pulse width is plotted against pulse area in order to exclude aggregates.(Figure 
reproduced from reference (124). 
 
The flow cytometry parameters were as follows: Fl2 linear to detect PI, FL2-Width 
linear, FL2-Area linear, FS linear, SS linear, and 20,000 events. 
 
 
 
 
This text box is where the original thesis contained the diagram showing ‘doublet 
discrimination’ which was reproduced from reference (124). 
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3.8 DNA synthesis measurement via BrdU assay 
3.8.1 Reagents and materials for BrdU assay 
 BrdU (1mM stock stored at -20oC) 
 Anti BrdU, mouse monoclonal, 20µl added to cell suspension of 100µl 
containing one million cells 
 Donkey- anti mouse antibody conjugated FITC, 2.7µl added to cell suspension of 
80µl containing one million cells. 
 HCl/Triton X-100 solution = 2 N HCl + 0.5% (v/v) Triton X-100  
 PBST = PBS + 0.5% (v/v) Tween-20  
 PBSTB = PBS + 0.5% (v/v) Tween-20 + 1% (w/v) BSA 
 Citrate phosphate/spermine = 3.4mM, pH 7 citrate phosphate + 0.5mg/ml 
spermine  
 Ethanol 200 proof made to 70% using distilled water. NB do not use ordinary 
ethanol as it contains metal contaminants 
 RNAse A 10mg/ml in 0.01M sodium acetate (section 3.7.1) 
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3.8.2 Protocol for BrdU assay 
In cell cycle profile analysis, of PI staining of fixed permeabilised cells, it is often hard 
to distinguish clearly between regions of S phase and either late G1 or early G2 phase. In 
order to identify cells which are specifically in S phase, cells can be pulsed with 
bromodeoxyuridine (BrdU). BrdU is a thymidine analog which is incorporated during 
DNA synthesis (S phase). Subsequently the presence of BrdU can be detected via the 
use of first primary monoclonal antibodies attaching to BrdU and then secondary 
antibodies conjugated to FITC (FL1). The primary antibody only binds to BrdU in single 
stranded DNA, therefore before the antibody can be used DNA must be denatured by 
either heat treatment or strong acids(125). 
 
 DNA is also stained with PI (FL2) and then FL2 vs. FL1 dot plots are created in order 
to see G1, S, and G2/M regions. Only cells which have undergone S phase at the time of 
BrdU application will be both FITC and PI positive whilst cells in G1 and G2/M will 
only be PI positive. 
 
Exponentially growing cells were pulsed for 30 minutes at a final concentration of 1µM 
BrdU (from 1mM stock) in current media at 37
o
C. Cells were then harvested as 
explained in section 3.6.3 and then centrifuged at approximately 173 × RCF. 
Supernatant was removed and the pellet was resuspended in PBS. Again the cells were 
centrifuged at approximately 173 × RCF, for 5minutes, and the pellet was resuspended 
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in 3ml spermine-citrate buffer in order for nuclei to be extracted from cells. Cells were 
left for ten minutes on ice. 
 
Nuclei were then centrifuged at 400 × RCF for 5 minutes, supernatant was removed, and 
the pellet was resuspended in 3ml PBST. Nuclei were then centrifuged again at 400× 
RCF and supernatant was removed. Nuclei were then fixed via vortexing and adding 
drop wise a total of 3ml of 70% ethanol (200 proof, ice cold), in order to make the 
nuclear membranes permeable to PI. Samples were left on ice for one hour. 
 
Nuclei were then centrifuged at 400 × RCF, for 5 minutes, and resuspended in 
PBS/Tween-20. Again samples were spun and resuspended in 100µl RNAse A solution 
as used in section 3.7.2. Samples were left on ice for five minutes.  
 
A total of 3ml of HCl/Triton X-100 solution was added drop wise to the above samples 
whilst vortexing . This was in order to denature the DNA so that they would become 
single stranded which would allow for primary antibody binding. Samples were left at 
room temperature for 30 minutes. 
 
Acid was then neutralised by adding 6 ml of 0.1M sodium borate (using twice the 
volume of HCl previously used). Samples were incubated for 10 minutes on ice. 
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Samples were centrifuged at 400 × RCF, supernatant was aspirated, and pellets were 
resuspended in 1 ml of PBSTB solution. Haemocytometer was used to adjust the 
concentration of nuclei to one million in 100µl of PBSTB solution.  
 
20µl of the primary antibody against BrdU was added to the above 100ul solution (20µl 
of the stock primary antibody per million nuclei). Samples were incubated for 30 
minutes in the dark at room temperature. 
 
Samples were centrifuged at 400 × RCF, for 5 minute, supernatant was aspirated, and 
pellets resuspended in 4 ml PBSTB solution. Samples were again centrifuged and 
resuspended in 80ul of PBSTB solution. 2.7 µl of FITC conjugated secondary antibody 
was then added. Samples were incubated for 30 minutes in the dark at room temperature. 
 
4 ml of PBSTB solution was then added and samples were centrifuged at 400 × RCF. 
Supernatant was removed and the pellet was resuspended in 1 ml of 10µg/ml PI in PBS 
solution. Samples were left in the dark on ice for ten minutes and then taken to the flow 
cytometer for analysis. 
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The flow cytometry parameters were as follows: FL1 linear to detect FITC, Fl2 linear to 
detect PI, FL2-Width linear, FL2-Area linear, FS linear, SS linear, and 20,000 events. 
Doublet discrimination as described in section 3.7.2 was also performed. 
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3.9 Detection of EGFR membrane expression via flow 
cytometry 
3.9.1 Reagents and materials 
 Anti EGFR (ICR10) antibody conjugated to PE from Abcam (ab27764) 
3.9.2 Protocol for detection of EGFR membrane expression 
In order to measure the expression of membrane EGFR levels as opposed to total 
cellular EGFR levels flow cytometric analysis was used. Anti EGFR (ICR10) antibody 
conjugated to PE from Abcam (ab27764) was used in order to detect membrane EGFR. 
This antibody was selected as it binds to an extracellular epitope of EGFR.  
 
Cells were grown, trypsinised and then adjusted in order to contain a million cells in 1 
ml of growth media, with the aid of a coulter counter. The cells were then incubated 
with 10 μl of the antibody and left in the dark at room temperature for 30 minutes. After 
this time cell were washed with 1 % BSA, PBS, pH 7.4 solution and centrifuged at 
approximately 173 × RCF for five minutes at 4
o
C. The supernatant was removed and 
cells were washed again for two more cycles. Washes were to ensure that any unbound 
antibody was removed from the sample before analysis. Finally the million cells were 
placed in 1 ml of 1% BSA, PBS, pH 7.4 solution and processed for flow cytometric 
analysis.  
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Beckman Coulter Epics XL flow cytometer was used and data was analysed using WIN 
MDI software (Windows multiple document interface for flow cytometry). FL2 log was 
used to detect PE average fluorescence (AF) was recorded via the FL2 log channel.  
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3.10 Immunohistochemistry 
 
A tissue micro array (TMA) consisting of tumour samples from 190 patients with head 
and neck squamous cell carcinoma was analysed via IHC for GRP78 expression. 28 
tumours were of hypopharynx origin, 92 were of laryngeal origin, and 70 were of 
oropharyngeal origin. For each patient, three separate representative tumour cores were 
included in the TMA. In addition to SCCHN cores taken from patients, 
histopathologically normal adjacent tissue samples were also acquired from 45 patients. 
The TMA was obtained from Aintree Hospital. 
 
3.10.1 Reagents and materials for immunohistochemistry 
 10mM citric acid buffer pH 6 (made freshly each time) 
 1% H2O2 in methanol 
 R.T.U Vectastain ABC reagent 
 DAB solution (step1: add 2 drops of buffer stock solution to 5ml distilled H2O. 
Step 2: Add 4 drops of DAB and 2 drops of hydrogen peroxide solution and mix 
well.) 
 Acid water = 2ml glacial acetic acid to 98 ml distilled H20  
 Bluing solution = 1.5ml NH4OH to 89.5ml of 70% (v/v) ethanol 
  Haemotoxylin 
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3.10.2 Protocol for immunohistochemistry 
There are two main antibody staining methods called direct and indirect method. The 
direct method involves the primary antibody being directly conjugated to horse radish 
peroxidase (122). The procedure is quick but there is not any signal amplification. 
 
 In the indirect method the unlabeled primary antibody attaches to the tissue antigen, 
followed by a secondary antibody which attaches to the primary antibody. The 
secondary antibody is against the IgG of the animal species in which the primary 
antibody was raised in. The indirect process produces a higher signal as several 
secondary polyclonal antibodies can react with various antigen sites on the primary 
antibody. 
  
 The secondary antibody is conjugated to biotin. Tissue samples are then incubated with 
avidin conjugated to the enzyme horse radish peroxidase. Avidin is a glycoprotein with a 
high affinity to biotin and therefore avidin biotin complexes (ABC) are formed. 3,3’-
diaminobenzodine (DAB) is then placed on the tissue samples along with H2O2. Where 
there is a complex of antigen-primary antibody-secondary conjugated biotin-avidin 
conjugated to horse radish peroxidase, H2O2. is able to oxidize DAB into a brown stain. 
The reaction is catalysed by horse radish peroxidase and H2O2 turns into water. 
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Although formalin fixation is good at preserving the morphology of the cell it may cause 
alterations in protein structure by forming crosslinks and therefore making the epitopes 
of interest unavailable to the primary antibody(122). Furthermore formalin may also 
reduce the overall antigen’s negative electrostatic charge therefore reducing the affinity 
between the epitopes and the positively charged antibodies. In order to reverse these 
changes, induced by formalin, a process known as antigen retrieval is used in cases 
where the primary antibody has failed to bind (122). 
 
Below I will discuss the protocol for the indirect ABC method of staining.  
 
Formalin fixed, paraffin embedded immunohistochemistry tissue slides were first 
dewaxed by placing then in xylene for 10 minutes. 
 
Slides were rehydrated by agitating them for 30 seconds in 100%, 95%, and 70 % 
ethanol. Slides were then washed in water for 5 minutes whilst agitating. 
 
Endogenous peroxidase activity was blocked by placing slides in 1%(v/v) H2O2 in 
methanol for 12 minutes. Slides were then washed and agitated in PBS Tween (section 
3.5.1) for 5 minutes. 
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For antigen retrieval slides were boiled in the microwave at maximum power for 15 
minutes in citric acid buffer solution. Slides were then left to cool in the buffer for 20 
minutes. This technique is known as heat induced epitope retrieval (HIER). 
 
Slides were then washed and agitated in PBS Tween (section 3.5.1) for 5 minutes. A 
PAP pen was used to make a hydrophobic barrier around the border of the tissue 
samples on the slides. 
 
Tissue samples were incubated for 20 minutes at room temperature in 2.5% (v/v) normal 
serum in PBS, from species in which secondary antibody was raised. This prevents non 
specific binding of secondary antibody. During all incubation periods slides were kept in 
a humidified chamber to prevent tissue samples drying out. 
 
Serum was removed and tissue samples were incubated with primary antibody diluted in 
the above 2.5% (v/v) serum in PBS. In order to test for the specificity of the secondary 
antibody the primary antibody was omitted.  
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Slides were then washed and agitated in PBS Tween (section 3.5.1) for 5 minutes. Slides 
were then incubated for 30 minutes in 0.5% (v/v) secondary antibody which was diluted 
in 2.5% (v/v) serum in PBS. 
 
Slides were then washed and agitated in PBS Tween (section 3.5.1) for 5 minutes. Slides 
were then incubated with RTU Vectastain ABC reagent for 30 minutes. 
 
Slides were then washed and agitated in PBS Tween (section 3.5.1) for 5 minutes. Slides 
were then incubated in DAB solution in the dark for 10 minutes. Staining intensity was 
checked every 5 minutes. After use of DAB solution, all DAB solution was bleached for 
24h as DAB is a suspected carcinogen. 
 
Slides were then rinsed in normal tap water for 5 minutes. Nuclear staining of tissue 
samples was performed via incubating slides in haemotoxylin for 1 minute. 
 
Slides were then rinsed under tap water until water turned clear (approximately 10 
seconds). Slides were agitated for ten seconds in acid solution and then rinsed in tap 
water. Slides were then agitated in bluing solution for 1 minute and then rinsed in tap 
water.  
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Samples were dehydrated by agitating in 70%, 95%, 100% ethanol and then left in 
xylene for 10 minutes. Cover slips were then placed onto slides with vectamount glue. 
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3.11 Clonogenic assay to measure effects of possible drug 
radiosensitivity 
3.11.1 Reagents and materials for clonogenic assay 
 Colony fixation staining solution consisting of: 
6% (v/v) glutaraldehyde, 0.5% (w/v) crystal violet, in PBS  
3.11.2 Protocol for clonogenic assay 
One of the main aims of cancer treatment is to prevent recurrence of tumour growth. 
Clonogenic assay measures the ability of individual cells to proliferate and form 
colonies after exposure to ionizing radiation, and this can be achieved in combination 
with cytotoxic drug treatments if required (126). 
 
Initially T25 flasks were used as these could fit easily into the radiation chamber. A 
separate T25 flask was used for each drug and radiation dose permutation. Equal number 
of cells were seeded into each T25 flask so that after 24h their confluence would be 
around 50%. Cells were then treated with drug or vehicle controls in appropriate media 
for a further 24h. Pilot studies were performed in order to find the maximum dose of 
drug that would not lead to a reduction in the number of colonies formed when 
compared to controls under no radiation exposure. 
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Cells were then irradiated with 0, 1, 2, or 4 Gy using a 
137
Cs source which delivers 1Gy 
in 23 seconds of γ-radiation.  
 
Plating of a sufficient number of cells, without there being an overgrowth of cells, was 
needed in order to be able to count a reasonable amount of individual colonies (50-150 
colonies per well). In order to determine the best concentration of cells for each cell line, 
cells were plated at a range of concentration from 100 to 10,000 per well of a six well 
plate and left for two weeks in pilot studies. It was found that the optimum number of 
cells to seed per well under 0 Gy were: UM-SCC 5 = 1200, UM-SCC 12 = 800, UM-
SCC 17A = 7000, UM-SCC 81B = 800.  
 
After radiation cells were then removed from T25 flasks and trypsinised as described in 
3.4.3.Cell suspension concentrations were determined by haemocytometer and adjusted 
so that equal number of cells were seeded into six well plates in set of triplicate samples. 
Cells were seeded at 1x, 3x and 10x of the above stated concentrations. At low radiation 
doses 1x cell concentrations would produce a sufficient number of colonies however at 
higher radiation doses of 6 Gy typically only 10x concentrations would produce enough 
colonies. 
 
 Cells were then left to grow for two weeks to allow for colony formation. Colonies are 
defined as a focus of 50 or more cells. This allows for five or more cell doublings.  
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Media was removed and cells were rinsed with PBS. 1 ml of colony fixation solution 
was placed in each well of the six well plates and left for 30 minutes. The solution was 
removed and wells were submerged under tap water to remove excess solution. Plates 
were then left to dry and colonies were counted using a light microscope. 
 
 Plating efficiency (PE) = number of colonies/number of cells seeded under 0 Gy 
and no drug treatment.  
 Survival fraction (SF) = no of colonies formed after treatment/(no of cells seeded 
× PE) 
 Survival (S) data after radiation dose (D) was fitted to the linear quadratic model 
S(D)/S(0) =exp(-(αD+βD2)). Where linear α and quadratic β values were 
calculated used SPSS PASW Statistics version 18 as described by Franken and 
colleagues (126).  
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3.12 MTT assay 
3.12.1 Reagents for MTT assay 
 MTT 5mg/ml in PBS (filter sterilized and kept as stock at -20oC) 
 DMSO 
3.12.2 Protocol for MTT 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT) assay is a rapid 
quantitative colorimetric method for measuring the amount of viable cells. It is often 
used to measure the cytotoxic effects of drugs in vitro. Healthy cells have viable 
mitochondria which contain mitochondrial dehydrogenase enzymes. These enzymes are 
capable of reducing yellow MTT into formazan a purple precipitate (127). The more 
cells that are viable the more MTT will be reduced, resulting in a higher MTT score. 
Therefore MTT score is a function of viability/growth of cells. DMSO was used to 
permeabilise cells and to dissolve formazan. The absorbance was measured at an optical 
density (OD) of 590 nm via a 96 well plate reader. 
 
Cells were harvested as described in section 3.4.3. A haemocytometer was used to count 
the concentration of cells. Cells were seeded in 96 well plates using a 12 multi channel 
tip pipette aid. 5000 cells per well were seeded for MEF cell lines; 10,000 cells per well 
were seeded for UM-SCC 1, 81B and Hepa 1c1c7; 15,000 cells per well were seeded for 
UM-SCC 5, 12, 17A and 17AS; 20,000 cells were seeded per well for UM-SCC 10A. At 
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these concentrations cells could proliferate for 7 days without the need for them to be 
passaged. 200µl of growth media was used per well. Hence for example 200µl of MEF 
cell solution at a concentration of 25,000 cells/ml was seeded into each well. Cells were 
then left for 24h for them to adhere to the plates.  
 
After the initial 24h fresh drugs (or drug vehicle control for comparison) and media were 
replaced daily for a total of 7 days via a multi channel pipette. Cells were seeded in 
quadruplicates for each of the different concentrations of drug used. Care was taken not 
to dislodge any cells when either aspirating off media or adding media to wells. 
 
For each of the 7 days a subset of cells were taken for MTT analysis. 20µl of MTT stock 
was added into each well, in addition to the existing 200µl of media. 96 well plates were 
then incubated for exactly 3 hours and 30 minutes at 37
o
C. 
  
190µl of solution was then removed from each well and discarded. 100µl of DMSO was 
then added to each well. Plates were then left for a further 30 minutes at 37
o
C. After this 
time plates were taken to the plate reader and the absorbance was read at an OD of 590 
nm.  
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3.13 Cell proliferation assay via cell counting 
3.13.1 Reagents and materials for cell counting 
 Isoton solution 
3.13.2 Protocol for cell counting 
Cell counting was performed in order to measure what effects drugs, such as cetuximab 
and EGF-SubA had upon cell proliferation. 
 
Cells were seeded evenly on 12 well plates at 30-40% confluence. At this confluence 
cells had room to grow for up to an additional seven days without being passaged. Each 
well had a surface area of 3cm
2 
and 1ml of growth media was provided in each well. 
Cells were left for 24h in order to give time for them to adhere to the surface of the well. 
After 24h, media was replaced with fresh media containing either drug or drug vehicle 
control. Cells were exposed to the drugs for a total period of five days with fresh drugs 
and media replaced daily. 
 
Cells were then harvested prior to drug treatment, and 1, 2, 3, 4, 5 days after drug 
treatment. Media was removed and wells were washed with 0.5ml PBS. PBS was 
removed and 0.3ml of trypsin was added. Once cells had detached 0.3ml of growth 
media was used to neutralise the trypsin in each well. The volumes of trypsin and 
neutralising media were kept constant throughout the experiment. 
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From the total 0.6ml of cell solution, from each well, 0.1ml was taken and added to 
10ml of Isoton solution (Beckman coulter). The concentration of cells per ml was then 
calculated using a Beckman coulter counter (Z2 coulter® particle count and size 
analyser). Prior to counting the cells the Beckman coulter was calibrated by flushing it 
with Isoton solution. Flushing was repeated until the machine gave a cell count of less 
than 4000 cells/ml from just Isoton solution alone. 
 
3.14 Statistics 
SPSS PASW statistics package version 18 was used to calculate the following statistics: 
log-rank test, univariate and multivariate Cox regression analysis, Pearson Chi Square 
test of independence and Spearman’s rank correlation coefficient. 
 
SPSS PASW statistics package version 18  was also used to calculate linear α and 
quadratic β components of the linear quadratic model S(D)/S(0) =exp(-(αD+βD2)), as 
described by Franken and colleagues (126). 
 
Student’s t test was calculated using Microsoft Excel 2007.  
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4 Results part 1: investigating GRP78 as a potential 
prognostic biomarker and inhibiting the activity of 
this protein with EGF-SubA 
4.1 Validation of anti-GRP78 antibody sc-13968 for use in 
IHC 
Hypoxia and glucose deprivation are prominent features in the tumour environment, due 
to the poorly established microvasculature (128-131). Under such conditions the 
Unfolded Protein Response is stimulated and a number of genes are induced including 
GRP78 (128-130). GRP78 has been shown in a number of studies, using proteomics and 
IHC, to be over-expressed in a variety of tumours including: hepatocellular carcinoma 
(HCC) (130), pancreatic adenocarcinoma (132), breast cancer (112), melanoma (133), 
oesophageal adenocarcinoma (120), glioblastoma (108), lung cancer (134) and prostate 
cancers (129) and in particular in those tumours which had a poorer outcome. This 
appears not to be a simple bystander effect as GRP78 is implicated in tumorigenesis as 
mammary tumours are more numerous and grow at a faster rate in wild-type GRP78+/+ 
mice compared with genetically modified GRP78 -/- or GRP78 +/- mice (see section 
1.3.3 for details) (98, 99).  
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Detection of squamous cell carcinoma of the Head and Neck (SCCHN) is based on 
clinical examination, tumour tissue biopsy and histopathological assessment. 
Identification of possible biomarkers that are predictive of early tumour development, or 
prognosticate response to treatment and/or survival outcome would be of obvious benefit 
in early diagnosis and for tailoring the best treatment options to individual patients. To 
date, only one study focusing on nasopharyngeal SCC by Feng et al., 2010, has 
identified GRP78 as a possible biomarker in head and neck tumours (see section 1.3.8) 
(3)Hence we investigated GRP78 as a prognostic biomarker of outcome using 
immunohistochemical analysis of a previously constructed tissue microarray consisting 
of tissue samples from laryngeal, oropharyngeal and hypopharyngeal tumours. 
 
An anti-GRP78 antibody (sc-1050) - a goat polyclonal antibody from Santa Cruz 
Biotechnology - has been used in several immunohistochemical studies, including the 
above mentioned study by Feng et al., in order to analyse the expression of GRP78 
between various patient samples (3, 4). Antibodies may cross react with other proteins 
and therefore it is important to first validate the antibody specificity prior to IHC via 
other techniques such as western blot analysis. This was particularly important in this 
instance as we noted a doublet in the 72kDa region during previous experiments using 
this anti-GRP78 antibody (sc-1050), in which we had used western blotting to quantify 
the relative presence of GRP78. The most obvious explanation for this finding is that sc-
1050 is cross reacting with another protein of similar molecular weight. 
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An initial BLAST search confirmed that the GRP78 protein shares 65% amino acid 
identity with HSP72 immediately suggesting its identity as the cross-reacting species.  
 
One of our initial objectives was to find an antibody to use for, IHC, which was specific 
for GRP78 and did not cross react with other proteins. First the specificity of anti-
GRP78 antibody (sc-1050) was tested by western blot. Paton and colleagues identified 
only GRP78 (a 72kDa protein) to be cleaved by SubA (7). 2D gel electrophoresis 
showed four spots that were specific to when cells were treated with SubA. Upon matrix 
assisted laser desorption/ionization-mass spectrometry (MALDI-MS) one of these four 
spots was identified as GRP78. Furthermore only GRP78 showed ‘significant size 
discrepancy’ from ~27kDa on the gel compared to 72 kDa on the database. GRP78, 
which consists of 654 highly conserved amino acids, is cleaved, by SubA between two 
leucine residues at position 416-417. In addition, Paton and colleagues demonstrated that 
a single amino acid substitution at L416 ensured that SubA was no longer able to cleave 
GRP78 into two fragments (7) Although HSP72 shares 7 out of 11 amino acid positions 
with GRP78, HSP72 does not contain the two leucine cleavage site. As expected Paton 
and colleagues did not find HSP72 to be cleaved by SubA (7). 
 
Cleavage of GRP78, by SubA, results in two fragments of approximately 44 and 28 kDa. 
Therefore we used EGF-SubA to test the specificity of anti-GRP78 antibodies since 
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following treatment with EGF-SubA we would expect a reduction in the intensity of the 
72kDa band and the appearance of a band corresponding to one or other of the cleavage 
products of GRP78, depending on which fragment contains the epitope recognised by 
the antibody. Therefore UM-SCC cells were treated with either 1nM EGF SubA for 24h 
or 48h or with drug vehicle control. UM-SCC cells were then processed for western blot 
analysis as described in section 3.5. The concentration used in our experiment was the 
same concentration of EGF-SubA as used by Backer and colleagues in their 2009 study 
on prostate and breast cancer cells (5).  
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Figure 4.1.1 EGF-SubA promotes cleavage of GRP78 in a panel of LSCC cell lines.  
Cells were either treated with EGF-SubA at 1nM or appropriate amount of drug vehicle 
for controls. 35 μg of protein was loaded into each lane and anti-GRP78 antibody (sc-
1050) was used at a concentration of 3 μg/ml. The antibody recognizes the epitope at the 
N- terminus of GRP78 protein and therefore cleaved GRP78 can be seen between 30 
kDa and 46 kDa molecular weight marker bands .In addition, the doublet referred to 
previously at the 72kDa region can also clearly be seen. 
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The western blot in Figure 4.1.1 shows two bands between marker weights of 58 kDa 
and 80 kDa. Upon application of EGF-SubA the slower migrating band disappeared. It 
was thought that this band was likely to be GRP78 as this was the only protein found to 
be cleaved by SubA in the study by Paton and colleagues (7). Subsequently a new band 
appeared between marker weights of 30 kDa and 46 kDa. It was suspected that the new 
band was the 44 kDa cleaved product of GRP78 which contains the N-terminal fragment 
recognised by anti-GRP78 antibody (sc-1050). 
 
Anti-GRP78 antibody (sc-1050) appeared to strongly cross react with another unknown 
protein running just ahead of the un-cleaved GRP78 band. Furthermore the intensity of 
this band was not altered by the application of EGF-SubA. If this antibody was used as a 
primary antibody for IHC, it would mean that analysis of GRP78 expression in the TMA 
would be unreliable as IHC staining from GRP78 to that of the unknown protein would 
be indistinguishable. Therefore this antibody was deemed unsuitable for use in IHC. 
 
Next the specificity of anti-GRP78 (sc-13968), rabbit polyclonal antibody as a possible 
alternative was examined by western blot. Gels were loaded with lysates from the same 
samples as used in the western blots shown in Figure 4.4.1. In order to determine 
whether anti GRP78 antibody (sc-13968) cross reacted with any other protein whole 
membranes were blotted with anti-GRP78 antibody (sc-13968). As seen in Figure 4.1.2 
anti-GRP78 antibody (sc-13968) revealed a band at a position between marker weights 
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of 58 kDa and 80 kDa. Upon application of EGF-SubA this band disappeared, and a new 
band between marker weights of 23 kDa and 30 kDa appeared. The new band appears to 
be the 28 kDa cleaved carboxy-terminal fragment of GRP78 which contains the epitope 
recognised by this antibody. There appeared to be considerably less cross reactivity to 
other proteins with anti-GRP78 antibody sc-13968 than with sc-1050.  
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Figure 4.1.2 EGF-SubA promotes cleavage of GRP78 in a panel of LSCC cell lines. 
 LSCC cells were treated with EGF-SubA at 1nM or appropriate amount of vehicle for 
controls in order to determine the specificity of anti-GRP78 antibody (sc-13968). 35 μg 
of protein was loaded into each lane and whole membranes were incubated with anti-
GRP78 antibody (sc-13968) at a concentration of 3μg/ml. The antibody recognizes the 
epitope at the C terminus of GRP78 protein and therefore cleaved GRP78 can be seen 
between molecular weight marker bands of 23 kDa and 30 kDa. 
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Figure 4.1.3 Anti-GRP78 antibody (sc-1050) cross reacts with HSP72. 
 UM-SCC 81B cells were treated with either HSP90 inhibitor AT13387 at 1μM for 24h 
or with drug vehicle control. Membranes were probed with antibodies as indicated: 
anti-HSP72 antibody at 50 ng/ml (lanes 1 & 2), anti-GRP78 antibody sc-13968 at 3 
µg/ml (lanes 3 & 4) and anti-GRP78 antibody sc-1050 at 3 µg/ml (lanes 5 & 6) Anti-
EGFR antibody was used at 3 µg/ml. Anti-actin antibody at 3 µg/ml was used as a 
loading control.  
 
 
 
 
 
AT13387 1 μM  - +               - +             - +
Column               1           2                            3            4                         5               6
Anti HSP72                  Anti GRP78 sc-13968           Anti GRP78 sc-1050
GRP78
HSP72
EGFR
Actin
Lane             1      2                 3       4                   5        6
AT13387      - +                  - +                   - +
GRP78
HSP72
EGFR
Actin
Anti HSP72            Anti GRP78             Anti GRP78                                              
sc-13968                 sc-1050 
Results part 1  
 
132 
 
In order to identify whether anti-GRP78 antibody (sc-1050) cross reacted with HSP72 
an HSP90 inhibitor was used. The HSP90 inhibitor AT13387 binds and competitively 
prevents ATP binding to the N-terminus of HSP90 (135). This results in the disruption 
of the inhibitory interaction of HSP90 with the transcription factor: Heat Shock Factor 
(HSF) (136). Upon HSP90 inhibition, by AT13387, HSF induces up-regulation of 
HSP72. Furthermore HSP90 inhibition leads to proteasomal degradation of HSP90 client 
proteins such as EGFR (137) and thus with HSP90 inhibitor AT13387 an increase in 
HSP72 levels and a decrease in EGFR levels is observed. See Appendix section 7.2 for a 
review of HSP90 inhibitors. 
 
UM-SCC 81B cells were treated with HSP90 inhibitor AT13387 at 1μM for 24h(135). 
SDS-PAGE followed by western blot analysis was used to identify whether or not 
HSP72 induction could be detectable by anti-GRP78 antibody (sc-1050). As presented 
in Figure 4.1.3 , when comparing lanes 1 and 2 it is clear that treatment with AT13387 
results in HSP72 induction as expected. Furthermore there was a reduction in EGFR 
levels in lane 2 compared to lane 1, again, as expected. 
 
Using anti-GRP78 antibody (sc-1050) a strong signal was detected, in untreated cells in 
lane 5, which was located at the same position as HSP72 in lanes 1 and 2. Furthermore 
this band was induced when cells were treated with AT13387 as shown in lane 6 with a 
stronger signal being emitted from this band compared to GRP78. This almost certainly 
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indicates that there is significant cross reaction with anti-GRP78 antibody (sc-1050) with 
HSP72. Therefore studies which have reported the expression of GRP78 via the use of 
immunohistochemical staining with anti-GRP78 antibody (sc-1050) may not be reliable. 
 
 Using anti-GRP78 antibody (sc-13968), GRP78 was the only protein detected in 
untreated cells (see lane 3). In cells treated with AT13387 a weak signal was visible 
running just ahead of GRP78 which was at the same position as HSP72 in lanes 1 and 2. 
However the majority of the signal was derived from GRP78 protein. Our study 
indicates that anti-GRP78 antibody (sc-13968) appears to cross-react to a much lesser 
degree with other proteins and, in our opinion, is therefore a more suitable antibody for 
GRP78 IHC studies than anti-GRP78 antibody (sc-1050). 
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4.2 GRP78 is up-regulated in laryngeal squamous cell 
carcinoma UM-SCC cells in vitro in conditions of hypoxia 
and low glucose 
 
Rapidly growing tumours quickly outgrow their blood supply leading to a typical micro-
environment of hypoxia, low pH, and nutrient starvation (138). Under these micro-
environmental conditions protein folding is disrupted resulting in the activation of the 
Unfolded Protein Response and the induction of GRP78 as described in section 1.3.3 
(139). Induction of chaperone GRP78 provides a cyto-protective function, under such 
stress conditions, by allowing for enhanced protein folding capacity, decreased global 
transcription of cellular proteins and the suppression of pro-apoptotic proteins. Whilst in 
some cases, the UPR is able to restore cellular homeostasis, should the cellular stresses 
be of sufficient duration or strength, the UPR is unable to restore cellular function and 
cell death occurs(140). LSCC cells were exposed to conditions of hypoxia and low 
glucose to determine whether these stimuli could induce GRP78 expression under 
conditions typically found in the tumour micro-environment  
 
Tumour hypoxia is commonly defined as an oxygen concentration lower than 3% 
compared to normal tissue oxygen concentrations which on average contain between 4 
and 9% oxygen (140). Tumour hypoxia has been detected in 78% head and neck 
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squamous cell carcinomas (141).As well as hypoxia, tumours are subject to low glucose 
levels. Normal tissue typically contains glucose levels of 5 mM whilst in many tumours 
glucose levels can range from anywhere between 0 and2 mM (83). Previous studies have 
investigated induction of GRP78 in hypoxic (less than 2% O2) (142) and low glucose 
conditions (less than 2 mM glucose) in a number of cell lines (139), however this was 
the first study to determine whether GRP78 could also be induced in laryngeal squamous 
cell carcinoma cell lines under typical tumour-microenvironments.  
 
UM-SCC cells were grown in the following conditions for 24 hours: 
 Normal conditions of 5% CO2 + 95% air and 4g/l glucose (20 mM) 
  Hypoxic conditions of 2% O2 with normal glucose levels 
 Anoxic condition of 0% O2 and normal glucose levels  
 Low glucose concentrations of either 0.4 g/l (2 mM) or 0.04 g/l (0.2 mM) under 
normoxia. 
 
All UM-SCC cells were plated on six well plates at a density of 50% and left over night, 
in normoxic and normal glucose conditions, in order for the cells to adhere. Cells were 
then grown in the above mentioned conditions for 24 hours as described in Methods 
section 3.4.5. 
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After 24 h cells were harvested and processed for western blot analysis (as described in 
section 3.5). Membranes were incubated with previously validated anti-GRP78 antibody 
(sc-13968) and luminescent signals produced from GRP78 bands were quantified by 
densitometry as shown in Figure 4.2.1. All UM-SCC laryngeal squamous cell carcinoma 
cell lines, that were tested, demonstrated induction of GRP78 in conditions of low 
oxygen and glucose compared to controls. The only exception to this was in UM-SCC 
81B cells which when grown in 2% O2 showed no increase in GRP78 levels. However 
GRP78 was induced in UM-SCC cells in anoxic conditions as well as in 0.4g/l glucose. 
Luminescent signals emitted from the GRP78 bands were increased by at least two fold, 
as measured by densitometry, in UM-SCC 5, 11B and 12, compared to controls, when 
these cells were grown either in low glucose media of 0.4g/l glucose or in hypoxic 
conditions of 2% O2.  
 
After establishing that GRP78 could be up-regulated in laryngeal squamous cell 
carcinoma cells, in vitro, we wanted to determine whether these tumour cells were 
capable of proliferating in conditions typical of the tumour micro-environment of 
hypoxia and low glucose. Cells were seeded into 12 well plates, in triplicate, and left to 
adhere over night. Cells were grown in conditions of normal glucose concentrations and 
normoxia, or in low glucose (0.4 g/l), or in hypoxia (2% O2) for a total of three days 
(Methods section 3.4.5). Each day, cells were counted as described in Methods section 
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3.13. Figure 4.2.2 shows the proliferation of UM-SCC cells under these conditions. Not 
only were all seven UM-SCC cell lines able to survive in conditions of low glucose and 
hypoxia but they were also able to proliferate. However the rate of proliferation was 
reduced compared to cells grown in normal glucose concentrations and normoxia.  
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Figure 4.2.1 Induction of GRP78 in conditions of low glucose and hypoxia in a 
panel of LSCC cells.  
Cells were grown in conditions of normoxia and normal glucose concentrations (4g/l)l 
(control), or low glucose of 0.4g/l glucose, or 0.04g/l glucose, or hypoxic condition of 
2% O2 , or anoxia (0% O2), as indicated for 24h. GRP78 protein expression was 
quantified by western blot analysis followed by densitometry. 35 μg of protein loaded 
into each lane. Membranes were  incubated with anti-GRP78 antibody (sc-13968) at 3 
μg/ml or with anti-tubulin at 1:10,000 dilution (loading control).  
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Figure 4.2.2 Growth of LSCC cells under hypoxia and low glucose.  
Cells were grown in triplicate in 12 well plates in normal glucose and normoxia, or 
hypoxia (2% O2), or low glucose levels (0.4 g/l). Cells were harvested and counted on a 
daily basis as described in section 3.13. Bars represent s.e.m.  
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4.3 GRP78 is up-regulated in vivo 
 
Results presented in this thesis have shown that an anti-GRP78 antibody (sc-1050) cross 
reacts with HSP72 (section 4.1). Studies by Du et al., and Feng et al., which have used 
this antibody for IHC in order to measure GRP78 expression levels in oesophageal and 
nasopharyngeal tumours, respectively, therefore probably examined the combined 
expression levels of GRP78 and HSP72 (3, 4). Our study indicates that anti-GRP78 
antibody (sc-13968) appears to be less cross-reactive with other proteins and may 
therefore be a more suitable antibody for IHC than anti-GRP78 antibody (sc-1050).  
 
Currently there are no published data regarding GRP78 levels in patients with laryngeal, 
hypopharyngeal and oropharyngeal tumours. By using validated anti-GRP78 antibody 
(sc-13968) as a primary antibody for IHC we wanted to determine whether or not 
GRP78 was up-regulated in these tumours and secondly whether GRP78 could be used 
as a prognostic biomarker for SCCHN.   
 
IHC was performed as described in section 3.10. Prior to performing IHC on the tissue 
micro array (TMA) the anti-GRP78 antibody (sc-13968) was tested on individual sample 
sections of SCCHN tissue. It was necessary to perform antigen retrieval as no staining 
was detected without this pre-treatment. For antigen retrieval, slides were boiled in the 
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microwave at maximum power for 15 minutes in citric acid buffer solution (see section 
3.10).  
 
Anti-GRP78 antibody (sc-13968) was tested at dilutions of 1:100, 1:200, 1:400 and 
1:800 on sequential sample sections of SCCHN tissue as well on adjacent histologically 
normal head and neck squamous epithelium, in order to determine the optimum dilution. 
 
 At all dilutions only cytoplasmic staining was observed with no staining within the 
nucleus which is in accordance with the known localisation of GRP78 in the cell (4). As 
previously mentioned Du and colleagues observed GRP78 to be up-regulated in tumours 
compared to histologically normal tissue and therefore we would expect GRP78 staining 
intensity to be greater in sample sections of SCCHN tissue as compared to histologically 
normal adjacent tissue (4). At dilutions of 1:100, 1:200 and 1:400 GRP78 staining 
intensity was greater in SCCHN tissue samples compared to adjacent histologically 
normal samples as expected. However at 1:800 the staining pattern appeared to be too 
week and no differences in staining intensity could be observed between histologically 
normal tissue and SCCHN tissue. Therefore Anti-GRP78 antibody (sc-13968) was used 
at 1:400 following empirical determination that this was the optimum dilution.  
 
The primary antibody was omitted in order to test the specificity of the secondary 
antibody as shown in photomicrograph Figure 4.3.1A. Without the primary antibody 
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there was no DAB staining. A different section from the same tumour block was then 
incubated with the primary antibody. Figure 4.3.1D shows homogeneous cytoplasmic 
staining with no staining within the nucleus as expected.  
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Figure 4.3.1 GRP78 protein detection via IHC on SCCHN sample tissues.  
IHC was performed as described in Methods section 3.10. For antigen retrieval, 
SCCHN tissue samples were boiled in the microwave at maximum power for 15 minutes 
in citric acid buffer solution. Samples were then incubated with anti-GRP78 primary 
antibody (sc-13968) at a dilution of 1:400. (A) SCCHN tissue sample with omission of 
primary antibody at 10X original magnification. (B, C and D) sequential sections of 
tissue but treated with primary antibody shown at the original magnification of 10X as 
well as magnifications of 200X and 400X respectively.  
A Primary antibody omitted at 10X original 
magnification 
B 10X original magnification
C 200X D 400X
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Figure 4.3.2 Immunohistochemical GRP78 staining and scoring of SCCHN.  
IHC was performed as described in Methods section 3.10. For antigen retrieval, 
SCCHN tissue samples were boiled in the microwave at maximum power for 15 minutes 
in citric acid buffer solution. Samples were then incubated with anti-GRP78 primary 
antibody (sc-13968) at a dilution of 1:400. TMA cores were scored simultaneously by 
two observers (the author and specialist registrar pathologist Dr Mike Wall). Score of 1 
represents weak GRP78 staining as shown in A and D, 2 for moderate staining as shown 
in B and E, and 3 for strong staining as shown in C. F shows a tissue micro dot 
containing mainly glandular tissue. G shows an example of squamous tissue (white 
arrow) surrounded by plasma cells (red arrow). H shows typical glandular tissue (green 
arrows). Both plasma cells and glandular tissue stained strongly and were not 
incorporated into the analysis as this study focused on the pathology of head and neck 
squamous tissue. 
A: SCCHN score 1 B: SCCHN score 2 C: SCCHN score 3 D: Normal 
squamous score 1
E: Normal 
squamous score 2
F: Normal 
glandular tissue 
G: Normal 
squamous
tissue amongst 
plasma cells
H: Normal 
glandular tissue
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The head and neck tissue micro array (TMA) as described in Methods section 3.10 was 
analysed via IHC for GRP78 expression. TMA tissue samples were collected at 
University Hospital Aintree. The TMA was constructed at Liverpool Tissue Bank (LTB) 
and then returned back to University Hospital Aintree for storage.  Scoring of the stained 
TMA was carried out by both the author and histopathologist, Dr Mike Wall. Statistical 
analysis of data was performed using StatView V5.0 and SPSS PASW Statistics version 
18. GRP78 staining intensity was scored as 1 for weak staining, 2 for moderate staining, 
and 3 for strong staining as shown in Figure 4.3.2. For each core the area of highest 
intensity of squamous epithelium was scored providing the area covered more than 10% 
of the epithelium. 
 
GRP78 staining scores of 45 head and neck tumours were compared to the scores from 
45 matched histologically normal tissue. Pearson Chi Square test of independence was 
used in order to establish whether there were differences in GRP78 expression between 
tumour tissues and histologically normal tissues. In order to perform Chi Square test, 
scores of the three tumour cores form each patient were averaged and rounded to the 
nearest whole number and then compared to scores from histologically normal matched 
tissue. 
 
GRP78 levels were significantly higher in the tumour tissue samples (n=45) compared 
with matched histologically normal tissue samples (n=45). 85% of tumour cores versus 
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24% of histologically normal cores were given a staining score of either 2 (moderate 
staining) or 3 (strong staining) (p(x2) <0.001). See Table 4.3.1 for more details. 
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Table 4.3.1 Comparison of GRP78 staining score between tumour tissue and 
matched histologically normal tissue. 
GRP78 staining scores of 45 head and neck tumours were compared to the scores from 
45 matched histologically normal tissue. There appears to be a strong association 
between high GRP78 levels and tumour tissue as compared to histologically normal 
tissue (p(Χ2)<0.001). 
 
 
 
 
 
 
 
 
 
Scoring Intensity 
Total 1.00 2.00 3.00 
Tissue 
Type 
Normal Count 34 10 1 45 
Expected Count 20.5 17.5 7.0 45.0 
% within Tissue 75.6% 22.2% 2.2% 100.0% 
Tumour Count 7 25 13 45 
Expected Count 20.5 17.5 7.0 45.0 
% within Tissue 15.6% 55.6% 28.9% 100.0% 
Total Count 41 35 14 90 
Expected Count 41.0 35.0 14.0 90.0 
% within Tissue 45.6% 38.9% 15.6% 100.0% 
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  Low GRP78 expression 
n=52 
High GRP78 expression 
n=138 
Gender Female 11 (21%) 24 (17%) 
Male 41 (79%) 114 (83%) 
Average age  60 ± 12 (stdev)  64 ± 10 (stdev) 
Tumour stage 1 9 (17%) 11 (8%) 
2 23 (44%) 47 (34%) 
3 15 (29%) 42 (30%) 
4 5 (10%) 38 (28%) 
Nodal involvement -ve 24 (46%) 49 (36%) 
+ve 28 (54%) 89 (64%) 
Recurrence No 34 (65%) 102 (74%) 
Yes 18 (35%) 36 (26%) 
Radiation treatment No 49 (94%) 124 (90%) 
Yes 3 (6%) 14 (10%) 
Table 4.3.2 Demographic information of 190 HNSCC patients who had tissue 
samples taken for TMA analysis.   
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Demographic information of patients can be seen in Table 4.3.2. When all tumour tissue 
samples were analysed on the TMA (n=190) no significant differences in GRP78 
expression were observed between stage 1 or 2 (n=90) and stage 3 or 4 (n=100) tumours 
(p(Χ2)=0.075) or between node negative (n=72) and node positive (n=118) tumours 
(p(Χ2)=0.547). Therefore GRP78 levels may not be a suitable as a diagnostic biomarker. 
 
 Survival analysis based on data from 190 SCCHN patients was performed using 
Kaplan-Meier method and statistical differences between curves were compared using 
log-rank test. As expected SCCHN patients with stage 1 or stage 2 tumours had a 
significantly better five year survival compared to patients with stage 3 or 4 tumours 
(p(log rank) < 0.001), as shown in Figure 4.3.3A. Furthermore patients without nodal 
involvement survived significantly longer than patients with nodal spread (p(log rank) = 
0.005) (Figure 4.3.3B). These findings are in line with previous studies which have also 
found high tumour stage and nodal involvement to be associated with poor survival 
outcome. (143, 144). 
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Figure 4.3.3 5 year SCCHN patient survival when compared to tumour stage and 
nodal status. 
 (A) Kaplan Meier overall 5 year survival curves for a total of 190 SCCHN patients with 
stage 1 and 2 tumours compared to stage 3 and 4 tumours. Upon log-rank analysis there 
was a significantly lower five year survival where p<0.001. (B) Kaplan Meier plot of the 
same cohort of SCCHN patients dichotomized according to lymph node spread versus 
no nodal involvement. Log-rank analysis showed patients with nodal involvement having 
a significant lower five year survival where p=0.005. 
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+ve node (censored=66)
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Several studies have reported that up-regulation of GRP78 is associated with poor 
survival in a variety of tumours including: hepatocellular carcinoma (HCC) (130), 
pancreatic adenocarcinoma (132), breast cancer (112), melanoma (133), oesophageal 
adenocarcinoma (120), glioblastoma (108), lung cancer (134) and prostate cancers (129).  
 
Here for the first time it was determined whether up-regulation of GRP78 was correlated 
with poor survival outcome in tumours of the larynx, hypopharynx and oropharynx. 
Tumours were arbitrarily classed as having high GRP78 expression if their three micro 
dots produced a mean score of 2 or more, or if the tumour in question had an 
exceptionally high area of GRP78 expression as indicated by at least one of the three 
microdots scoring a 3.  
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Figure 4.3.4 Association between GRP78 levels in tumours and survival in 190 
SCCHN patients. 
 (A) Kaplan Meier overall 5 year survival curves for 190 SCCHN for patients with high 
GRP78 levels versus patients with low GRP78 levels. (B) Kaplan Meier overall 2 year 
survival curves for 190 SCCHN for patients with high GRP78 levels versus patients with 
low GRP78 levels. Statistical significance was determined by log-rank analysis.  
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Figure 4.3.5 Relationship between GRP78 expression and survival status in patients 
with LSCC (n=92). 
 (A) Kaplan Meier overall 5 year survival curves for 92 laryngeal squamous cell 
carcinoma patients with high GRP78 levels versus patients with low GRP78 levels. (B) 
Kaplan Meier overall 2 year survival curves for 92 laryngeal squamous cell carcinoma 
patients with high GRP78 levels versus patients with low GRP78 levels.  
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The Kaplan Meier 2 year survival analysis of SCCHN patients (n=190) showed that 
GRP78 up-regulation was significantly associated with lower survival as compared to 
patients with low GRP78 expressing tumours (p(log rank) = 0.032) (Figure 4.3.4B). 
Although log-rank is useful in comparing differences in survival in two or more groups 
on non-parametric censored data, multivariate Cox regression analysis is required to 
compare the influence of several risk factors on survival at the same time (145). 
 
Initially univariate Cox regression analysis was performed on several factors against two 
year survival for all head and neck tumours (n=190): gender (p = 0.935), age (p = 
0.261), tumour stage (p = 0.001), nodal status (0.018), whether or not patient received 
radiation therapy (p = 0.523), tumour recurrence (p = 0.004) and GRP78 expression (p 
=0.038) (as shown in Table 4.3.3). In order to screen for possible significant predictive 
indicators of survival, covariates were selected for multivariate analysis if their p value 
was either equal to or less than 0.1. As expected upon multivariate Cox regression 
analysis tumour stage (p = 0.004), nodal status (p = 0.005) and recurrence (p = 0.001) 
were found to be significant independent factors in determining two year survival. 
Patients with high tumour stages of 3 and 4 had an increased hazard ratio of  2.5 
compared to patients with stage 1 and 2 tumours. Similarly patients with tumours with 
nodal involvement had worse prognosis with a hazard ratio of 2.6. Although high 
GRP78 levels are suggestive of poorer survival outcome with a hazard ratio of 2.04 this 
finding is not statistically significant (p=0.069). 
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 Univariate 
analysis 
 Multivariate 
analysis 
Category  HR P value Category  HR P value 
Gender female 1 0.935     
male 1.03   
Age <60 1 0.261     
≥60 1.413   
Tumour stage 1 or 2 1 0.001 Tumour stage 1 or 2 1 0.004 
3 or 4 2.8 3 or 4 2.5 
Nodal status -ve 1 0.018 Nodal status -ve 1 0.005 
+ve 2.2 +ve 2.6 
Radiation 
treatment 
no 1 0.523     
yes 1.3   
Tumour 
recurrence 
no 1 0.004 Tumour 
 recurrence 
no 1 0.002 
yes 2.3 yes 2.5 
GRP78 
expression 
low 1 0.038 GRP78 
 expression 
low 1 0.069 
high 2.2 high 2.044 
Table 4.3.3 Covariates of 190 HNSCC patients from TMA data were analysed in 
order to assess which factors may help to determine two year survival outcome. 
In order to screen for possible predictive indicators of survival, covariates were selected 
for multivariate analysis if their p value was either equal to or less than 0.1. Upon 
multivariate analysis only tumour stage, nodal status and tumour recurrence appeared 
to be significantly independent factors in predicting survival outcome. 
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As there may be different pathologies involved between the different sub-groups of 
SCCHN, subsets of this cohort were analysed separately. Upon log rank analysis two 
year survival was significantly higher for laryngeal patients with low expressing GRP78 
tumours (p=0.006) as shown in Figure 4.3.5. Univariate Cox regression analysis was 
performed against two year survival for laryngeal SCC (n=92) for the following 
covariates: gender (p = 0.471), age (p = 0.452), tumour stage (p =0.084), nodal status 
(p=0.005), whether or not patients received radiation therapy (p = 0.69), tumour 
recurrence (p = 0.741) and GRP78 expression (p =0.026) (as shown in Table 4.3.4). In 
order to screen for possible significant predictive indicators of survival, covariates were 
selected for multivariate analysis if their p value was either equal to or less than 0.1. 
Upon multivariate analysis only nodal status (p = 0.041) was a significantly independent 
predictor of survival where patients with nodal involvement had an increased hazard 
ratio of 2.3 compared to patients without nodal involvement. Unexpectedly tumour stage 
(p = 0.376) was no longer a significant predictor of survival outcome.  Although high 
GRP78 levels are suggestive of poorer survival outcome with a hazard ratio of 7.3 this 
finding is just below being statistically significant (p=0.052). A larger sample of 
laryngeal squamous cell carcinoma patients may be needed in order to clarify whether or 
not GRP78 as well as tumour stage may be suitable prognostic biomarkers. 
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 Univariate 
analysis 
 Multivariate 
analysis 
Category  HR P value Category  HR P value 
Gender female 1 0.471     
male 1.698   
Age <60 1 0.452     
≥60 1.4   
Tumour stage 1 or 2 1 0.084 Tumour stage 1 or 2 1 0.376 
3 or 4 2.3 3 or 4 1.6 
Nodal status -ve 1 0.005 Nodal status -ve 1 0.041 
+ve 3 +ve 2.3 
Radiation 
treatment 
no 1 0.69     
yes 1.2   
Tumour 
recurrence 
no 1 0.741     
yes 1.3   
GRP78 
expression 
low 1 0.026 GRP78 
 expression 
low 1 0.052 
high 9.684 high 7.311 
Table 4.3.4 Covariates of 92 laryngeal patients from TMA data were analysed in 
order to assess which factors may help to determine two year survival outcome. 
In order to screen for possible predictive indicators of survival, covariates were selected 
for multivariate analysis if their p value was either equal to or less than 0.1. Upon 
multivariate analysis only nodal status appeared to be a significantly independent factor 
in predicting survival outcome. 
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Prognostic biomarkers predict individual patient outcome, regardless of disease 
management, ‘distinguishing between good outcome tumours from poor outcome 
tumours’ (146). In this way prognostic biomarkers may help to decide which patients to 
treat or what modality to use as well as the aggressiveness of the treatment regime (146). 
Results presented within this thesis have shown that GRP78, although up-regulated in 
tumours compared to histologically normal tissue, may not be a significant independent 
prognostic biomarker. Zhuang et al., also found upon log rank analysis, that patients 
with high GRP78 expression in melanomas had significantly lower overall survival 
compared to patients with low GRP78 expression (p=0.0123) (133). However, when 
multivariate analysis was performed by Zhuang et al., GRP78 was no longer a 
significant independent factor in determining survival (p=0.178). It seems likely that the 
simultaneous use of multiple biomarkers may be more suited in predicting patient 
outcome as opposed to reliance on one single biomarker. For example multigene 
expression tests such as MammaPrint (Agendia) can be used to assess whether, after 
surgery, breast cancer patients, should receive adjuvant therapy or not, in order to avoid 
relapse (146). A similar ‘multiple biomarker’ approach may be also more applicable for 
head and neck cancers. 
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Furthermore there were no significant differences between survival rates of patients with 
high versus low GRP78 expressing tumours in oropharynx (where 5 and 2 year survival 
p=0.7 and 0.9 respectively) or hypopharynx (where 5 and 2 year survival p=0.2 and 0.56 
respectively) squamous cell carcinoma patients upon log rank analysis. This could be 
due to different pathologies involved in the various sub-sites. For example it is known 
that SCCHN patients with HPV are more responsive to chemo- and radiation therapy 
(p≤ 0.05) as compared to HPV negative patients and have better survival outcome (19, 
21). Therefore HPV infection which is more prevalent in oropharyngeal tumour 
compared to laryngeal tumours would be of greater prognostic value in such tumour sub-
sites 
 
4.4 Cleavage of GRP78 with EGF-SubA leads to suppression 
of LSCC cell proliferation 
 
As shown in section 4.3 GRP78 is significantly up-regulated in vivo in SCCHN tumours 
(Figure 4.3.3) as compared to normal histopathological tissue. Furthermore we have 
demonstrated that GRP78 can be up-regulated in UM-SCC in vitro under typical tumour 
environmental conditions of hypoxia and low glucose (Figure 4.2.1). GRP78 may help 
protect cancer cells from these adverse conditions therefore making inhibition of this 
protein potentially important for cancer therapy in SCCHN.A study by Chiu and 
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colleagues in 2008, used GRP78-siRNA to down regulate the protein in a range of 
SCCHN cells (1). Growth of cells in vitro was suppressed in a range between 18-55% by 
day five following knockdown of GRP78 by siRNA. As mentioned in section1.3.9, 
SubA is a protease which is only known to act on GRP78 (72 kDa), cleaving it into 44 
and 28 kDa fragments (7). Subsequently the results in this thesis confirm that EGF-
SubA is able to cleave GRP78 in UM-SCC cells (Figure 4.1.1and Figure 4.1.2).  
 
Currently only two studies, Backer and colleagues in 2009 and Yahiro and colleagues in 
2010, have explored the cytotoxic effects of SubA on prostate, breast, myeloma, rat 
glioma and cervical cancer cell lines (5, 147). The combination of covalently binding 
EGF to SubA enhances the toxicity of SubA in EGFR expressing cell lines. The IC50 
value for SubA in Hela cells has been reported to be 1.43nM (147). The IC50 values 
reported for EGF-SubA were considerably lower with a range between 2pM to 20pM in 
EGFR expressing cancer cell lines. In EGFR expressing rat glioma cells the IC50 was 
20pM, whereas in EGFR-null rat glioma cells the IC50 value for EGF-SubA was at 6nM 
(5). 
 
For the first time the effects of EGF-SubA on UM-SCC laryngeal squamous cell 
carcinoma cell lines were investigated within this thesis. In order to establish what 
inhibitory effects EGF-SubA had upon the growth of UM-SCC cells a cell counting 
assay was used where the number of cells per ml in the drug treated group were 
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compared to the number of cells in the control group. UM-SCC cells were treated with 
either EGF-SubA, in the same range of drug concentrations as used in the study by 
Backer and colleagues in 2009 (3pM to 1nM ), and compared with drug vehicle control, 
for a total of five days (5). The experiment was set up as described in section 3.13. Both 
drugs and media were replaced daily. Number of cells per ml, from three individual 
wells, were counted using a Beckman Coulter counter, for each individual condition. 
Typical dose response curves can be seen in Figure 4.4.1 where increasing doses of 
EGF-SubA lead to a decreasing cell number. 
 
IC50 values were calculated from data collected on day five. This was the same time 
period which Backer and colleagues used to calculate the EGF-SubA IC50 for prostate 
PC3 (IC50 = 1pM) and breast cancer cells MDA231luc (IC50 = 6pM) (5). IC50 curves 
were plotted as: percentage of cells in the drug treated group as a proportion of cells in 
the control group (y-axis) against the dose of the drug on a log scale (x-axis). IC50 values 
were within the 6 to 100pM range for UM-SCC cells (Figure 4.4.2).  
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Figure 4.4.1 EGF-SubA is cytotoxic to LSCC cells at pM concentrations.  
UM-SCC cells were seeded in 12 well plates and allowed to adhere for 24 hours (day 0). 
Cells were then treated with either EGF-SubA at ½ log10 incremental concentrations of 
3pM, 10pM, 30pM, 100pM, 300pM, and 1nM or with vehicle control, for up to five days. 
Both media and drugs were replaced every 24h. Cells were harvested and counted via a 
Beckman Coulter counter for each of the days. Error bars represent the s.e.m. from 
three independent wells.  
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Figure 4.4.2 EGF-SubA IC50 plots in a panel of LSCC cells. 
 IC50 data derived from day five of UM-SCC cells being treated with either EGF-SubA at 
concentrations of 3pM, 10pM, 30pM, 100pM, 300pM, and 1nM or drug vehicle control. 
IC50 curves were plotted as percentage of cells in the drug treated group as a proportion 
of cells in the control group (y-axis) against the dose of the drug on a log scale (x-axis). 
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4.5 EGF-SubA induces G1 arrest in LSCC cells 
 
Results in section 4.4 of this thesis have shown that EGF-SubA was able to inhibit the 
proliferation of UM-SCC cells. Morinaga and colleagues observed a decrease in basal 
levels of cyclin D1 as well as G1 cell cycle arrest after application of SubA in vitro in 
Hela and Vero cells (148). As cyclin D1 is important in order to allow for cell cycle 
progression from G1 to S phase it was proposed that loss of cyclin D1 through SubA 
was the mechanism behind G1 arrest (148).  
 
Phosphorylation of cyclin D1 is required for ubiquitin targeted proteasomal degradation. 
Upon SubA increased levels of phosphorylated cyclin D1 was observed. Furthermore 
the use of proteasomal inhibitor MG132 suppressed downregulation of cyclin D1 by 
SubA. Thus implying that SubA may indirectly induce the proteasomal degradation of 
cyclin D1.   
 
Flow cytometry was used, in our study, to determine what effects EGF-SubA had upon 
the cell cycle profile of UM-SCC cells in vitro. Conventional analysis of DNA content 
by staining cells with Propidium Iodide (PI) alone, provides a snapshot of what 
proportion of cells are in G1, S or G2/M phase at a particular point in time. However 
because of the overlapping DNA content between G1 with early S phase and mid to late 
S with G2 and M phases it is hard to accurately distinguish between these. 
Results part 1  
 
165 
 
Bromodeoxyuridine propidium iodide (BrdU)-(PI) double staining easily differentiates 
between overlapping DNA content of S phase fractions and at the same time provides 
information on the proportion of cells in G1 and G2. BrdU is a thymidine analogue 
which is incorporated during DNA synthesis (S phase) into viable cells. Subsequently 
the presence of BrdU can be detected via the use of monoclonal antibodies that 
recognise BrdU which are then labelled using secondary antibodies conjugated to FITC 
(this signal appears in the FL1 channel of the flow cytometer). The primary antibody 
only binds to BrdU present in single stranded DNA, therefore before the antibody can be 
used DNA must be denatured by either heat treatment or the use of strong acids(125). 
 
DNA can also be stained with PI once cells have been fixed with ethanol (detected in the 
FL2 channel of the flow cytometer) and then FL2 vs. FL1 dot plots are created in order 
to visualise G1, S, and G2/M regions. Only cells which have undergone S phase at the 
time of BrdU application will be both FITC and PI positive whilst cells in G1 and G2/M 
will only be PI positive. 
 
Currently there are no studies which have investigated the effect of SubA on cell cycle 
analysis via BrdU-PI double staining method. Here this method is performed 
simultaneously alongside the conventional fixed and permeabilised cell staining with PI 
to produce DNA histograms.  
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p53 is a tumour suppressor which can act as a transcription factor to promote G1 cell 
cycle arrest via induction of p21, in response to an array of stimuli such as DNA 
damage. Therefore, we examined a variety of UM-SCC cells of differing p53 status, to 
determine whether or not any impact of EGF-SubA upon the cell cycle was independent 
of p53 status (149). The cell lines studied were UM-SCC 17A which is wild-type for 
p53, UM-SCC 12 which is p53 null (homozygous Q104X), and UM-SCC 5 which has 
one p53 wild type allele and a single p53 mutation (heterozygousV157F).  
 
Experiments were performed as described in sections 3.7 and 3.8. UM-SCC cells were 
first transferred to culture dishes and left to adhere for 24 hours. Cells were then treated 
with drugs or respective drug vehicles for two days with fresh drugs and media being 
replaced daily. As this study was the first to perform cell cycle analysis on UM-SCC cell 
lines with EGF-SubA, a relatively high drug dose (i.e. above the IC50 levels) at 300pM 
was chosen, in order to maximise the chance of detecting any effect. At all times doublet 
discrimination, as described in section 3.7, was performed in order to discriminate 
between signals produced from single cells in G2 and doublets of cells in G1. 
 
Regardless of p53 status EGF-SubA was able to induce G1 arrest in all cell lines tested, 
as shown in Figure 4.5.1 and Figure 4.5.2. The amount of cells in G1 after treatment 
with EGF-SubA in UM-SCC 17A, 12 and 5 increased by 19%, 7%, and 5%, 
respectively, as analysed by PI staining of fixed permeabilised cells and 37%, 26% and 
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6%, as deduced by BrdU-PI double staining. As expected for a G1 arrest, there was a 
reduction in cells entering S phase. The percentage decreases in the S phase cell fraction 
after treatment with EGF-SubA as compared to controls in UM-SCC 17A, 12 and 5 were 
10%, 9%, and 5% respectively, as analysed by PI staining of fixed permeabilised cells 
and 46%, 19% and 12%, as deduced by BrdU-PI double staining. This observation may 
be important since it has been reported by Pawlik and colleagues that cells in G1 are 
twice as radiosensitive as cells in S phase and therefore EGF-SubA may act as a 
radiosensitiser (150). The potential for EGF-SubA as a radiosensitiser was explored in 
Results section 5.4.  
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Figure 4.5.1 EGF-SubA induces G1 cell cycle arrest regardless of p53 status.  
(A)UM-SCC cells were treated with either EGF-SubA at 300pM, or drug vehicle control 
for 48h. Cell cycle analysis was performed via BrdU-PI double staining as described in 
Methods section 3.8. (B) Cells in each phase of the cell cycle in treatment and control 
groups. Data was analysed on CellQuest Pro Software.  
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Figure 4.5.2 EGF-SubA induces G1 cell cycle arrest regardless of p53 status.  
(A) UM-SCC cells were  treated with either EGF-SubA at 300pM  or drug vehicle 
controls for 48h. Cell cycle analysis was performed via staining fixed permeabilised 
cells with PI (Methods section 3.7). (B) Percentage of cells in each phase of the cell 
cycle. Data analysed on CellQuest Pro Software. Note that in (A) the axes values are not 
the same.  
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4.6 EGF-SubA toxicity is dependent on the presence of the 
EGFR 
  
Backer and colleagues in 2009, discussed the cytotoxicity of EGF-SubA and that this 
appeared to be EGFR-dependent with EGFR positive cells having an IC50 within the 
pico molar range and EGFR negative cells having an IC50 in the nano molar range(5). 
For example U266-B1 human myeloma cells which do not express EGFR had an EGF-
SubA IC50 greater than 6nM compared to EGFR positive human prostate PC3 cells 
which had an IC50 of 1pM (5). Interestingly, the IC50 value for SubA tends to be in the 
nano molar range, regardless of EGFR density, as found in EGFR positive Hela cells 
which had an IC50 of 1.4nM (147). Comparable to the study by Backer and colleagues 
which focused mainly on prostate, glioma and breast cancer cells, results in this thesis 
demonstrate that the EGF-SubA IC50 of EGFR positive laryngeal squamous carcinoma 
are also below 1nM with a range of 4pM to 100pM.  
 
Backer and colleagues examined human prostate and breast cancer xenografts in 
immuno-deficient mice. Following a one week course of intra-peritoneal EGF-SubA 
injections the study found a 4-10 fold reduction in tumour volume compared to controls, 
without ‘signs of toxicity being observed in any of the treated groups.’ 
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Currently it is unclear whether such xenograft models provide a reasonable test of 
toxicity, for pre-clinical studies, since EGF-SubA might not enter mouse cells due to 
differences in binding of human EGF to murine EGFR. Furthermore we wanted to 
clarify whether the cytotoxicity of EGF-SubA was, as suggested by Backer and 
colleagues, dependent on the presence of EGFR. If cytotoxity of EGF-SubA is 
dependent on EGFR then these effects in theory may be mitigated by cetuximab, which 
is a mAb against EGFR.  
 
In order to address the question of whether EGF-SubA is toxic to mouse cells at the pico 
molar level and to confirm simultaneously that EGF-SubA toxicity is dependent on the 
expression of EGFR, mouse liver HEPA 1c1c7 cells, which express EGFR, and mouse 
embryonic fibroblasts (MEF) that do not express EGFR were treated with EGF-SubA 
for a period of five days and a MTT assay was used to measure cell 
proliferation/viability as described in Materials and method section 3.12.  
 
Initially EGFR expression was confirmed to be present in HEPA 1c1c7 and absent in 
MEF cells by direct western blot comparison with UM-SCC 12 which is known to 
express EGFR as shown in Figure 4.6.1A. Secondly Hepa 1c1c7 and MEF cells were 
treated with EGF-SubA at a range of concentrations between 1pM to 1nM for up to five 
days as shown in Figure 4.6.1B. As expected the growth of Hepa 1c1c7 EGFR positive 
cells was inhibited by EGF-SubA, albeit that the IC50 was at a relatively high pico molar 
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concentration of 700pM, whilst no inhibitory effects upon MEF cells were observed, 
even at an EGF-SubA concentration of 1nM. Thus these results indicate that murine 
cells which do not express EGFR are not as sensitive to the effects of EGF-SubA 
compared to murine cells which do express EGFR. Therefore potentially the effects of 
EGF-SubA may be blocked by cetuximab. 
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Figure 4.6.1 EGF-SubA is toxic to Hepa 1c1c7 EGFR expressing cells but not to 
MEF cells which do not express EGFR.  
 (A) Western blot analysis of UM-SCC 12, Hepa 1c1c7 and MEF. All lanes were loaded 
with 35 μg protein. Blots were probed with anti EGFR antibody at 3 µg/ml and anti 
actin antibody at 3µg/ml (protein loading control). (B) Hepa 1c1c7 and MEF cells were 
treated with either EGF-SubA at concentrations of 1pM, 3pM, 10pM, 30pM, 100pM, 
300pM and 1nM or with drug vehicle control, for up to five days. MTT assay was used 
to assess the quantity/viability of cells. Absorbance was measured at an OD of 590 nm. 
Error bars represent the s.e.m. from four independent wells. 
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4.7 EGFR membrane expression is correlated with EGF-
SubA sensitivity 
 
Results in section 4.6 indicate that cells that do not express EGFR are not as sensitive to 
EGF-SubA as EGFR expressing cells. Therefore it was further investigated whether 
there was a correlation between cell surface EGFR expression and sensitivity to EGF-
SubA between cells.  
 
In order to measure membrane EGFR levels as opposed to total cellular EGFR levels, 
flow cytometric analysis was used. Anti EGFR (ICR10) antibody conjugated to PE from 
Abcam (ab27764) was used in order to detect membrane EGFR. This antibody was 
selected as it binds to an extracellular epitope of EGFR.  
 
In pilot western blot experiments it was observed that there were fluctuating amounts of 
EGFR expression within any one cell line and it seemed likely that this was cell density-
dependent. Therefore in order to determine whether EGFR expression changed with cell 
density, UM-SCC 12 and 81B were grown and harvested at 30%, 60% and 90% 
confluence as shown in Figure 4.7.1. These cells were chosen on the basis that they were 
the easiest of the cell lines to grow. It can be seen through western blot analysis that 
higher total cellular EGFR expression levels were observed at lower cellular density. In 
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both UM-SCC 12 and 81B EGFR levels were greater at 30% confluence and lower at 
90% confluence.  
 
In order to negate the effects of confluence on EGFR expression all cells were harvested 
at 90% confluence and processed for flow cytometry to determine surface EGFR levels 
as described in Methods section 3.9.  
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Figure 4.7.1 Higher total cellular EGFR expression was observed at lower cellular 
confluences.  
Western blot analysis of UM-SCC 12 and 81B which were seeded for 24h and then 
harvested the next day to ensure a confluence of 30%, 60% and 90%. All lanes were 
loaded with 35 μg protein. Blots were probed for EGFR at 3 µg/ml and tubulin (protein 
loading control) at a dilution of 1:10,000. 
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Figure 4.7.2 EGFR membrane expression levels in a panel of LSCC and MEF cells 
correlates with sensitivity to EGF-SubA. 
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 (A) EGFR expressing UM-SCC 10A, 5, 11B, 12, 17A, 17AS and 81B, as well as MEF 
cells absent of EGFR were grown for 24h and harvested at 90% confluence. Cells were 
then incubated with a PE-conjugated anti EGFR antibody (ab27764) and fluorescence 
detected in the FL2 channel using a log scale to detect mean PE average fluorescence 
(AF). (B) UM-SCC and MEF membrane EGFR AF levels were plotted against EGF-
SubA sensitivity (ranked by IC50 values). Cells were ranked from the lowest AF value 
(MEF=1) to the highest AF value (UM-SCC 11B=7). Cells were also ranked on the 
sensitivity towards EGF-SubA from the most resistant (MEF=1) to the most sensitive 
(UM-SCC=7). There was a strong association between high levels of membrane EGFR 
and increased sensitivity to EGF-SubA with a Spearman’s rank correlation coefficient 
(rs) = 0.919 (p=0.007). UM-SCC 12 was excluded from correlation analysis as it was 
an outlier with one of the higher AF levels but being the most resistant UM-SCC cell 
line to EGF-SubA and therefore would have appeared at the furthest point 
perpendicular to line of best fit. 
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There appears to be a strong positive association between increasing EGF-SubA 
sensitivity and high EGFR fluorescence levels, as shown in Figure 4.7.2B where 
Spearman’s rank correlation coefficient (rs) = (0.919) (p=0.007). Therefore it is likely 
that cytotoxicity of EGF-SubA is, at least partly, dependent on the amount of surface 
EGFR present on cells. This may be an advantage in selectively targeting tumour cells 
since EGFR is frequently up-regulated in SCCHN as mentioned in section 1.2.2 (50). 
EGFR over-expression in head and neck cancer may be due to multiple gene copies 
and/or to a reduced rate of EGFR targeted ubiquitin degradation (29, 49). UM-SCC 12 
appears to be an outlier with the second highest EGFR membrane concentration yet is 
the most resistant of the cells to EGF-SubA suggesting that EGF-SubA cytotoxicity may 
in some tumours/cells be dependent on other factors as well. 
 
4.7.1 Cetuximab has little effect on cell proliferation on laryngeal 
squamous cell carcinoma cells in vitro 
 
As seen in sections 4.6 and 4.7 EGF-SubA cytotoxicity appears to be dependent on the 
presence of membrane bound EGFR. Ultimately therefore it would be interesting to 
determine if the effects of EGF-SubA could be mitigated by sub-toxic doses of 
cetuximab. This could potentially mean that EGF-SubA could be used as a topical 
treatment peri- or post- operatively after resection of a tumour with systemic side effects 
Results part 1  
 
180 
 
of EGF-SubA being blocked with cetuximab, thus widening the therapeutic window of 
EGF-SubA.  
 
Recently in 2008 the National Institute of Clinical Excellence (NICE) recommended the 
concurrent use of cetuximab with radiation in patients with locally advanced SCCHN 
with a Karnofsky performance status score of 90% or above for whom all forms of 
platinum based chemo-radiotherapy had failed(23).  
 
Efficacy of cetuximab in combination with radiation was analysed by Bonner and 
colleagues who reported in 2006 on a Phase III clinical trial involving stage III or IV, 
non-metastatic squamous cell carcinoma of the oropharynx, hypopharynx, or larynx 
(151). Median local regional control improved collectively for all three tumour sites 
from 14.9 months for patients treated with radiotherapy alone to 24.4 months for patients 
treated with radiotherapy and cetuximab (p=0.005). When analyzing the median local 
regional control for individual sites: oropharynx patients greatly improved from 29 to 49 
months, however loco-regional control was marginally improved for laryngeal SCC 
patients from 11.9 to 12.9 months, and for hypopharynx SCC patients from 10.3 to 12.5 
months. As the study was not powered to detect differences in between these subgroups 
no p values were provided.  
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Collectively overall survival improved from 29 to 49 months (p=0.03). When analyzing 
the median overall survival for individual subgroups: oropharynx patients enjoyed 
improved survival from 30 months to 66 months, however laryngeal patients 
experienced only marginal improvement in survival outcome, from 31.6 to 32.8 months, 
whilst the survival of hypopharynx patients improved from 13.5 months to 13.7 months.  
 
In summary when the survival and progression free survival were analysed collectively 
in all three tumour sites there were statistically significant improvements for patients 
treated with cetuximab and radiotherapy as opposed to just radiotherapy alone. However 
when analysing the individual subgroups only patients with oropharyngeal cancers, 
which formed 60% of the overall number of participants in the trial, appeared to benefit 
from the combination of cetuximab with radiation therapy whilst and there was little 
benefit for people with laryngeal cancers. This may be due to different pathologies 
involved in the various sub-sites. For example it is known that SCCHN patients with 
HPV are more responsive to chemo- and radiation therapy(p ≤ 0.05) compared with 
HPV negative patients and have better survival outcome (19, 21). Therefore HPV 
infection which is more prevalent in oropharyngeal tumour compared to laryngeal may 
be a determining factor to cetuximab sensitivity.  
 
Amplification of EGFR genes, over expression of EGFR protein, and autocrine TGF-α 
stimulation which are features present in head and neck cancers, have all been correlated 
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with poor survival outcome and increased metastatic potential (29, 49, 50) (see section 1.2.2 
for more detail). Cetuximab is a monoclonal IgG antibody which binds to EGFR with a 
greater affinity than either EGF or TGF-α (54). Binding inhibits the activation of EGFR 
tyrosine kinases and thus prevents Ras associated downstream signalling pathways that 
are associated with cell proliferation, prevention of apoptosis, cellular repair and 
survival as described in section 1.2.3(54). Furthermore radiation is known to increase 
EGFR expression and blockage of EGFR signalling can sensitizes cells to radiation 
(151) 
 
Although one of the main aims of this thesis was to determine whether cetuximab could 
act as an antagonist to EGF-SubA, currently there is very little published data on the 
growth inhibitory effects of cetuximab against laryngeal squamous cell carcinoma both 
as a single agent and in combination with radiation. Therefore the potency of cetuximab 
on laryngeal sqaumous cell carcinoma cells was first explored. 
 
In order to establish what inhibitory effects cetuximab had upon the growth of UM-SCC 
cells an MTT assay was set up as described in section 3.12. The MTT assay is often used 
to measure the cytotoxic effects of drugs in vitro. Healthy cells have viable mitochondria 
which contain mitochondrial dehydrogenase enzymes. These enzymes are capable of 
reducing yellow MTT into formazan a purple precipitate (127). The more cells that are 
viable the more MTT will be reduced, resulting in a higher MTT score. Therefore MTT 
Results part 1  
 
183 
 
score is a function of viability/growth of cells. MTT was found to be less time 
consuming and more cost effective method as compared to cell counting.  
 
UM-SCC cell lines were seeded into 96 well plates and left for 24h. Cells were then 
treated with cetuximab at dilutions of 10nM, 100nM and 1μM or with drug vehicle 
control for a total of seven days. Fresh media and drugs were replaced daily.  
 
As can be seen in Figure 4.7.3 cetuximab had little effect on viability/growth of 
laryngeal squamous cell carcinoma cell lines, compared to drug vehicle controls, as 
observed through MTT assay. Maximum effects of cetuximab at reducing 
viability/growth were reached at 10nM with higher concentrations of cetuximab not 
leading to any further reduction in MTT score. The most sensitive line was UM-SCC 5 
with a 47% decrease in cell viability/proliferation, as compared to controls, after seven 
days of treatment with 10nM cetuximab. The most resistant cell line was UM-SCC 
17AS which showed no response to cetuximab even at 1μM. 
 
As it was observed that cetuximab had little effect on viability/growth on the laryngeal 
squamous cell carcinoma cells there were concerns as to whether the samples of 
cetuximab used were functionally active. MTT assay was therefore also performed on a 
known cetuximab sensitive cell line UM-SCC 1 (derived from an oral tumour). 
Benavente and colleagues in 2009 had reported an IC50 of 5nM for UM-SCC 1 after 
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three days treatment with cetuximab (152). It was noted that although Benavente and 
colleagues had shown that UM-SCC 1 was a cetuximab-sensitive cell line, results within 
this thesis show only a 25% decrease in cell viability/growth after using cetuximab at 
1μM for seven days as shown in Figure 4.7.3 (152). Drug assays were repeated on at 
least one or more occasions, on both laryngeal squamous cell carcinoma cell lines and 
on UM-SCC 1 cell lines, using more recently obtained vials of cetuximab however no 
additional toxic effects were observed.  
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UM-SCC cell line 1 5 10A 11B 12 17A 17AS 81B 
Percentage decrease in MTT scores at 
1µM cetuximab as a proportion of 
controls, as recorded on the last day 
25% 47% 32% 10% 28% 25% 0% 35% 
 
Figure 4.7.3 Cetuximab has little toxicity even at 1μM on UM-SCC cells.  
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UM-SCC squamous carcinoma cells were seeded in 96 well plates and allowed to 
adhere for 24 hours (shown as day 0). Cells were then treated with either cetuximab at 
dilutions of 10nM, 30nM, 100nM, 300nM and 1μM or with drug vehicle control. As it 
was observed that cetuximab had little effect on viability/growth on the laryngeal 
squamous cell carcinoma cells there were concerns as to whether the samples of 
cetuximab used were functionally active. MTT assay was therefore also performed on a 
known cetuximab sensitive cell line UM-SCC 1 (derived from an oral tumour). However 
here it was found that UM-SCC 1 was also not sensitive to cetuximab. Experiments were 
repeated on at least one or more occasions using more recently obtained vials of 
cetuximab however no further toxic effects were observed. Table shows the percentage 
decrease in MTT scores of UM-SCC cells exposed to 1μM of cetuximab as a proportion 
of controls on day 7 for laryngeal carcinoma cells and day 5 for UM-SCC 1 cells. Both 
media and drugs were replaced every 24h. MTT assay was used to assess the 
viability/growth of cells. Absorbance was measured at an OD of 590 nm. Error bars 
represent the s.e.m. from four independent wells. 
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4.7.2 Cetuximab is able to inhibit EGF induced phospho EGFR in 
UM-SCC cells 
 
From previous results shown in this thesis EGF-SubA cytotoxicity appears to be 
dependent on EGFR (see Results sections 4.6 and 4.7). Therefore one of the objectives 
of this thesis was to investigate whether cytotoxic effects of EGF-SubA could be 
inhibited by cetuximab. Benavente and colleagues found that cetuximab was able to 
block the EGF-stimulated activation of EGFR resulting in reduction in phospho-EGFR 
levels in UM-SCC 1 cells (152). Cetuximab in a similar fashion may be able to prevent 
EGF-SubA from binding to EGFR.  
  
From the previous results as shown in Figure 4.7.3 it was seen that cetuximab failed to 
inhibit the proliferation/viability of UM-SCC cells to an extent where even IC50 levels 
could not be achieved. Therefore it was felt necessary to clarify whether or not 
cetuximab was at least able to prevent the binding of EGF on EGFR.  
 
The same experiment as performed by Benavente, on UM-SCC 1 cells, was repeated 
here on range of laryngeal cells including the most sensitive to cetuximab UM-SCC 81B 
and the most resistant UM-SCC 17AS as well as UM-SCC 5, 12, and 17A, and UM-
SCC 1. All cells were harvested once they had reached a confluence of 30%, as it had 
been previously noted through general observation that EGFR levels fluctuate at 
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different cell densities (see Figure 4.7.1.). UM-SCC cells were pre-treated with 300nM 
of cetuximab for two hours followed by addition of EGF at10 μg/ml, or treated with 
EGF at 10 μg/ml alone, or with drug vehicle control. 
 
In order to prevent phosphatase enzymes from dephosphorylating phospho-EGFR, 
phosphatase inhibitors were used as well as harvesting cells on ice to further inhibit 
cellular metabolism (see Methods section 3.5.8 for more details). Lysates were then 
processed for SDS-PAGE and western blot analysis. Anti phospho-EGFR antibody was 
used to detect levels of phosphorylated EGFR. Anti EGFR antibody was used to ensure 
that differences detected in phospho-EGFR expression were not due to fluctuations in 
EGFR levels. Anti tubulin antibody was used as a loading control. Despite UM-SCC 
lines showing high resistance to cetuximab in the MTT assay as shown in Figure 4.7.3, 
Figure 4.7.4 shows that cetuximab was able to adequately reduce EGF binding and 
prevent subsequent EGFR phosphorylation in all cell lines including UM-SCC 17AS 
which was the most resistant cell line to cetuximab. Regardless of the fact that 
cetuximab has little effect on viability/growth of UM-SCC cells, cetuximab may 
however be able to inhibit cytotoxic effects of EGF-SubA. Furthermore cetuximab 
resistance has been reported in the literature as being due to mutations downstream the 
EGFR signalling pathway such as Ras mutations and not on the ability of cetuximab to 
bind onto EGFR (52). Resistance to cetuximab has been discussed in the literature 
review (see section 1.2.3).  
Results part 1  
 
189 
 
 
Figure 4.7.4 Cetuximab inhibits EGF mediated phosphorylation of EGFR 
effectively.  
UM-SCC cells were grown and harvested at 30% confluence and either pre-treated with 
300nM of cetuximab for two hours followed where indicated by addition of EGF at 10 
μg/ml, or treated only with EGF at 10 μg/ml, or with drug vehicle as indicated. Cells 
were then harvested via cell scraping on ice using SLIP buffer mixed with 5 mM sodium 
fluoride, 1 mM sodium orthovandate and 10 mM sodium pyrophosphate. All lanes were 
loaded with 35 μg protein. Membranes were incubated with 3 µg/ml anti p-EGFR 
antibody, 3 µg/ml anti EGFR antibody and 1:10,000 dilution of anti tubulin antibody 
(protein loading control) as indicated. 
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EGF activates EGFR signalling pathway which can then help promote cell proliferation 
and survival (37). Cetuximab competitively binds to EGFR at a greater affinity than 
EGF thus preventing cell proliferative and pro-survival effects induced by EGF (54). 
Growth media of UM-SCC cells consists of in part foetal bovine serum which may not 
effectively stimulate the EGFR pathway way due to either a lack of EGF or bovine 
derived EGF which may not be able to interact with human EGFRs. Therefore 
inadequate stimulation of EGFR in present growth media may explain why the addition 
of cetuximab may not be effective at inhibiting the proliferation of laryngeal UM-SCC 
cells in vitro, even though it can efficiently block EGF induced phospho-EGFR as 
shown in Figure 4.7.4.  
 
As activation of EGFR signalling pathway is reported in part to be responsible for the 
proliferation and enhanced survival of cells, experiments conducted as part of this thesis 
aimed to determine whether the addition of recombinant human EGF (rhEGF) could 
enhance cell viability/growth as compared to cells grown without rhEGF (37). Secondly 
it was investigated whether cetuximab could block this potential rhEGF induced 
enhancement in cell viability/growth. 
 
 A preliminary experiment was used in order to establish dilutions of rhEGF that would 
achieve maximum phospho-EGFR levels. UM-SCC 81B cells at 30% confluence were 
incubated with either 0.1 μg/ml, 1 μg/ml or 10 μg/ml EGF for 45 minutes. Cells were 
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then harvested on ice using phosphatase inhibitors as described in Methods section 3.5.8. 
and then processed for western blot analysis. Figure 4.7.5 shows that the maximum level 
of phospho-EGFR was achieved at 1 μg/ml of EGF with no further increases in 
phospho-EGFR levels being detected at higher concentrations of rhEGF.  
 
One of the most sensitive laryngeal cell lines to cetuximab UM-SCC 81B and the most 
resistant cell line UM-SCC 17AS were then grown in 96 well plates with fresh media 
and reagents replaced daily. MTT assay was performed on days 0, 2, 4 and 6. UM-SCC 
cells were grown under the following conditions:  
 with cetuximab at 300nM alone 
 or with cetuximab at 300nM for two hours followed by 0.1 μg/ml or 1 μg/ml 
EGF. 
 or with 0.1 μg/ml or 1 μg/ml EGF. 
 or with drug vehicle control.  
It was predicted that the addition of human rhEGF would increase cell viability/growth 
in UM-SCC cells, compared to controls, and that cetuximab would be able to inhibit this 
enhancement in cell viability/growth. However as it can be seen in Figure 4.7.5 there 
was no increase in cell growth/viability in EGF-treated groups compared to controls in 
both UM-SCC 17AS and 81B and therefore no additional inhibitory effects of 
cetuximab were observed as compared to previous experiments as shown in Figure 4.7.3 
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Figure 4.7.5 UM-SCC 17AS and 81B cell viability/growth were not increased with 
the addition of EGF and there was no change to the inhibitory effect of cetuximab. 
 (A) Cells were incubated with dilutions of rhEGF for 45 minutes. Cells were harvested 
via scraping on ice using SLIP buffer mixed phosphatase inhibitors (Methods section 
3.5.8) followed by western blot analysis. Membranes were incubated with 3 µg/ml anti 
p-EGFR antibody, 3 µg/ml anti EGFR antibody and 1:10,000 dilution of anti tubulin 
antibody (protein loading control) as indicated. (B) UM-SCC 17AS and 81B were pre-
treated with cetuximab for 2 h followed by rhEGF, or both agents alone, or with drug 
vehicle control, for up to 6 days. MTT assay used to assess viability/growth (Methods 
section 3.12) . Error bars represent the s.e.m. from four independent wells.    
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4.7.3 Cetuximab does not act as a radiosensitizer in laryngeal 
squamous cell carcinoma cells.  
 
The above experiments showed that cetuximab has little effect at reducing the 
proliferation or viability of laryngeal and oral squamous carcinoma cells in vitro as 
determined by MTT assay. Although NICE guidelines in 2008 recommended the use of 
cetuximab in combination with radiation in locally advanced SCCHN there is currently 
very little published data which supports the use of cetuximab with radiation for 
laryngeal squamous cell carcinoma (as reported in section 4.7.1) with Bonner and 
colleagues phase III trial showing only marginal improvements in disease free and 
overall survival between patients with laryngeal cancer patients treated with cetuximab 
with radiotherapy as opposed to radiotherapy alone (151). As radiotherapy is one of the 
main treatment modalities in SCCHN it was felt necessary to clarify whether or not 
cetuximab acts as a radiosensitising agent, in vitro, to laryngeal squamous cell 
carcinoma cells. Therefore the radio-enhancing effects of cetuximab were studied on 
four laryngeal cell lines with varying p53 expression. Loss of p53 function has been 
associated with chemo- and radioresistance (153). Therefore, we examined a variety of 
UM-SCC cells of differing p53 status, to determine whether or not any potential 
radiosensitising effects of cetuximab observed were present regardless of p53 status 
(149). The cell lines studied were UM-SCC 17A which is wild-type for p53, UM-SCC 
12 which is p53 null (homozygous Q104X), UM-SCC 81B which has no p53 wild-type 
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alleles (mutant H193R), and UM-SCC 5 which has one p53 wild-type allele and a single 
p53 mutation (heterozygous V157F) in the absence of loss of heterozygosity (i.e. it 
retains a wild-type allele).  
 
 
In order to test possible radiosensitisation effects of cetuximab in vitro, a clonogenic 
assay was used. One of the main aims of cancer treatment is to prevent recurrence of 
tumour growth. A clonogenic assay measures the ability of individual cells to proliferate 
and form colonies after exposure to ionizing radiation, and this can be achieved in 
combination with cytotoxic drug treatments if required (126). A colony was defined as 
more than or equal to 50 cells which allows for an individual cell to have divided more 
than 5 times. Clonogenic assays were carried out as described in section 3.11.  
 
Pilot studies were performed in order to establish the highest drug concentration that 
cells could tolerate for 24h without radiation that would provide survival fractions equal 
to that of drug omitted controls. UM-SCC 12 and 81B were able to tolerate a cetuximab 
dose of 100nM without differences in survival fraction as compared to controls. Both 
UM-SCC 5 and UM-SCC 17A when treated with 100nM cetuximab without radiation 
had survival fractions below the controls and so cells were treated with a lower dose of 
cetuximab at 10nM. UM-SCC cells were pre-incubated with cetuximab or drug vehicle 
control for 24h before being irradiated with 0, 1, 2, or 4 Gy. Cells were then seeded in 
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triplicate into six well plates, in normal growth media without drug and monitored for 
colony formation for 2-3 weeks. 
 
Colonies were counted using a light microscope. The mean number of colonies were 
recorded for each set of triplicate samples. Survival fractions were calculated and 
radiation survival curves were fitted according to the linear-quadratic model 
S(D)/S(0)=exp (-(αD + βD2)), where D is the irradiation dose in Gy; α is the cell kill per 
Gy of the initial linear component and β is the cell kill per Gy2 of the quadratic 
component of the survival curve. SPSS PASW statistics package version 18 was used to 
find values of α and β and survival curves were plotted as seen in Figure 4.7.6. 
 
Regardless of p53 status cetuximab did not appear to act as a radiosensitising agent as no 
significant differences, as determined by unpaired Student’s t test, were found in 
survival fraction at 2 Gy(SF2) between radiated cells pre-treated with cetuximab 
compared to cells treated only with radiation as shown in Figure 4.7.6.  
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Figure 4.7.6 Cetuximab does not enhance the effect of radiation in LSCC cells.  
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(A, B, C, and D) UM-SCC cells were pre-treated for 24h with either 10 or100nM 
cetuximab or drug vehicle control and then exposed to γ-irradiation at 0, 1, 2, or 4 Gy 
as indicated. Clonogenic assays were established to allow for colony formation over a 
time period of two to three weeks. A colony was defined as equal to or more than 50 
cells in order to allow for at least five cell doubling times. Crosses and squares indicate 
means of three survival fractions for each data point with appropriate s.e.m. Cell 
survival curves were then fitted to the quadratic equation S(D)/S(0)= exp (-(αD + βD2)). 
(E) Table showing survival fractions at 2 Gy (SF2) with and without cetuximab. 
Unpaired Student’s t test was used to calculate differences in SF2 between controls and 
treated cells.  
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4.8 Cetuximab inhibits the cytotoxic effects of EGF-SubA 
 
Previous experiments conducted for this thesis indicate that the cytotoxicity of EGF-
SubA is dependent on the expression of EGFR. For example when EGF-SubA was 
tested on EGFR expressing mouse liver HEPA 1c1c7 cell lines the IC50 was 600pM 
whilst no cytotoxic effects were observed even at 1nM in mouse embryonic fibroblasts 
(MEFS) which do not express EGFR (Figure 4.6.1.). In addition there was a strong 
association between high levels of membrane EGFR and increased sensitivity to EGF-
SubA with a Spearman’s rank correlation coefficient of (rs) = 0.919 (p=0.007) (Figure 
4.7.2). 
 
It was also shown that pre-incubation of cetuximab for two hours was able to efficiently 
block EGF induced phospho-EGFR in a range of UM-SCC cells as shown Figure 4.7.4. 
 
Based on these previous findings cell counting assays were conducted in order to 
elucidate whether cetuximab, a mAb against EGFR, could inhibit the cytotoxic effects of 
EGF-SubA. These experiments were conducted with a view that EGF-SubA could be 
used as a topically peri or post operatively adjuvant with the aim of enhancing loco-
regional control, whilst cetuximab, which is already licensed for use in humans, could be 
used systematically to prevent any possible organ specific toxicity which might result 
from the use of EGF-SubA. 
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UM-SCC 12, 17A and 81B cells were seeded in 12 well plates, in sets of triplicate, and 
left to adhere for 24 hours. Cells were then treated with either EGF-SubA above and 
below IC50 doses, or pre-incubated with sub-toxic concentrations of cetuximab (10, 30 
and 100nM) for two hours prior to the application of EGF-SubA, or treated with drug 
vehicle control. Fresh drugs and media were replaced daily for a total of four days. Cell 
concentrations for each condition were determined by cell counting as explained in 
Methods section 3.13. p-values were calculated between samples exposed to the highest 
dose of EGF-SubA used with and without cetuximab, in order to establish whether there 
were statistically significant differences in cell number via the unpaired Student’s t test.  
 
In all cases, as shown in Figure 4.8.1, cetuximab even at 10nM was able to dramatically 
rescue cells from the cytotoxic effects of EGF-SubA. In UM-SCC 12 (Figure 4.8.1) 
untreated cells reached concentration of 7.3 × 10
5
 cells per ml. Cells treated with 
cetuximab at 10nM had a similar concentration of 7.4 × 10
5
 cells per ml. Cells treated 
with 1nM EGF-SubA had a reduced population of 2 × 10
5
 cells per ml whilst cells 
incubated with 10nM cetuximab prior to EGF-SubA had a significantly higher 
concentration of 6.8 × 10
5
 cells per ml where p < 5 × 10
-5
. 
 
In UM-SCC 17A (Figure 4.8.1) untreated cells reached a concentration of 6.3 × 10
5
 cells 
per ml. Cells treated with cetuximab at 10nM had a similar concentration of 6.8 × 10
5
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cells per ml. Cells treated with 50pM EGF-SubA had a reduced population of 2.1 × 10
5
 
cells per ml whilst cells incubated with 10nM cetuximab prior to EGF-SubA had a 
significantly higher concentration of 5.1 × 10
5
 cell per ml where p < 0.002. 
 
In UM-SCC 81B (Figure 4.8.1) untreated cells reached a concentration of 11.1 × 10
5
 
cells per ml. Cells treated with cetuximab at 10nM had a similar concentration of 8.4 × 
10
5
 cells per ml. Cells treated with 200pM EGF-SubA had a reduced population of 2.2 × 
10
5
 cells per ml whilst cells incubated with 10nM cetuximab prior to EGF-SubA had a 
significantly higher concentration of 10.0 × 10
5
 cell per ml where p < 9 × 10
-6
. 
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Figure 4.8.1 Pre-incubation with cetuximab is able to rescue cells from the 
cytotoxic effects of EGF-SubA.  
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Cells were seeded into 12 well plates and left to adhere for 24h. Cells were then treated 
with EGF-SubA above and below IC50 doses or pre-incubated with sub-toxic 
concentrations of cetuximab (10, 30 and 100nM) for two hours prior to the application 
of EGF-SubA, or with drug vehicle control. Fresh drugs and media were replaced daily 
for a total of four days. Cells were harvested and counted via a Beckman Coulter 
Counter on the last day. Error bars represent the s.e.m. from three independent wells. p-
values were calculated between the highest dose of EGF-SubA used with and without 
cetuximab, in order to establish whether there were statistically significant differences 
in cell number via unpaired Student’s t test.  
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5 Results part 2: EGF-SubA enhances the effect of 
current treatment modalities: 
a) by acting synergistically with cisplatin 
b) and as a radiosensitising agent. 
 
5.1 EGF-SubA acts synergistically with cisplatin 
 
Cisplatin is one of the main chemotherapeutic agents used in the treatment of head and 
neck cancer (106). Cisplatin forms DNA adducts by binding to DNA resulting in DNA-
DNA inter and more commonly intra-strand crosslinks. These cross links interfere with 
DNA replication, leading to suppression of RNA transcription and inhibition of cell 
division (107). DNA damage by intra-strand crosslinks are detected by damage 
recognizing proteins which coordinate the repair process in a response known as the 
nucleotide excision repair (NER) (154). DNA damage recognizing proteins also activate 
several signal transduction pathways including those involving ATR, p53 and MAPK 
which, in turn can promote cell cycle arrest and cell death – typically via apoptosis 
(107).  
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Tumour resistance to cisplatin is a major barrier to effective head and neck cancer 
therapy. Resistance to cisplatin induced apoptosis has been related to several factors 
such as: enhanced activity of PI3K/AKT, Ras mutations, hyper-activation of ErbB2, 
down regulation of proapoptotic proteins such as Bax and Bad, increase in Bcl-2 and 
Bcl-xL, and loss of p53 function (107).  
 
Recent studies suggest that over expression of GRP78 in tumours may contribute to 
cisplatin resistance. Lee and colleagues in 2008, transfected glioma cells with GRP78. 
Subsequent increases in GRP78 expression in these transfected cells lead to decrease in 
caspase 7 activation and rendered cells resistant to cisplatin induced apoptosis. Upon 
siRNA treatment against GRP78, decreased cell growth was observed as well as 
increased sensitisation to both cisplatin and radiation (108). Jiang and colleagues in 
2009, demonstrated that cisplatin mediated cytotoxicity of melanoma cells was 
significantly reduced in cells transfected with siRNA against caspase 4 and 7 siRNA 
(p<0.01) (110). Jiang and colleagues also explored the role of GRP78 in altering 
cisplatin induced activation of caspase 4 and 7. Upon siRNA knockdown of GRP78 
there was increased caspase 4 and 7 activity upon cisplatin treatment, whilst over 
expression of GRP78 suppressed caspase 4 and 7 activity (110). Hence up-regulation of 
GRP78 may suppress cisplatin induced cytotoxicity by inhibiting caspase activity. 
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GRP78 is known to inhibit apoptosis through direct interaction with BIK and procaspase 
7 (104), (109). Furthermore continued removal of GRP78 stimulates further the 
Unfolded Protein Response which activates both intrinsic apoptotic pathways through 
the induction of such proapoptotic proteins such as Bim and extrinsic apoptotic 
pathways through the induction of TRAIL ligand DR5 (92, 105). In addition Backer and 
colleagues in 2009 have shown that 1nM EGF-SubA treatment after 24h resulted in a 3-
fold increase in activated caspase 3 levels thus implying that EGF-SubA may induce 
apoptosis. For further information on how GRP78 and the Unfolded Protein Response 
regulate apoptosis see sections 1.3.5 and 1.3.6. 
 
Based on the studies by Lee and colleagues in 2008, and Jiang and colleagues in 2009, 
which point towards up-regulation of GRP78 contributing to cisplatin resistance we 
investigated, as part of this thesis whether or not EGF-SubA, which cleaves GRP78, 
could act synergistically with cisplatin. The use of multiple drugs with different 
mechanisms of action may help to ‘improve the efficacy of the therapeutic effect, 
decrease the dosage but increase or maintain the same efficacy in order to avoid toxicity 
such as nephrotoxicity and otoxicity which are side effects of cisplatin treatment (155), 
and minimize or slow down the development of drug resistance’ (156).  
 
Initially an MTT growth curves were established in order to measure the effects of 
cisplatin on the viability/growth of UM-SCC cells, as described in Methods section 3.12. 
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UM-SCC cells were treated with either cisplatin or with control vehicle for a total of 
seven day. Cisplatin IC50 values were taken on the seventh day of drug treatment as 
shown in Figure 5.1.1 and Figure 5.1.2. and ranged between 0.6 to 4μM. 
 
Published data regarding cisplatin sensitivity and p53 status is conflicting with some 
papers suggesting that cisplatin is more sensitive in p53 wild-type cells whilst other 
studies indicating that p53 mutant cells are more sensitive to cisplatin (107) (157). In 
order to determine whether EGF-SubA in combination with cisplatin, reduces cell 
viability/growth, regardless of p53 status a variety of UM-SCC cells were used. The cell 
lines studied were UM-SCC 17A which is wild-type for p53, UM-SCC 12 which is p53 
null (homozygous Q104X), UM-SCC 81B which has no alleles which are p53 wild-type 
(mutant H193R), and UM-SCC 5 which has one p53 wild-type allele and a single p53 
mutation (heterozygous V157F).  
 
Cells were treated with each of the two drugs individually, in combination, or with just 
control vehicle in quadruplicate sets. Fresh media and drugs were replaced daily for a 
total of seven days. Cell viability/growth was assed at the end of day seven via MTT 
assay. A range of values above and below the IC50 of both EGF-SubA and cisplatin were 
combined in order to establish whether there was any synergy, additive or antagonistic 
effect between these two drugs. 
 
Results part 2 
 
207 
 
 
Figure 5.1.1 UM-SCC cells dose response curves with cisplatin.  
UM-SCC Cells were seeded in 96 well plates and allowed to adhere for 24 hours (shown 
as day 0). Cells were then treated with cisplatin at concentrations of 0.1, 0.3, 1, 3,10 and 
30μM or with drug vehicle control, for up to seven days. Fresh media and drugs were 
replaced daily. MTT assay was used to assess the viability/growth of cells. Absorbance 
was measured at an OD of 590 nm. Error bars represent the s.e.m. from four 
independent wells. 
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Figure 5.1.2 UM-SCC cell IC50 curves with cisplatin.  
IC50 data derived from day seven of UM-SCC cells being treated with cisplatin at 
concentrations of 0.1, 0.3, 1, 3, 10 and 30μM or just drug vehicle control. IC50 curves 
were plotted as: percentage MTT scores of UM-SCC cells exposed to drug as a 
proportion of controls on day 7 (y axis) against the dose of the drug on a log scale (x 
axis). 
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For quantification of synergy or antagonism the Combination Index (CI) was used (156). 
A range between 0.9-1.1 was defined as additive, less than 0.9 indicated synergism and 
more than 1.1 was described as an antagonistic effect. CI was calculated as (D)1/(Dx)1 + 
(D)2/(Dx)2. The denominator, (Dx)1 and (Dx)2 is the dose of each of the drugs which, 
when used alone results in a fixed affect, for example the IC50. The numerators (D)1 and 
(D)2 are the doses of each drug which when used in combination, to achieve the same 
fixed effect (156). 
 
An isobologram is a visual representation of the CI. The x and y axis represents the dose 
of each drugs used. A line is then drawn linking (Dx)1 and (Dx)2 together. Points are then 
plotted along the graph where combined doses produce the same fixed effect as when 
both drugs are used individually. Points close to the line represent CI of 1 or an additive 
effect. Points to the left of the line represent a synergistic effect and points to the right 
represent an antagonistic effect. The distance away from the line indicates the magnitude 
of the synergistic or antagonistic effect.  
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Figure 5.1.3 UM-SCC cells treated with either EGF-SubA, or cisplatin or in 
combination. 
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EGF-SubA (pM)      7.5  15   30   60          - - - - 7.5  7.5   7.5   7.5      15   15   15    15      30   30   30   30          60   60   60   60
Cisplatin (µM)      - - - - 0.5   1       2     4           0.5   1     2      4          0.5   1   2      4          0.5   1     2     4           0.5    1     2     4     
p<0.05 p<0.05                                p<0.05
20
30
40
50
60
70
80
UM-SCC 81B
EGF-SubA (pM)     5     10   15  22.5       - - - - 5      5     5    5            10    10  10   10        15     15   15  15     22.5  22.5 22.5 22.5      
Cisplatin (µM)       - - - - 0.6   1.2    2    2.6        0.6  1.2  2   2.6          0.6  1.2   2    2.6        0.6   1.2   2   2.6       0.6   1.2   2   2.6                                          
p<0.05                                       p<0.05                    p<0.05
0
10
20
30
40
50
60
70
80
90
UM-SCC 12
EGF-SubA (pM)     25   50  100   200       - - - - 25    25     25    25      50     50   50     50    100  100  100 100     200 200 200 200 
Cisplatin (µM)    - - - - 0.5   1     2       4        0.5    1     2      4          0.5   1    2      4        0.5   1       2     4         0.5    1     2     4
p<0.05                                                        p<0.05% 
MTT 
score
% 
MTT 
score
% 
MTT 
score
% 
MTT 
score
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UM-SCC 5,12, 17A and 81B cells were seeded in 96 well plates and allowed to adhere 
for 24 hours. Cells were then treated with either cisplatin at the stated concentrations or 
with EGF-SubA at the stated concentrations, or in combination, or with drug vehicle 
control. Fresh media and drugs were replaced daily for a total of seven days. MTT assay 
was used to assess the viability/growth of cells after day seven. Absorbance was 
measured at an. OD of 590 nm. Bars represent the percentage MTT score of treated 
groups as a proportion of controls. Error bars show the s.e.m. from four independent 
wells. In the majority of cases there were statistically significant reductions in MTT 
score when MTT scores from cells treated with single agents were compared to MTT 
scores of cells treated with both cisplatin and EGF-SubA as deduced by unpaired 
Student’s t test (p<0.05). 
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Figure 5.1.4 IC50 plots for UM-SCC cells treated with either EGF-SubA, or 
cisplatin, or in combination. 
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IC50 values were calculated from log plots derived from data as shown in Figure 5.1.3 
for either cisplatin on its own, EGF-SubA on its own and any IC50 values established 
when cisplatin and EGF-SubA were used in combination. IC50 curves were plotted as: 
percentage MTT score in the drug treated group as a proportion of the control group (y-
axis) against the dose of the drug on a log scale (x-axis). 
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Figure 5.1.5 IC50 Isobolograms summarising the combinatorial effect of cisplatin 
with EGF-SubA 
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(25/70)+(0.6/2.5)= CI 0.597
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Data derived from Figure 5.1.4 was used to plot isobolograms for UM-SCC cells 5, 12 
and 17A. A line joining the IC50 value of EGF-SubA and the IC50 value of cisplatin for 
each of the cell lines was plotted. Any IC50 values derived form the combination of both 
EGF-SubA with cisplatin were also plotted as indicated by triangles. Triangles to the 
left of the isobolar line indicate synergistic effects between cisplatin and EGF-SubA 
(where combination indexes are 0.9 or less). Triangles plotted on the line indicate 
additive effects (where combination indexes are close to 1). Triangles plotted to the right 
indicate antagonistic effects (where combination indexes are greater than 1.1). CI was 
calculated as (D)1/(Dx)1 + (D)2/(Dx)2. The denominator, (Dx)1 and (Dx)2 is the dose of 
each of the drugs which, when used alone results in a fixed affect, for example the IC50. 
The numerators (D)1 and (D)2 are the doses of each drug which when used in 
combination, to achieve the same fixed effect (156) 
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EGF-SubA and cisplatin, regardless of p53 status, when used together produced 
combination index (CI) scores of less than 0.9 in UM-SCC 5, UM-SCC 12 and UM-
SCC 17A as seen in Figure 5.1.5 and this is indicative of synergy. Furthermore a 
statistically significant reduction in MTT score was observed in UM-SCC 81B when 
MTT scores from cells treated with single agents were compared to MTT scores of cells 
treated with both cisplatin and EGF-SubA (p<0.05) (Figure 5.1.3). An IC50 isobologram 
could not be plotted or CIs calculated in order to quantify whether the effects observed 
in UM-SCC 81B cells were either additive or synergistic as drug combinatorial MTT 
scores were greater than the IC50 and MTT scores when drugs were used as single agents 
were less than the IC50.  
 
5.2 Cisplatin in combination with EGF-SubA reduces levels of 
GRP78. 
 
Cleavage of GRP78 via EGF-SubA induces the Unfolded Protein Response (5). This 
then results in the activation of transcription factor ATF6 which up-regulates GRP78 
(87) (see section 1.3.2 for more detail). From previous results in this thesis (see section 
5.1) it has been shown that cisplatin acts synergistically with EGF-SubA. McCollum and 
colleagues have demonstrated that cisplatin prevents induction of the protein chaperone 
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HSP72 upon treatment with geldanamycin so here we investigated whether cisplatin 
may also prevent the induction of GRP78 upon treatment of cells with EGF-SubA.   
 
From Figure 4.1.2 it can be seen that treatment with 1nM EGF-SubA after 24h did not 
leave any uncleaved GRP78 intact. As one of the aims of this experiment was to 
determine whether cisplatin could further reduce the level of uncleaved GRP78 in 
combination with EGF-SubA a lower dose of 100pM EGF-SubA for 24h was chosen 
which was found to be sufficient to cleave a portion of the GRP78 in the cells but not all. 
A high dose of cisplatin at 20μM for 24h, which is at least five times the IC50 of the UM-
SCC cell lines, was chosen in order to exert the maximum effect of cisplatin on levels of 
GRP78. In summary, cells were treated with either EGF-SubA at 100pM, or cisplatin at 
20μM, separately or in combination, or with drug vehicle control, for 24h. Cells were 
then harvested and processed for SDS-PAGE as explained in section 3.5 and GRP78 
levels were analysed via western blot as shown in Figure 5.2.1. EGF-SubA at 100pM 
was able to cleave GRP78 as. However in all four cell lines there did not appear to be 
any loss in uncleaved levels of GRP78 upon treatment of EGF-SubA alone, implying 
that the UPR, via presumably ATF6, was stimulating the up-regulation of additional 
GRP78. (87). In UM-SCC 5, 12, and 81B cisplatin as a single agent did not alter levels 
of GRP78. However there was a demonstrable reduction in GRP78 levels in wild-type 
p53 cell line UM-SCC 17A when cisplatin was used alone. Published data provides 
conflicting evidence on the effect cisplatin has upon basal levels of GRP78. Some 
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studies have shown that levels of GRP78 are unaffected by treatment with cisplatin 
(158), whilst others have demonstrated evidence of increased GRP78 (159) or even 
decreased GRP78 levels (160). 
 
When EGF-SubA was combined with cisplatin there was a marked loss of uncleaved 
GRP78 compared to either cisplatin alone, EGF-SubA alone, or drug vehicle control. 
Just as cisplatin is able to block the binding of HSF-1 to chromatin, upon treatment with 
geldanamycin leading to inhibition of HSP72 induction (161), it could be hypothesised 
that cisplatin may also block the interaction of ATF6 with chromatin thus preventing the 
induction of GRP78. The reduced levels of whole GRP78 when combining EGF-SubA 
with cisplatin may explain the synergistic effects found in Results section 5.1. 
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Figure 5.2.1 Cisplatin in combination with EGF-SubA reduces uncleaved GRP78 
levels.  
Western blot analysis of UM-SCC 5, 12, 17A and 81B treated as indicated with either 
EGF-SubA at 100pM, or cisplatin at 20μM, or in combination, or with drug vehicle 
control for 24h. All lanes were loaded with 35 μg protein. Blots were probed for GRP78 
(sc-13968) at 3 µg/ml and actin at 3 µg/ml (protein loading control).  
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5.3 EGF-SubA in combination with cisplatin enhances 
apoptosis in three out of the four UM-SCC cell lines 
examined.  
GRP78 is known to inhibit apoptosis through direct interaction with BIK and procaspase 
7 (104), (109). Furthermore cleavage of GRP78 initiates the UPR which activates both 
the intrinsic apoptotic pathway through the induction of proapoptotic proteins such as 
Bim and the extrinsic apoptotic pathway through the induction of TRAIL ligand DR5 
(92, 105). For further information on how GRP78 and the Unfolded Protein Response 
regulate apoptosis see sections 1.3.5 and 1.3.6. In addition Backer and colleagues have 
shown that 1nM EGF-SubA treatment after 24h increased activated caspase 3 levels by 
three folds in prostate and breast cancer cells thus suggesting that EGF-SubA may lead 
to apoptosis. 
 
As previously mentioned Lee and colleagues as well as Jiang and colleagues, 
demonstrated that up- regulation of GRP78 suppressed caspase 4 and 7 activation in 
cisplatin treated cells whilst siRNA against GRP78 sensitised cells to cisplatin and 
increased caspase 4 and 7 activation (108, 110). 
 
 Results in this thesis (see section 5.1) have shown that cisplatin in combination with 
EGF-SubA produces a synergistic effect dramatically reducing cell viability/growth of 
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laryngeal squamous cell carcinoma cells when compared to cells being treated with 
either cisplatin or EGF-SubA alone. Although previous studies have reported that 
cisplatin induces apoptosis in laryngeal cells (162) currently EGF-SubA has only been 
shown to induce apoptosis in prostate and breast cancer cells (5). Here for the first time 
it was investigated whether EGF-SubA was able to induce apoptosis in laryngeal 
squamous carcinoma cells and secondly whether cisplatin in combination with EGF-
SubA enhances further apoptosis.  
 
In order to quantify the amount of cell undergoing apoptosis an Annexin V-PI apoptosis 
assay as described in section 3.6. was used. During the early stages of apoptosis there is 
loss of phospholipid membrane symmetry which leads to exposure of protein 
phosphatidyl serine (PS) from the inside to the outside of the cell membrane (123). 
Annexin V can bind to PS in the presence of calcium and therefore Annexin V 
conjugated to fluorochrome FITC can be used to indicate early stages of apoptosis. 
During late apoptosis there is loss in membrane integrity and PI can now enter cells. A 
population of unfixed cells can therefore be stained simultaneously with both PI (red 
fluorescence) and FITC (green fluorescence) conjugated Annexin V, and analysed by 
flow cytometry. 
 
 Four subset populations of cells will appear on a dot plot graph of Annexin V versus PI. 
Cells which remain unstained are healthy cells. Cells which stain with just Annexin V 
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are undergoing early apoptosis. Cells which stain with just PI are necrotic cells and cells 
which stain with both Annexin V and PI are cells which have entered late apoptosis. 
These four subsets can be divided using a quadrant grid and the percentage of cells in 
each quadrant can be calculated. 
 
In order to first calibrate the position of the four quadrants, for each of the cell lines, a 
known healthy population of cells had to be compared to an acknowledged apoptotic 
population of cells. Staurosporine is a tyrosine kinase inhibitor which is a known potent 
inducer of apoptosis. Cells were treated with 2μM staurosporine or drug vehicle control 
for 24h. All cells including any cells which were floating in the media, which were most 
likely dead, were harvested and processed for apoptosis analysis as described in section 
3.6. A BD FACSCalibur flow cytometer was used and the data were analysed on 
CellQuest Pro Software.  
 
As seen in Figure 5.3.1 staurosporine induced apoptosis in UM-SCC 5, 12, 17A and 
81B, increasing the amount of cells in the apoptotic state by 82.5%, 71%, 89% and 89% 
respectively. Following calibration, the defined quadrants were used in order to 
investigate the level of apoptosis induced in these series of experiments. 
 
Cells were treated for four days with either EGF-SubA at 300pM, or with cisplatin at 
2μM, or in combination, or with drug vehicle control. Fresh drugs and media were 
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replaced daily. As in the calibration experiments, all cells including any cells which 
were floating in the media, which were most likely dead, were harvested and processed 
for apoptosis analysis as described in section 3.6. A BD FACSCalibur flow cytometer 
was used and the data were analysed on CellQuest Pro Software.  
 
EGF-SubA can be seen to induce apoptosis in all four cell lines (Figure 5.3.2). The 
percentage of apoptotic cells compared to controls increased by: 9% in UM-SCC 5, 21% 
in UM-SCC 12, 45% in UM-SCC 17A and 12% in UM-SCC 81B.  
 
Similarly cisplatin also induced apoptosis in all four cell lines (Figure 5.3.2). The 
percentage of apoptotic cells compared to controls increased by: 24% in UM-SCC 5, 
23% in UM-SCC 12, 58% in UM-SCC 17A and 28% in UM-SCC 81B. 
 
When EGF-SubA was combined with cisplatin the percentage of apoptotic cells 
compared to cells treated with either cisplatin alone or EGF-SubA alone increased by at 
least: 19% in UM-SCC 12, 21% in UM-SCC 17A and 8% in UM-SCC 81B(Figure 
5.3.2). However no further increase in the percentage of cells undergoing apoptosis was 
observed in UM-SCC 5 when EGF-SubA was combined with cisplatin as opposed to 
cells treated with either cisplatin alone or EGF-SubA alone. 
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Figure 5.3.1 Staurospine induces apoptosis in UM-SCC cells. 
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Cells were treated with either 2μM staurosporine, which is a known apoptotic inducing 
agent, or drug vehicle control for 24h in order to calibrate the quadrants for further 
apoptosis studies. Cells were analysed for signs of apoptosis using Annexin V/PI 
staining followed by flow cytometry. Data were processed on CellQuest Pro Software. 
Upper left quadrant shows necrotic cells (Annexin V –ve/ PI +ve), lower right shows 
healthy population of cells (Annexin V –ve/ PI –ve), upper right shows cells which have 
entered late apoptosis (Annexin V +ve/ PI +ve), and lower right quadrant shows cells 
which are entering early apoptosis (Annexin V +ve/ PI –ve). Numbers represent the 
percentage of cells in each quadrant.  
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Figure 5.3.2 Apoptosis assays measuring the effects of either EGF-SubA, or 
cisplatin, or in combination, upon UM-SCC cells.  
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Cells were treated with either EGF-SubA at 300pM, or with cisplatin at 2μM,or in 
combination or with drug vehicle control For 4 days. Apoptosis was assessed  using 
Annexin V/PI followed by flow cytometry. Data was processed on CellQuest Pro 
Software with numbers representing the percentage of cells in each quadrant. 
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5.4 EGF-SubA acts as radiosensitising agent. 
 
Radiation therapy is one of the main treatment modalities for head and neck cancer. 
Radio-sensitizing agents may help in reducing the known side effect of radiotherapy 
such as xerostomia, mucositis and dermatitis, by facilitating a decrease in the overall 
dose of radiation required to achieve a desired effect. 
 
Up-regulation of transmembrane protein EGFR in SCCHN is implicated in 
radioresistance. A correlative study was performed, by Ang and colleagues, which 
examined EGFR levels in patients with advanced head and neck cancer who had undergone 
radiotherapy (51). Patients who had low levels of EGFR had significantly greater overall 
survival rates, disease frees survival, and local regional control (51). Cetuximab which 
blocks the EGFR proliferative pathway has been shown to be a radiosensitising agent. A 
study by Liang and colleagues demonstrated that there was increased radioresistance in 
clones over expressing EGFR compared to parental lines and that radioresistance was 
reduced with the addition of cetuximab (61). Therefore other drugs which result in the 
decrease of EGFR levels may also act to enhance the effects of radiation.  
 
The endoplasmic reticulum (ER) is a site which processes many proteins which are 
destined for the cell membrane. As GRP78 is a protein chaperone responsible for the 
correct folding of nascent proteins which enter the ER we investigated whether cleavage 
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of GRP78 via EGF-SubA could lead to the reduction of the transmembrane protein 
EGFR. UM-SCC cells were treated with either EGF-SubA at 1nM for 24 h or drug 
vehicle control. Subsequent western blot analysis revealed that EGF-SubA was able to 
reduce EGFR protein levels in UM-SCC 10A, 5, 11B, and 12 (Figure 5.4.1).  
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Figure 5.4.1 EGF-SubA reduces EGFR levels. 
 Western blot analysis of UM-SCC 10A, 5, 11B and 12 treated with either EGF-SubA at 
1nM or drug vehicle control for 24h. All lanes were loaded with 35 μg protein. Blots 
were probed with EGFR at 3 µg/ml and actin 3 µg/ml (protein loading control).  
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In addition, several studies have associated elevated GRP78 per se with a radio resistant 
phenotype. Lin and colleagues in 2010, and Feng and colleagues in 2010, found GRP78 
to be up-regulated in clones which were able to survive a higher dose of ionising 
radiation compared to their parental cell lines (3, 8). Feng and colleagues also found up-
regulation of GRP78 in radio resistant nasopharyngeal carcinomas thereby implying the 
possibility that elevated GRP78 could act as a biomarker of radiosensitivity. Lee and 
colleagues in 2008, found that silencing of GRP78 via transfection with siRNA against 
GRP78, significantly enhanced the sensitivity of glioblastoma cells to radiation (108).  
 
Several lines of evidence from data presented in this thesis suggest that EGF-SubA may 
be a radiosensitising agent. As seen in Figure 5.4.1, EGF-SubA is capable of down 
regulating EGFR as well as cleaving GRP78 (see Figure 4.1.1). High levels of EGFR 
and GRP78 are implicated in radioresistance and therefore any reduction in their levels 
may be expected to confer radiosensitivity. We have also shown that EGF-SubA leads to 
G1 cell cycle arrest (see Figure 4.5.1). Cells in G1 are known to be more sensitive to 
radiation compared to cells in S phase (150). Following on from these findings we 
investigated whether pre-treatment with EGF-SubA was able to radiosensitise UM-SCC 
cells.  
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In order to test radio sensitisation in vitro, a clonogenic assay was used as described in 
section 3.11. Loss of p53 function has been associated with chemo- and radioresistance 
(153). Therefore, we examined a variety of UM-SCC cells of differing p53 status, to 
determine whether or not any potential radiosensitising effects of EGF-SubA observed 
were present regardless of p53 status (149). As described previously, the cell lines 
studied were UM-SCC 17A which is wild-type for p53, UM-SCC 12 which is p53 null 
(homozygous Q104X), UM-SCC 81B which has no alleles which are wild-type p53 
(mutant H193R) and UM-SCC 5 which has one wild-type p53 allele and a single p53 
mutation (heterozygous V157F).  
 
Pilot studies were performed in order to establish the highest drug concentration applied 
over 24 hours, which cells could tolerate as measured by survival fractions equal to that 
of drug omitted controls. UM-SCC 12, 17A and 81B were able to tolerate an EGF-SubA 
dose of 10pM without differences in survival fraction as compared to controls. UM-SCC 
5 treated with 10pM EGF-SubA without radiation had a survival fraction below the 
control and so cells were treated with a 3pM dose of EGF-SubA. UM-SCC cells were 
pre-incubated with EGF-subA or appropriate drug vehicle control for 24h before being 
irradiated with 0, 1, 2, or 4 Gy. Cells were then seeded in triplicate into six well plates, 
in normal growth media without drug and monitored for colony formation for 2-3 
weeks. 
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Colonies were counted using a light microscope. The mean number of colonies were 
recorded for each set of triplicate samples. Survival fractions were calculated and 
radiation survival curves were fitted according to the linear-quadratic model 
S(D)/S(0)=exp (-(αD + βD2)), where D is the irradiation dose in Gy; α is the cell kill per 
Gy of the initial linear component and β is the cell kill per Gy2 of the quadratic 
component of the survival curve. SPSS PASW statistics package version 18 was used to 
find values of α and β and survival curves were plotted as seen in  
Figure 5.4.2 
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Figure 5.4.2 EGF-SubA is able to radiosensitise UM-SCC cells regardless of p53 
status.  
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UM-SCC cells were pre-treated for 24h with EGF-SubA at either 3 or 10pM or drug 
vehicle control and then exposed to γ-irradiation at 0, 1, 2, or 4 Gy as indicated. 
Clonogenic assays were established to allow for colony formation over a time period of 
two to three weeks. A colony was defined as equal to or more than 50 cells in order to 
allow for at least five cell doubling times. Crosses and squares indicate means of three 
survival fractions for each data point with appropriate s.e.m. Survival curves were then 
fitted to the quadratic equation S(D)/S(0)= exp (-(αD + βD2)). (E) Bar charts showing 
survival fractions at 2 Gy with and without EGF-SubA. Unpaired Student’s t test was 
used to calculate differences in SF2 between controls and treated cells. 
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EGF-SubA was able to radiosensitise UM-SCC cells, regardless of p53 status as shown 
in  
Figure 5.4.2. At 2 Gy the survival fraction was significantly reduced by 17% (p<0.03), 
30% (p<0.02), 34% (p<0.002), 27% (p<0.002) in UM-SCC 5, 12, 17A and 81B 
respectively as compared to controls.  
 
From previous experiments in section 5.1 it was seen that EGF-SubA acted 
synergistically with cisplatin in reducing cell viability/growth, therefore it was 
investigated whether EGF-SubA in combination with cisplatin could further enhance the 
effects of radiation. Pilot studies were performed in order to establish the highest 
combined drug concentrations that cells could tolerate for 24h without radiation as 
measured by survival fractions equal to that of drug omitted controls. UM-SCC 5cells 
were pre-incubated with either EGF-SubA at 3pM alone, or with cisplatin at 1µM alone, 
or both drugs in combination, or with drug vehicle control for 24h before being 
irradiated with 0, 1, 2, or 4 Gy. Cells were then seeded in triplicate into six well plates, 
in normal growth media without drugs and monitored for colony formation for 2-3 
weeks. 
 
Clonogenic assays were set up as described in section 3.11. SF2 of EGF-SubA was 17% 
lower than controls (p=0.027), SF2 of cisplatin was 21% lower than controls (p=0.046). 
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When EGF-SubA was combined with cisplatin the SF2 was 24% lower than controls 
(p=0.008) as seen in Figure 5.4.3. Although EGF-SubA combined with cisplatin reduced 
the survival fraction by a further 3% as compared to when cisplatin was used alone this 
difference was not significant (p=0.6)  
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Figure 5.4.3 EGF-SubA in combination with cisplatin does not significantly 
enhance the effect of radiation any further than when these drugs are used 
independently.  
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(A) UM-SCC 5 cells were pre-treated for 24h with either EGF-SubA at 3pM, or cisplatin 
at 1μM, or in combination, or drug vehicle control and then exposed to γ-irradiation at 
0, 1, 2, or 4 Gy as indicated. Clonogenic assays were established to allow for colony 
formation over a time period of two to three weeks. A colony was defined as equal to or 
more than 50 cells in order to allow for at least five cell doubling times. Circles and 
triangles indicate means of three survival fractions for each data point with appropriate 
s.e.m. Survival curves were then fitted to the quadratic equation S(D)/S(0)= exp (-(αD + 
βD2)). (B) Bar charts showing survival fractions at 2 Gy with and without EGF-SubA. 
Unpaired Student’s t test was used to calculate statistical differences in SF2 between 
various treatment groups. 
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6 Discussion 
 
Protein chaperone GRP78, a key component of the Unfolded Protein Response which is 
induced as part of a survival response under certain conditions of stress common in 
cancer (hypoxia/hypoglycaemia), has been shown to be up-regulated in a wide variety of 
cancers(1, 4). The up-regulation of GRP78 in tumours has been associated with poor 
survival outcome as well as increased resistance to current cancer therapies (1, 8, 97, 
120). Thus we examined GRP78 expression in head and neck cancers. In addition to this 
we investigated the impact of a novel compound EGF-SubA, which promotes 
proteolysis of GRP78. EGF-SubA was tested upon a panel of LSCC cells, in vitro, used 
alone and in combination with clinically relevant agents.  
 
6.1 Validation of anti-GRP78 antibody for use in IHC 
Currently there are no published data regarding GRP78 expression levels in patients 
with laryngeal cancers which constitute the largest sub group of head and neck patients 
or in and oropharyngeal and hypopharyngeal tumours (10). Immunohistochemical (IHC) 
staining of a tissue micro array (TMA) was used in order to determine GRP78 
expression levels in laryngeal, oropharyngeal and hypopharyngeal squamous cell 
carcinoma tissues compared to histologically normal adjacent tissue samples.  
Discussion 
 
241 
 
 
The position and intensity of DAB staining in IHC is meant to be representative of the 
location and quantity, respectively, of the protein of interest, however this is based on 
the ‘assumption that both the primary and secondary antibodies are selectively bound to 
their targets’ (163).  
 
Antibodies may cross-react with other proteins and therefore it is important to first 
validate the antibody specificity prior to IHC via other techniques such as western blot. 
An initial BLAST search confirmed that the GRP78 protein shares 65% amino acid 
identity with HSP72. Therefore there is a strong possibility that a specific epitope on 
GRP78 which is recognised by an antibody will also be present on HSP72.  
 
One of our initial objectives was to find an antibody for IHC, which was specific for 
GRP78 and did not cross-react with other proteins. First the specificity of anti-GRP78 
antibody (sc-1050) was tested via western blot as this antibody had been previously used 
in the IHC head and neck study by Feng et al.,(3). As mentioned in section 1.3.11, SubA 
is only known to cleave protein GRP78 (a 72kDa protein) (7). Cleavage of GRP78 by 
SubA results in 44 and 28 kDa fragments. Therefore we used EGF-SubA to test the 
specificity of anti-GRP78 antibodies since following treatment with EGF-SubA we 
would expect a reduction in the intensity of the 72kDa band on a western blot and the 
appearance of a band corresponding to one or the other cleavage products of GRP78. 
Discussion 
 
242 
 
 
The western blot in Figure 4.1.1 shows two bands between marker weights of 58 kDa 
and 80 kDa. Upon application of EGF-SubA the slower migrating band, which was 
thought to be GRP78, disappeared and a new band appeared between marker weights of 
30 kDa and 46 kDa. It appears likely that the new band was the 44 kDa cleaved product 
of GRP78, which contains the N-terminus recognised by the anti-GRP78 antibody (sc-
1050). 
 
The anti-GRP78 antibody (sc-1050) appeared to strongly cross-react with an unknown 
protein running just ahead of the uncleaved GRP78 band between marker weights of 58 
kDa and 80 kDa. Furthermore, intensity of this band was not altered by the application 
of EGF-SubA. If this antibody was used as a primary antibody for IHC, it would mean 
that analysis of GRP78 expression in the TMA would be unreliable, as IHC staining 
would be indistinguishable between GRP78 and the unknown protein. Therefore this 
antibody was deemed unsuitable for use in IHC. 
 
Next, the specificity of anti-GRP78 (sc-13968), rabbit polyclonal antibody, as a possible 
antibody for IHC was examined by western blot. Gels were loaded with the lysates from 
the same samples as used in the western blots shown in Figure 4.4.1. In order to 
determine whether anti-GRP78 antibody (sc-13968) cross-reacted with any other 
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protein, whole membranes were blotted with anti-GRP78 antibody (sc-13968). As seen 
in Figure 4.1.2, anti-GRP78 antibody (sc-13968) revealed a band which lay between 
marker weights of 58 kDa and 80 kDa. Upon application of EGF-SubA this band 
disappeared, therefore it was deduced that this band was GRP78 and a new band 
between marker weights of 23 kDa and 30 kDa appeared. The new band appears to be 
the 28 kDa cleaved carboxyl-terminal fragment of GRP78 which contains the epitope 
recognised by this antibody. Apart from the bands believed to be those of GRP78 and 
cleaved GRP78 no other bands were visible, therefore it was concluded that there was 
considerably less cross-reactivity to other proteins with anti-GRP78 antibody (sc-13968) 
compared to (sc-1050).  
 
As previously mentioned incubating membranes with anti-GRP78 antibody (sc-1050) 
revealed a non-specific band migrating just ahead of the main GRP78 band, as seen in 
Figure 4.1.1, which was not affected by EGF-SubA. As HSP72 and GRP78 antibody 
share 65% identity and are of similar molecular weight, it appears likely that this non-
specific band was HSP72. In order to identify whether anti-GRP78 antibody (sc-1050) 
cross-reacted with HSP72, an HSP90 inhibitor was used. HSP90 inhibitors AT13387 
competitively prevents ATP binding to the N-terminus of HSP90 (135). This results in 
the disruption of the inhibitory interaction of HSP90 with the transcription factor, heat 
shock factor (HSF) (136). Upon HSP90 inhibition HSF induces up-regulation of HSP72. 
Furthermore, HSP90 inhibition leads to proteasomal degradation of HSP90 client 
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proteins such as EGFR (137). Thus with HSP90 inhibitors an increase in HSP72 levels 
and a decrease in EGFR levels is observed. See Appendix section 7.2 for a review of 
HSP90 inhibitors. 
 
UM-SCC 81B cells were treated with HSP90 inhibitor AT13387 at 1μM for 24h(135). 
SDS-PAGE followed by western blot analysis was used to identify whether or not 
HSP72 induction could be detected by anti-GRP78 antibody (sc-1050). As presented in 
Figure 4.1.3, HSP72 was detected using anti-HSP72 antibody in lanes 1 and 2. 
Comparing lanes 1 and 2 it is clear that treatment with AT13387 lead to HSP72 
induction as expected. Furthermore, there was a reduction in EGFR levels in lane 2 
compared to lane 1, again, as expected. 
 
Using anti-GRP78 antibody (sc-1050) a strong signal was detected in untreated cells in 
lane 5, which was located at the same position as HSP72 in lanes 1 and 2. Furthermore, 
this band was induced when cells were treated with AT13387, as shown in lane 6, with a 
stronger signal being emitted from this band compared to GRP78. This almost certainly 
indicates that there is significant cross-reaction of the anti-GRP78 antibody (sc-1050) 
with HSP72. Therefore, studies which have reported the expression of GRP78 via the 
use of immunohistochemical staining with anti-GRP78 antibody (sc-1050) may not be 
reliable. 
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 Using anti-GRP78 antibody (sc-13968), GRP78 was the only protein detected in 
untreated cells present in lane 3. In cells treated with AT13387 a weak signal was visible 
running just ahead of GRP78, which was at the same position as HSP72 in lanes 1 and 2. 
However, the majority of the signal was derived from the GRP78 protein. Results 
presented in this thesis indicate that anti-GRP78 antibody (sc-13968) appears to be less 
cross-reactive with other proteins and may therefore be a more suitable antibody for IHC 
than anti-GRP78 antibody (sc-1050). Although there is one commercially available 
monoclonal antibody to GRP78 sold by Abcam (ab12223), which in theory could be 
more specific to GRP78 than equivalent polyclonal antibodies, Abcam has shown that it 
cross-reacts considerably with GRP94 (164). Therefore it was decided to proceed with 
anti GRP78 antibody sc-13968 for use as the primary antibody for IHC. 
 
Prior to performing IHC on the TMA, the anti-GRP78 antibody (sc-13968) was tested 
on sections of SCCHN tissue samples as shown in Figure 4.3.1. Omission of the primary 
antibody was used in order to test the specificity of the secondary antibody as shown in 
Figure 4.3.1A . Without the primary antibody there was no DAB staining. A different 
section from the same tumour block was then incubated with the primary antibody. 
Figure 4.3.1D at 400X original magnification shows homogeneous cytoplasmic staining 
with no staining within the nucleus, in accordance with expected the localisation of 
GRP78 in the cell (4).  
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6.2 GRP78 is significantly up-regulated in SCCHN 
GRP78 levels were significantly higher in the tumour tissue samples (n=45) compared 
with matched histologically normal tissue samples (n=45). 84% of tumour cores versus 
24% of histologically normal cores were given a staining score of either 2 (moderate 
staining) or 3 (strong staining) (p (Χ2)<0.001). See Table 4.3.1 for more details. These 
findings are in line with the study by Du et al., where it was found that GRP78 levels 
were significantly higher in oesophageal squamous cell carcinoma tissue compared to 
normal histological tissue (p = 0.047).  
 
6.3 GRP78 can be induced in typical tumour 
microenvironmental conditions, in vitro 
As mentioned in the literature review section, 1.3.2, GRP78 binds to PERK, IREα1,and 
ATF6 under ‘non stress’ conditions thus suppressing the Unfolded Protein Response 
(133). Under ‘stressed’ conditions such as low ATP availability (due to low availability 
of both oxygen and glucose which are typical of the tumour microenvironment) or 
excess protein production, unfolded proteins accumulate. GRP78 preferentially binds to 
these unfolded proteins resulting in GRP78 disassociating from PERK, IREα1 and 
ATF6. In turn this causes the activation of the Unfolded Protein Response. Under such 
UPR-activating conditions ATf6 is now free to act as a transcription factor inducing the 
up-regulation of GRP78 (133). 
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 Hypoxia has been detected in 78% of head and neck squamous cell carcinoma tumours 
(141). Hence, this may be one of the reasons why GRP78 is significantly up-regulated in 
these tumours. Hypoxia is defined as an oxygen concentration lower than 3% compared 
to normal tissue, which on average has a range between 4 and 9% (140). Normal tissue 
typically contains glucose levels of 5 mM, whilst in many tumours this can range from 
anywhere between 0 and 2 mM (83).  
 
In order to determine whether GRP78 is induced in the above typical tumour 
environment s UM-SCC cells were grown in hypoxic (less than 2% O2) (142) and low 
glucose conditions (less than or equal to 2 mM glucose) (139). All UM-SCC laryngeal 
squamous cell carcinoma cell lines, that were tested, demonstrated induction of GRP78 
in conditions of low oxygen and low glucose compared to controls, as seen in    Figure 
4.2.1. The only exception to this was in UM-SCC 81B which when grown in 2% O2 
showed no further increase in GRP78 levels. However GRP78 was induced in UM-SCC 
81B when grown in 0.4g/l glucose. In 0.4g/l glucose and also in 2% O2, GRP78 
expression was increased by a minimum of two fold, as measured by densitometry, in 
UM-SCC cells 5, 11B, and 12. 
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6.4 Analysis of whether GRP78 protein levels may be a 
prognostic indicator for SCCHN  
Survival analysis based on data from 190 SCCHN patients was performed using Kaplan-
Meier method and statistical differences between curves were compared using log-rank 
test. As expected SCCHN patients with stage 1 or stage 2 tumours had a significantly 
better five year survival compared to patients with stage 3 or 4 tumours (p(log rank) < 
0.001), as shown in Figure 4.3.3A. Furthermore patients without nodal involvement 
survived significantly longer than patients with nodal spread (p(log rank) = 0.005) (Figure 
4.3.3B ). These findings are in line with previous studies which have also found high 
tumour stage and nodal involvement to be associated with poor survival outcome. (143, 
144). 
 
Several studies have reported that up-regulation of GRP78 is associated with poor 
survival outcome in a variety of tumours including: hepatocellular carcinoma (HCC) 
(130), pancreatic adenocarcinoma (132), breast cancer (112), melanoma (133), 
oesophageal adenocarcinoma (120), glioblastoma (108), lung cancer (134) and prostate 
cancers (129). Here for the first time it was determined whether up-regulation of GRP78 
was associated with poor survival outcome in tumours of the larynx, hypopharynx and 
oropharynx. 
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The Kaplan Meier 2 year survival analysis of SCCHN patients (n=190) showed that 
GRP78 up-regulation was significantly associated with lower survival rates (p(log rank) = 
0.032) (Figure 4.3.4B). Although log-rank is useful in comparing differences in survival 
in two or more groups on non-parametric censored data, multivariate Cox regression 
analysis is needed in order to compare the influence of several risk factors upon survival 
outcome at the same time (145).  
 
 As expected upon multivariate Cox regression analysis tumour stage (p = 0.004), nodal 
status (p = 0.005) and recurrence (p = 0.001) were found to be significant independent 
factors in determining two year survival. Patients with high tumour stages of 3 and 4 had 
an increased hazard ratio of  2.5 compared to patients with stage 1 and 2 tumours. 
Similarly patients with tumours with nodal involvement had worse prognosis with a 
hazard ratio of 2.6. Although high GRP78 levels are suggestive of poorer survival 
outcome with a hazard ratio of 2.04 this finding is not statistically significant (p=0.069). 
As there may be different pathologies involved between the different sub-groups of 
SCCHN, subsets of this cohort were analysed separately. Upon log rank analysis both 
five- and two-year survival were significantly higher for laryngeal patients (n=92) with 
low-expressing GRP78 tumours (p=0.028 and p=0.006 respectively) as shown in Figure 
4.3.5. Upon multivariate analysis only nodal status (p = 0.041) was a significantly 
independent predictor of survival where patients with nodal involvement had an 
increased hazard ratio of 2.3 compared to patients without nodal involvement. 
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Unexpectedly tumour stage (p = 0.376) was no longer a significant predictor of survival 
outcome.  Although high GRP78 levels are suggestive of poorer survival outcome with a 
hazard ratio of 7.3 this finding is just below being statistically significant (p=0.052). A 
larger sample of laryngeal squamous cell carcinoma patients may be needed in order to 
clarify whether or not GRP78 as well as tumour stage may be suitable prognostic 
biomarkers. Alternatively GRP78 may not, when used in isolation, be a suitable 
prognostic biomarker for predicting survival outcome.  
 
Prognostic biomarkers predict individual patient outcome, regardless of disease 
management, ‘distinguishing between good outcome tumours from poor outcome 
tumours’ (146). In this way prognostic biomarkers may help to decide which patients to 
treat or what modality to use as well as the aggressiveness of the treatment regime (146). 
Results presented within this thesis have shown that GRP78, although up-regulated in 
tumours compared to histologically normal tissue, may not be a significant independent 
prognostic biomarker. Zhuang et al., also found upon log rank analysis, that patients 
with high GRP78 expression in melanomas had significantly lower overall survival 
compared to patients with low GRP78 expression (p=0.0123) (133). However, when 
multivariate analysis was performed by Zhuang et al., GRP78 was no longer a 
significant independent factor in determining survival (p=0.178). It seems likely that the 
simultaneous use of multiple biomarkers may be more suited in predicting patient 
outcome as opposed to reliance on one single biomarker. For example multigene 
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expression tests such as MammaPrint (Agendia) can be used to assess whether, after 
surgery, breast cancer patients, should receive adjuvant therapy or not, in order to avoid 
relapse (146). A similar ‘multiple biomarker’ approach may be also more applicable for 
head and neck cancers. 
 
Furthermore, there were no significant differences between survival rates of patients 
with low versus high GRP78 expressing tumours of the oropharynx or hypopharynx 
upon log rank analysis. This could be due to different pathologies involved in the 
various sub-sites. For example it is known that SCCHN patients with HPV are more 
responsive to chemo- and radiation therapy(p ≤ 0.05) compared with HPV negative 
patients and have better survival outcome (19, 21). Therefore HPV infection which is 
more prevalent in oropharyngeal tumour compared to laryngeal tumours would be of 
greater prognostic value in such tumour sub-sites 
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6.5 EGF-SubA is toxic to laryngeal squamous cell carcinoma 
cells at pM concentrations, and induces G1 arrest and 
apoptosis. 
 
A study by Daneshmand and colleagues showed that GRP78 was up-regulated in 
approximately two thirds of prostate cancer patients and this up-regulation was 
associated with higher risk of clinical recurrence (relative risk=2 p=0.001) and death 
(relative risk=1.8 p=0.024) compared to patients with low GRP78 expression (165). 
Hence there is an indication that GRP78 may have a role in tumour development and 
treatment resistance. A study by Fu and colleagues in 2008 reported that homozygous 
deletion of GRP78 in the prostates of mice lead to suppression of prostate tumour 
development and growth (97). All mice, in the study, had inactive form of the 
phosphatase and tensin gene (PTEN). Inactivation of PTEN is a common occurrence in 
prostate cancers and leads to excessive stimulation and phosphorylation of the 
PI3K/AKT pathway and subsequent enhanced cell growth and proliferation (see section 
1.2.1 for a review of the EGFR signalling pathway). All of mice with PTEN inactivation 
developed tumours within 12-20 weeks of birth. Whilst none of the eight mice with both 
PTEN inactivation and GRP78 double allele knockout developed any tumours or 
precancerous lesions (97).  
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A study by Dong and colleagues in 2009 (98), compared mammary tumour development 
in mice that were GRP78 homozygous +/+ to heterozygous GRP78 +/- mice. All mice 
expressed the polyoma middle T oncogene (PyT) (98). Tumours were first detectable 
around 8-10 weeks in the homozygous group but in the heterozygous group tumours 
were detectable between 10-12 weeks . Furthermore tumour size was reduced by 60% in 
the heterozygous group as compared to the homozygous group (p<0.001). Hence even 
partial reduction in GRP78 may be sufficient to impede tumour growth and size (98). 
 
Results presented in this thesis have shown that GRP78 is both significantly up-
regulated in head and neck squamous cell carcinoma patients, as well as being induced 
in vitro under typical tumour micro-environmental conditions of hypoxia and low 
glucose. Induction of GRP78 may offer tumours a protective role, therefore making 
GRP78 advantageous for tumorigenesis. Previous studies by Fu and colleagues and 
Dong and colleagues indicate that loss or reduction of GRP78 expression suppresses 
tumour development (97, 98). Hence EGF-SubA may offer a novel way, through 
cleavage of GRP78, of suppressing the growth and development of cancers.  
 
Here we determined whether EGF-SubA was able to impede the growth of laryngeal 
sqaumous cell carcinoma cells, in vitro. 
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In vitro studies were focused on laryngeal squamous cell carcinoma (LSCC) for two 
reasons. Firstly, laryngeal carcinoma patients are the largest sub-groups of head and 
neck patients, and secondly, to avoid the issue of confounding factors caused by the 
differences in pathogenesis and prognosis, due in part to HPV status, of different 
anatomical sub-sites (166) .  
 
Cell proliferation assays revealed that EGF-SubA IC50 levels were between 4 and 
100pM in UM-SCC laryngeal squamous cell carcinomas (Figure 4.4.1). This IC50 range 
is comparable to the results of the study by Backer and colleagues who tested EGF-
SubA on prostate PC3 and breast MDA231luc cancer cells and found IC50s of 1 and 
30pM, respectively (5). 
 
In order to explore how EGF-SubA may stop the proliferation of UM-SCC cells, cell 
cycle analysis and apoptosis assays were performed. 
 
The conventional method to perform cell cycle analysis of DNA content is by PI 
staining of fixed permeabilised cells. However, because of the overlapping DNA content 
of G1 with early S phase, and late S with G2 and M phases, it is hard to accurately 
distinguish between these . Bromodeoxyuridine (BrdU) is a thymidine analogue which 
can be incorporated into DNA during DNA synthesis (S phase). Flow cytometry can 
then detect the quantity of BrdU via the use of anti BrdU antibodies conjugated with 
Discussion 
 
255 
 
FITC. BrdU-PI double staining easily differentiates between overlapping DNA content 
of S phase fractions whilst at the same time quantifying the amount of cells in G1 and 
G2.  
 
Currently there are no studies which have investigated the effect of SubA on cell cycle 
analysis via the BrdU-PI double staining method. Here, this method was performed 
simultaneously alongside the conventional fixed and permeabilised cell staining with PI 
to produce DNA histograms. We examined a variety of UM-SCC cells of differing p53 
status to determine whether or not any impact of EGF-SubA upon the cell cycle was 
independent of p53 status (149). The cell lines studied were UM-SCC 17A which is 
wild-type for p53, UM-SCC 12 which is p53 null (homozygous Q104X), and UM-SCC 
5 which has one wild-type p53 and a single p53 mutation (heterozygous V157F) .  
 
EGF-SubA was able to induce G1 arrest regardless of p53 status, as shown in Figure 
4.5.1 and Figure 4.5.2. The amount of cells in G1  after treatment with EGF-SubA  in 
UM-SCC 17A, 12 and 5 increased by 19%, 7%, and 5%, respectively, as analysed by PI 
staining of fixed permeabilised cells and 37%, 26% and 6%, as deduced by BrdU-PI 
double staining. As expected for a G1 arrest, there was a reduction in cells entering S 
phase. The percentage decreases in the S phase cell fraction after treatment with EGF-
SubA as compared to controls in UM-SCC 17A, 12 and 5 were 10%, 9%, and 5% 
respectively, as analysed by PI staining of fixed permeabilised cells and 46%, 19% and 
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12%, as deduced by BrdU-PI double staining. This observation may be important since 
it has been reported by Pawlik and colleagues that cells in G1 are twice as radiosensitive 
as cells in S phase and therefore EGF-SubA may act as a radiosensitiser (150). The 
potential for EGF-SubA as a radiosensitiser was explored in Results section 5.4.  
 
Morinaga and colleagues observed a decrease in basal levels of cyclin D1 as well as G1 
cell cycle arrest after application of SubA in vitro in Hela and Vero cells (141). As 
cyclin D1 is important in order to allow for cell cycle progression from G1 to S phase it 
was proposed that loss of cyclin D1 through SubA was the mechanism behind G1 arrest 
(148).  
 
Phosphorylation of cyclin D1 is required for ubiquitin targeted proteasomal degradation. 
Upon SubA increased levels of phosphorylated cyclin D1 was observed. Furthermore 
the use of proteasomal inhibitor MG132 suppressed downregulation of cyclin D1 by 
SubA. Thus implying that SubA may indirectly induce the proteasomal degradation of 
cyclin D1.   
 
Our research has shown that cells treated with EGF-SubA have reduced levels of EGFR 
expression, as shown by western blot analysis in Figure 5.4.1.As part of future 
investigations it would be interesting to determine whether exposure to EGF-SubA leads 
to proteasomal degradation of EGFR. This could be in part determined by whether 
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proteasomal inhibitor MG132 could suppress the down regulation of EGFR upon 
exposure to EGF-SubA. . 
 
Backer and colleagues observed an increase in activated caspase 3 in prostate carcinoma 
cells when treated with EGF-SubA, thus suggesting that this drug can induce apoptosis(5). 
In order to confirm whether EGF-SubA was able to induce apoptosis in LSCC cells the 
Annexin V-PI apoptosis assay was used. The main advantage of this assay over simply 
monitoring levels of PARP or caspase 3 is that the fraction of cells which are healthy, 
undergoing early apoptosis, late apoptosis, or necrosis can be quantified.  
 
p53 is known to be a key regulator of pro-apoptotic proteins such as Puma and Noxa 
(100). Therefore, we examined a variety of UM-SCC cells of differing p53 status to 
determine whether or not any impact of EGF-SubA upon induction of apoptosis was 
independent of p53 status (149). The cell lines studied were UM-SCC 17A which is 
wild-type for p53, UM-SCC 12 which is p53 null (homozygous Q104X), UM-SCC 81B 
which is p53 mutant (H193R) and UM-SCC 5 which has one wild type p53 allele and a 
single p53 mutation (heterozygous V157F).  
 
EGF-SubA can be seen to induce apoptosis in all four cell lines regardless of p53 status 
(Figure 5.3.2). The percentage of apoptotic cells compared to controls increased by: 9% 
in UM-SCC 5, 21% in UM-SCC 12, 45% in UM-SCC 17A and 12% in UM-SCC 81B. 
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Therefore these results are in line with Backer’s finding where EGF-SubA was found to 
induce caspase 3 activity (5).  
 
As mentioned previously, inhibition of GRP78 via SubA cleavage results in the 
activation of the Unfolded Protein Response (UPR). A study by Yahiro and colleagues 
(2010) observed that SubA was able to induce the activity caspase 3, 8, and 9 and 
subsequent PARP cleavage (147). Simultaneous silencing of proapoptotic Bax and Bak 
genes resulted in: reduction of cytochrome c release less caspase 3 activation and loss of 
DNA ladder formation upon treatment of Hela cells with SubA, suggesting that 
activation of Bax and Bak proteins may contribute towards SubA induced apoptosis. 
However, the complete mechanism behind how SubA induces Bax and Bak are activity 
is still not known.  
 
Upon activation of the Unfolded Protein Response, PERK, ATF6 and IRE1 are released 
by GRP78. Several pathways initiated through the UPR have been implicated in causing 
apoptosis. As discussed in section 1.1.2, CHOP is induced during the activation of both 
PERK and ATF6 (92). CHOP causes the up-regulation of Bim, a proapoptotic BH3 only 
proteins (92).  
 
Activation of IRE1 also increases levels of JNK. JNK-mediated phosphorylation inhibits 
anti-apoptotic activity of BCl-2 whilst activating Bim and inducing BAX (83). A study 
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by Urano and colleagues in 2000 (105), showed that upon ER stress, IRE1 wild-type 
fibroblasts increased JNK levels by two-fold, whilst JNK expression was impaired in 
IRE1 knockout fibroblasts (105). 
 
 In order to confirm whether SubA activated UPR mediates cytochrome c release, 
Yahiro and colleagues (2010) used siRNA to silence IRE1α, JNK and CHOP. However, 
there was no decrease in cytochrome c release, suggesting that  IRE1α, JNK and CHOP 
were not necessary for SubA induced apoptosis. Although GRP78 can initiate the UPR, 
another way in which the cleavage of GRP78 could possibly result in apoptosis is 
through the loss of direct interaction with proapoptotic proteins. For example, one study 
observed that the ATP domain of GRP78 was able to bind procaspase 7 and prevent 
caspase 7 activation and subsequent apoptosis (104). Further co-immunoprecipitation 
studies may be needed in order to investigate what other proapoptotic proteins GRP78 
can interact with and inhibit the function of. 
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6.6 EGF-SubA is dependent on EGFR for its cytotoxicity, 
which can be blocked by cetuximab. 
 
EGF-SubA is a novel cytotoxic drug that encompasses a bacterial endotoxin (SubA) 
covalently bound to EGF to permit targeting of EGFR-expressing cells whilst the 
enzymatically active moiety, SubA, promotes proteolytic cleavage of GRP78 (5). 
 
Backer and colleagues in 2009 discussed the cytotoxicity of EGF-SubA and that this 
appeared to be EGFR-dependent, with EGFR expressing cells having an EGF-SubA IC50 
within the picomolar range and EGFR negative cells having an EGF-SubA IC50 in the 
region of the nanomolar range (5).  
 
In their 2009 study, Backer and colleagues examined the effectiveness of EGF-SubA 
against human prostate and breast cancer tumour xenografts in immuno-deficient mice. 
Following a one week course of intra-peritoneal EGF-SubA injections, the study found a 
4-10 fold reduction in tumour volume compared to controls, without any ‘clinical signs 
of toxicity observed in any of the treated groups.’ 
 
As part of  future work members of our research group intend to perform related studies 
growing human laryngeal tumours in mice and treating them with intra-peritoneal EGF-
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SubA injections. Similarly, these studies intend to monitor these mice for evidence of 
toxicity or other adverse events.  
 
Currently it is unclear whether such xenograft models provide a reasonable test of 
toxicity, for pre-clinical studies, since EGF-SubA might not enter mouse cells due to 
differences in binding of human EGF to murine EGFR. Furthermore we wanted to 
clarify whether the cytotoxicity of EGF-SubA was, as suggest by Backer and colleagues, 
dependent on the presence of EGFR. If cytotoxity of EGF-SubA is dependent on EGFR 
then these effects in theory may be mitigated by cetuximab, which is a mAb against 
EGFR.  
 
In order to address the question of whether EGF-SubA is toxic to mouse cells at the 
picomolar level and to confirm simultaneously that EGF-SubA toxicity is dependent on 
the expression of EGFR, mouse liver HEPA 1c1c7 cells, which express EGFR, and 
mouse embryonic fibroblasts (MEF) that do not express EGFR were treated with EGF-
SubA for a period of five days and MTT was used to asses cell proliferation/viability as 
described in the materials and method section 3.12.  
 
Initially, EGFR expression was confirmed to be present in HEPA 1c1c7 and absent in 
MEF cells by direct comparison with UM-SCC 12, which is known to express EGFR as 
shown in Figure 4.6.1A. Secondly, Hepa 1c1c7 and MEF cells were treated with EGF-
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SubA at a range of concentrations between 1pM to 1nM for up to five days as shown in 
Figure 4.6.1B. As expected, growth of Hepa 1c1c7 EGFR positive cells were inhibited 
by EGF-SubA, albeit that the IC50 was at a relatively high picomolar concentration of 
700pM, whilst no inhibitory effect in MEF EGFR negative cells was seen, even at an 
EGF-SubA concentration of 1nM.  
 
Thus these results indicate that murine cells which do not express EGFR are not as 
sensitive to the effects of EGF-SubA compared to murine cells which do express EGFR. 
However it is still unclear whether the effects observed in murine cells were indeed 
EGFR dependent as the EGF-SubA IC50 of 700pM for Hepa 1c1c7 cells lies above the 
EGF-SubA IC50 range in human originated cell lines (1-100pM) but is below the IC50 
range of SubA (>1nM) . In order to addrsss this, further studies could be used which 
involve comparing SubA IC50 levels to EGF-SubA IC50 levels in murine cells or the use 
of cetuximab to try and block the EGF-SubA toxicity.  
 
Results in section 4.6 indicate that EGFR negative cells are not as sensitive to EGF-
SubA as EGFR expressing cells. Therefore it was further investigated whether there 
were correlations between cell surface EGFR expression and sensitivity to EGF-SubA 
between different cell lines. 
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In order to measure the expression of membrane EGFR levels as opposed to total 
cellular EGFR levels, flow cytometric analysis was used. Anti-EGFR (ICR10) antibody 
conjugated to PE from Abcam (ab27764) was used in order to detect membrane EGFR. 
This antibody was selected as it binds to an extracellular epitope of EGFR. Average 
florescence (AF) generated from PE was taken as a surrogate marker for the level of 
membrane EGFR.  
 
As expected the cytotoxicity of EGF-SubA appears to be substantially dependent on 
EGFR membrane expression as cells expressing higher EGFR levels were associated 
with increased sensitivity to EGF-SubA where Spearman’s rank correlation coefficient = 
0.919 (p=0.003)(see Figure 4.7.2.) Therefore, in conclusion, cytotoxicity of EGF-SubA 
is in part dependent on the amount of surface EGFR present on cells. As EGFR is often 
over expressed in tumour cells this may be an advantage in targeting cancer cells 
specifically and sparing histologically healthy tissue (50).  
 
Based on these findings it was investigated whether cetuximab could inhibit the 
cytotoxic effects of EGF-SubA. Previously it could be seen that pre-incubation of 
cetuximab for two hours was able to efficiently block EGF induced phospho-EGFR in a 
range of UM-SCC cells, as shown in Figure 4.7.4. UM-SCC 12, 17A and 81B (Figure 
4.8.1) were treated with EGF-SubA above and below IC50 doses or with cetuximab at 
sub-toxic concentrations of 10, 30 and 100nM, or pre-incubated with cetuximab for two 
Discussion 
 
264 
 
hours prior to the application of EGF-SubA. In all three cell lines pre-incubation of 
cetuximab was able to significantly rescue cells from the effects of EGF-SubA even at 
the lowest concentration of cetuximab (p<0.05) (10nM).  
  
SubA is an endotoxin which is produced by Shiga toxigenic Escherichia coli which is 
known to cause haemorrhagic colitis and haemolytic uremic syndrome, which consists 
of a triad of: haemolytic anaemia, thrombocytopenia and renal failure (167). EGF-SubA 
could be used topically peri- or postoperatively around tumours in order kill any 
remaining cancer cells, whilst cetuximab could be used systematically to prevent any 
possible organ toxicity, therefore widening the therapeutic window of this drug.  
 
Although one of the main aims of this thesis was to determine whether cetuximab could 
act as an antagonist to EGF-SubA, currently there is very little published data on the 
growth inhibitory effects of cetuximab against laryngeal squamous cell carcinoma both 
as a single agent and in combination with radiation. Therefore the toxicity of cetuximab 
on laryngeal squamous cell carcinoma cells was also explored. 
 
Even though results presented in this thesis show that cetuximab is able to adequately 
block EGF induced phosphoylation of EGFR as well as act as an antagonist to EGF-
SubA it is unclear why the MTT assay used, was not able to demonstrate that cetuximab 
was able to significantly suppress the growth of laryngeal squamous cell carcinoma cells 
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in vitro. Subsequently these experiments were repeated on at least one or more occasions 
using more recently acquired batches of cetuximab, however no additional toxic effects 
were observed. Furthermore MTT assays in our study have demonstrated typical dose 
response curves for EGF-SubA, cisplatin and AT13387 suggesting that there is no 
apparent problem in performing the technique. One possibility is that these UM-SCC 
cells may contain mutations downstream the EGFR signalling pathway such as Ras and 
PTEN mutations (52). Gene mutations may be identified by such techniques as 
restriction fragment length polymorphism (RFLP) (168). 
 
MTT assay was also performed on a known cetuximab sensitive cell line UM-SCC 1 
(derived from an oral tumour). Benavente and colleagues in 2009 had reported an IC50 of 
5nM for UM-SCC 1 after three days treatment with cetuximab (152). It was noted that 
although Benavente and colleagues had shown that UM-SCC 1 was a cetuximab-
sensitive cell line, results within this thesis show only a 25% decrease in cell 
viability/growth after using cetuximab at 1μM for seven days as shown in Figure 4.7.3 
(152). Benavente and colleagues measured the cytotoxic effects of cetuximab by 
staining cells with crystal violet and measuring the colour intensity, which acts as a 
surrogate indicator of how many cells are present, via a plate reader. MTT assay is an 
indicator of cell viability/proliferation as the change in recorded absorbance is dependent 
on how many viable mitochondrial dehydrogenase enzymes are present. For future 
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studies it may be worth comparing whether crystal violet assays produce different levels 
of IC50 compared to MTT assays. 
 
6.7 EGF-SubA acts as a radiosensitiser and synergistically 
with cisplatin 
An increasing body of evidence suggests that up-regulation of GRP78 in tumours may 
lead to chemo- and radioresistance (1, 8, 97, 120). Therefore we explored whether EGF-
SubA could enhance sensitivity in vitro to current clinically relevant treatment 
modalities used for head and neck cancer, such as cisplatin and radiation, in a panel of 
LSCC cell lines. 
 
Several studies have associated GRP78 as a radioresistant phenotype. Lin and colleagues 
in 2010 and Feng and colleagues in 2010, found GRP78 to be up-regulated in clones 
which were able to survive a higher dose of ionising radiation compared to their parental 
cell lines (3, 8). Feng and colleagues also found GRP78 to be a potential biomarker with 
up-regulation of GRP78 in tumours corresponding to radioresistance in patients with 
nasopharyngeal carcinoma. Lee and colleagues in 2008 found that silencing of GRP78 
via transfection with siRNA significantly enhanced the sensitivity of glioblastoma cells 
to radiation (108).  
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Several lines of evidence from results presented in this thesis suggest that EGF-SubA 
may be a radiosensitising agent. As seen in Figure 5.4.1, EGF-SubA is capable of down 
regulating EGFR as well as cleaving GRP78 (see Figure 4.1.1) and both EGFR and 
GRP78 are implicated in radioresistance. Results in this thesis also demonstrate that 
EGF-SubA leads to G1 cell cycle arrest (see Figure 4.5.1). Cells in G1 are known to be 
more sensitive to radiation compared to cells in S phase (150). Based on these findings 
we investigated whether pre-treatment with EGF-SubA was able to radiosensitise UM-
SCC cells.  
 
In order to test radio sensitisation in vitro, a clonogenic assay was used as described in 
section 3.11. One of the main aims of cancer treatment is to prevent recurrence of 
tumour growth. A clonogenic assay measures the ability of individual cells to proliferate 
and form colonies after exposure to ionising radiation, and this can be achieved in 
combination with cytotoxic drug treatments if required (126). 
  
 Loss of p53 function has been associated with chemo- and radioresistance (153). 
Therefore, we examined a variety of UM-SCC cells of differing p53 status to determine 
whether or not any potential radiosensitising effects of EGF-SubA observed were 
present regardless of p53 status (149). The cell lines studied were UM-SCC 17A which 
is wild-type for p53, UM-SCC 12 which is p53 null (homozygous Q104X), UM-SCC 
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81B were there are no alleles with wild-type p53 (mutant H193R) and UM-SCC 5 which 
has one wild-type allele and a single p53 mutation (heterozygous V157F)..  
 
EGF-SubA was able to radiosensitise UM-SCC cells, regardless of p53 status, as shown 
in  
Figure 5.4.2. At 2 Gy the survival fraction was significantly reduced by 17% (p<0.03), 
30% (p<0.02), 34% (p<0.002), 27% (p<0.002) in UM-SCC 5, 12, 17A and 81B, 
respectively, as compared to controls.  
 
Current studies suggest that over expression of GRP78 in tumours may contribute to 
cisplatin resistance. Lee and colleagues in 2008 transfected glioma cells with GRP78. 
Subsequent increases in GRP78 expression in these transfected cells led to a decrease in 
caspase 7 activation and rendered cells resistant to cisplatin-induced apoptosis. Upon 
transfection with siRNA against GRP78, decreased cell growth was observed as well as 
increased sensitisation to both cisplatin and radiation (108). Jiang and colleagues in 2009 
found that cisplatin-mediated cytotoxicity of melanoma cells was significantly reduced 
in cells transfected with caspase 4 and 7 siRNA compared with control siRNA treated 
cells (p<0.01) (110). Jiang and colleagues also explored the role of GRP78 in altering 
cisplatin induced activation of caspase 4 and 7. siRNA knockdown of GRP78 increased 
cisplatin induced caspase 4 and 7 activity, whilst over expression of GRP78 suppressed 
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caspase 4 and 7 activity (110). Hence up-regulation of GRP78 may evoke resistance to 
cisplatin cytotoxity by inhibiting caspase activity. 
 
Based on the studies by Lee and colleagues in 2008 and Jiang and colleagues in 2009 
which demonstrate that up-regulation of GRP78 leads to cisplatin resistance, we 
investigated, in this thesis, whether or not EGF-SubA, which cleaves GRP78, could act 
synergistically with cisplatin. The use of multiple drugs with different mechanisms of 
action may help to ‘improve the efficacy of the therapeutic effect, decrease the dosage 
but increase or maintain the same efficacy in order to avoid toxicity such as 
nephrotoxicity and otoxicity which are side effects of cisplatin treatment (155), and 
minimise or slow down the development of drug resistance’ (156). 
 
An MTT assay was used to assess the viability/growth of UM-SCC cells treated with 
cisplatin, EGF-SubA, or in combination.  
 
EGF-SubA and cisplatin when used together produced combination index (CI) scores of 
less than or equal to 0.9, regardless of p53 status, and this is indicative of synergy. The 
lowest CI scores in UM-SCC 5 was 0.82, UM-SCC 12 was 0.597, and in UM-SCC 17A 
was 0.786. (see Figure 5.1.5).  
 
Discussion 
 
270 
 
To examine the possible mechanism behind this synergistic interaction between EGF-
SubA and cisplatin the effects of both drugs upon GRP78 levels were studied. 
McCollum and colleagues in 2008 demonstrated that cisplatin was able to block the 
binding of transcription factor HSF-1 to chromatin upon treatment with geldanamycin, 
leading to inhibition of HSP72 induction and a synergistic interaction between cisplatin 
and geldanamycin (161). Our results show that when EGF-SubA was combined with 
cisplatin there was a marked loss of uncleaved GRP78 compared to all other conditions 
including controls, cisplatin alone, and EGF-SubA alone as shown in Figure 5.2.1. One 
hypothesis could be that cisplatin may also block the interaction of transcription factor 
ATF6 with chromatin, thus preventing the induction of GRP78. The reduced levels of 
functional GRP78 when combining EGF-SubA with cisplatin may explain the 
synergistic effects found in section 5.1 
 
In addition, flow cytometry-based Annexin V/PI assays were performed in order to 
determine what combinatorial effects of these two drugs had upon apoptosis. In UM-
SCC 12, 17A and 81B the proportion of cells undergoing apoptosis increased by 19%, 
21% and 8%, respectively, when cisplatin was combined with EGF-SubA, as opposed to 
when cells were treated with either cisplatin or EGF-SubA as single agents (see Figure 
5.3.2). However no further increase in apoptosis was detected in UM-SCC 5 cells. 
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As described above McCollum and colleagues in 2008 demonstrated that cisplatin was 
able to block the binding of transcription factor HSF-1 to chromatin upon treatment with 
geldanamycin. In a similar fashion, as part of future investigations it would be 
interesting to determine if cisplatin could prevent ATF6 interaction with chromatin by 
performing chromatin immunoprecipitation (ChIP) experiments.  
 
6.8 Summary of main findings 
For the first time it has been shown that GRP78 is significantly up-regulated in 
laryngeal, oropharyngeal and hypopharyngeal sqaumous cell carcinomas compared to 
histologically normal tissue (p(Χ2)<0.001) and, therefore, up regulation of GRP78 may be  
important to the development of head and neck cancers. We propose that up-regulation 
of GRP78 in these tumours may be due to the typical tumour microenvironment of 
hypoxia and low glucose and have further shown that, in vitro, LSCC cells can induce 
GRP78 under such conditions.  
 
Cleavage of GRP78 through EGF-SubA may provide a potential means of suppressing 
tumour development. Results in this thesis show EGF-SubA to be cytotoxic to laryngeal 
squamous cell carcinoma cells in the pM range. It was further demonstrated in vitro, that 
EGF-SubA, was able to enhance the effects of the main treatment modalities of head and 
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neck cancer - radiation and cisplatin. Xenograft studies are now needed in order to 
confirm whether or not similar effects can be observed, in vivo.  
 
Lastly, the toxicity of EGF-SubA appears to be substantially dependent on EGFR 
membrane expression since cells expressing higher EGFR levels were more sensitive to 
EGF-SubA where Spearman’s rank correlation coefficient= 0.919 (p=0.003). 
Furthermore, pre-incubation of LSCC cells with sub-toxic doses of cetuximab, a 
therapeutic monoclonal antibody to EGFR, completely rescued cells from the cytotoxic 
effects of EGF-SubA (p(t test)≤0.005). This is an important proof of principal for a 
combined toxin-protectant approach that would permit topical use of EGF-SubA peri- or 
postoperatively after tumour resection in order to kill any remaining tumour cells, or as 
an oral rinse in patients who present with pre-malignant lesions of the oral cavity, with 
any potential systemic toxicity being abrogated by cetuximab. 
 
In summary our study has found that GRP78 is up-regulated in head and neck cancers 
suggesting that this protein may be important for tumour development and survival. 
Thus inhibition of GRP78 through EGF-SubA may offer a novel approach to cancer 
therapy. In addition to suppressing the growth of LSCC cells, EGF-SubA was found to 
enhance the effects of relevant genotoxic agents in vitro of cisplatin and radiation. 
Furthermore cetuximab was able to inhibit the toxicity of EGF-SubA thus potentially 
allowing for a combined toxin-protectant approach.  
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 In order to evaluate whether EGF-SubA can inhibit tumour growth in vivo, an athymic 
nude mice model could be used to grow human head and neck tumour xenografts. 
Similar to the study by Backer and colleagues which performed xenograft studies of 
human prostrate and breast tumours, mice could be then given intraperitonial injections 
of EGF-SubA once tumour cell implantations became palpable (5). Changes in tumour 
volume could be assessed through direct removal of the tumour or through such 
techniques as MRI. Furthermore mice could be exposed to combinations of cisplatin or 2 
Gy accelerated fractions of radiation with EGF-SubA, in order to establish whether there 
are either any synergistic interactions between these two drugs or any radio-
enhancement effect in vivo. 
 
One of the potential uses of EGF-SubA could be as a topical agent to be applied on 
resected tumour margins in order to remove any remaining tumour cells. Macroscopic 
excisions of tumour xenografts may be performed on mice with the intent of leaving a 
small section of tumour behind. These tumour margins could then be exposed to EGF-
SubA topically. Core biopsies could then be taken from such treated regions and 
monitored for any remaining tumour tissue after a suitable time frame.  
 
As previously mentioned Subtilase A toxin is known to cause haemolytic uraemic 
syndrome  therefore it would be important to take full blood counts in mice to assess for 
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the potential toxicity of EGF-SubA (7). Furthermore toxicity to vital organs such as the 
liver and kidney should be monitored by assessing levels of alanine transaminase (ALT) 
and performing creatinine clearance tests, respectively. 
 
The above work would help to assess the efficacy and toxicity of EGF-SubA, in vivo, 
and aid in the progress towards phase I clinical trials. 
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7 Appendix: Investigating cytotoxicity of HSP90 
inhibitor AT13387 in laryngeal squamous cell 
carcinoma cells, in vitro.  
7.1 Abstract 
HSP90 is required for the stability and development of several oncoproteins including: 
EGFR, ErbB2, PKB/AKT, HIF-1α and telomerase (137). HSP90 inhibition leads to 
proteasomal degradation of such client proteins (137). Therefore HSP90 inhibitors 
provide a means of targeting several oncoproteins at once resulting in attenuation of 
angiogenesis, cell cycle arrest and apoptosis. Over-expression of the oncoprotein EGFR 
has been found in more than 50% of head and neck cancer patients and therefore HSP90 
inhibitors may be particularly useful in these cancers. Therefore the use of AT13387, 
which is a novel experimental HSP90 inhibitor, was explored as a potential cytotoxic 
agent on a panel of laryngeal carcinoma cells.  
The IC50 range of AT13387 (Astex therapeutics) was found to be between 40nM-
1µM on a panel of seven LSCC. Similar to EGF-SubA, AT13387 significantly enhanced 
the 2 Gy survival fraction in three out of four LSCC cell lines. Furthermore a synergistic 
effect was found when AT13387 was combined with cisplatin where the IC50 drug 
combination index = 0.875. 
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 In conclusion AT13387 enhances current treatment modalities in head and neck 
cancer by acting as radiosensitizer and synergistically with cisplatin. In vivo work is 
needed to assess the efficacy and toxicity of this drug before phase I clinical trials can 
commence.  
7.2 Literature review: HSP90 inhibitors in cancer therapy 
 
Heat shock proteins are a highly conserved family of molecular chaperones which are 
induced under cellular stresses such as high temperature and hypoxia (169). Under such 
stress, the transcription factor known as heat shock factor (HSF) dissociates from HSP90 
and HSP70 and initiates transcription of HSPs (169). HSP90 is known to be 
overexpressed in cancer and correlates with decreased survival in breast cancer, 
gastrointestinal stromal tumours (GIST) and non-small cell lung cancer (NSCLC) (170).  
 
Unlike other chaperones, HSP90 is not involved in folding of nascent proteins but is 
rather engaged in enhancing protein activity and stability. When ATP is bound to HSP90 
it induces a conformational change that allows HSP90 to interact with approximately 
200 client proteins. The majority of HSP90 client proteins are involved in some aspect 
of signal transduction including protein kinases, hormone receptors and transcription 
factors and therefore interest has grown in targeting HSP90 as a means of cancer therapy 
(170, 171).  
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Geldanamycin and AT13387 are HSP90 inhibitors which prevent HSP90 interaction 
with client proteins by competitively occupying the ADP/ATP binding site of HSP90. 
Inhibition of HSP90 leads to client proteins interacting with ubiquitin ligase CHIP, 
resulting in the eventual proteasomal degradation of these client proteins(170).  
 
Steroids are responsible for a wide range of functions including glucose metabolism 
(glucocorticoids), mineral uptake (mineralcorticoids), female development (estrogens) 
and male development (androgens) (172). For each individual steroid there are steroid 
hormone receptors (SHR) which become activated transcription factors upon steroid 
binding. In order for SHRs to be functional an open conformation of the steroid binding 
cleft is needed. This is created through the interaction between SHRs and HSP90 
proteins(172). For instance, the use of HSP90 inhibitors prevent oestrogen receptor –α 
(ERα) development and ERαs are subsequently degraded. Thus HSP90 inhibitors may 
prove useful in oestrogen receptor positive breast cancer patients who have developed 
tamoxifen resistance (169).  
 
HSP90 is also required for the stability and development of several oncoproteins 
including: EGFR, ErbB2, PKB/AKT, HIF-1α and telomerase (137). HSP90 inhibition 
leads to proteasomal degradation of such client proteins (137). Therefore HSP90 
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inhibitors provide a means of degrading several oncoproteins at once resulting in 
attenuation of angiogenesis, cell cycle arrest and apoptosis.  
 
The importance of EGFR and its downstream signalling pathway in cancer has been 
reviewed in section 1.2. The process of apoptosis has been reviewed in section 1.3.4. 
One of the downstream pathways of EGFR, PI3K-AKT acts to suppress apoptosis. 
PI3K-AKT leads to the inhibition of proapoptotic protein BAD as well as induction of 
anti apoptotic protein bcl-xl (169). PI3K-AKT pathway can also block the action of 
cyclin CDK complex inhibitors p27 and p21 thus ensuring the progression of the cell 
cycle. As AKT is a client protein, PI3K-AKT prosurvival effects can be attenuated with 
HSP90 inhibitors, even in cases where there is loss of tumour suppressor PTEN (169).  
 
Ras-Raf-ERK pathway is also important in cell survival and proliferation. Mutations in 
B-Raf and N-Ras lead to subsequent, EGFR independent, autonomous signalling. A 
derivative of geldanamycin, 17AAG, can also inhibit HSP90 but has the advantage of a 
wider therapeutic window when compared to geldanamycin which is known to induce 
liver toxicity. A study by Grbovic and colleagues showed that 17AAG induced the 
degradation of mutant form V600 B-Raf but not wild-type B-Raf and also wild-type 
Raf-1, suggesting that HSP90 is required for the stability of mutant but not wild-type B-
Raf as shown Figure 7.2.1A (173). 17AAG also induced G1 arrest and reduced levels of 
pMAPK, and cyclin D in both mutant melanoma B700 B-Raf cell line SK-Mel-28 and 
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wild-type melanoma cell line SK-Mel-31 as shown in Figure 7.2.1B (173). Hence 
HSP90 inhibitors may be more potent than cetuximab or TKIs in treating tumours with 
Ras, Raf mutations or even PTEN loss. 
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Figure 7.2.1Effects of 17AAG on wild-type B-Raf and mutant V600 B-Raf 
(A)Degradation of mutant B-Raf (SK-Mel 28) and wild-type Raf-1 but not wild-type B-
Raf (SK-Mel 31) upon application of 17AAG. (B) 17AAG induces G1 arrest in both wild-
type (SK-Mel 31) and mutant B-Raf (SK-Mel 28) melanoma cells as well as decrease in 
cyclin D and pMAPK levels. Figures reproduced from reference (173).  
 
This text box is where the original thesis contained the diagram showing ‘effects 
of 17AAG on wild-type B-Raf and mutant V600 B-Raf cells’ which was 
reproduced from reference (173).   
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Bagatell and colleagues showed that the treatment of neurobalstoma and osteosarcoma 
cell lines with geldanamycin in combination with cisplatin resulted in greater than 
additive inhibition of survival and proliferation (174). Normally under HSP90 inhibition, 
HSF induces transcription of genes such as HSP72 and HSP27 (161). However when 
cells were treated with both geldanamycin and cisplatin there was no further rise in 
HSP72 levels as compared to controls as shown in Figure 7.2.2 (174). 
 
 
 
 
 
 
 
Figure 7.2.2 Effects of cisplatin and geldanamycin on HSP90 associated proteins 
AKT and HSP72. 
Osteosarcoma cell lines (Saos-2 cells) were treated with either geldanamycin at 0.5μM 
(GA),or cisplatin at 50μM (CDDP) or both (G+C). Figure reproduced from reference 
(174) 
 
This text box is where the original thesis contained the diagram showing 
‘effects of cisplatin and geldanamycin on HSP90 associated proteins AKT and 
HSP72’ which was reproduced from reference (174) 
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A similar study by McCollum and colleagues found synergistic effects, as studied by 
colony forming assay, when treating A459 and Hela cells in combination with cisplatin 
and geldanamycin (161). The study showed that cisplatin abrogated the binding of HSF-
1, upon treatment with geldanamycin, to chromatin therefore inhibiting the 
transcriptional activity of HSF-1 and subsequent induction of HSP70(161). Hence the 
induction of HSP70 may be implicated in the resistance to HSP90 inhibitors and this 
resistance can be prevented by the use of cisplatin.  
 
Inhibition of EGFR, Raf-1, p53 or NF-κB. has been shown to enhance radiosensitivity in 
some tumours (171). Russell and colleagues investigated the effects of radiation on 
glioma (U251 and SF539) and prostate cancer cells (DU145 and PC3) after pre 
treatment with 17AAG (175). The study showed that client proteins AKT, ErbB2 and 
Raf-1 were reduced upon exposure of 25-75nM of 17AAG. There was also significant 
radiosensitisation in all four cell lines with a radiation enhancement ratio ranging 
between 1.3-1.7 (175) when cells were pre-treated with 75nM 17AAG for 24h. Similar 
17AAG radiosensitising results were found in mice with human cervical tumours (176). 
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7.3 Aims 
AT13387 and HSP90 
Protein chaperone HSP90 enhances the activity and stability of key oncoproteins EGFR, 
ErbB2, Raf, PKB/AKT and HIF-1α. HSP90 inhibitors lead to the degradation of such 
HSP90 client proteins (137). Current HSP90 inhibitors such as geldanamycin have been 
shown to reduce tumour volume, attenuate angiogenesis and act as radiosensitising 
agents in a variety of tumours including glioma, prostate, pancreas and cervix (137). 
However they are limited in their clinical use due to poor solubility, extensive 
metabolism, and hepatic toxicity (177).  
 
Over expression of EGFR has been found in more than 50% of head and neck patients 
and has been correlated with poor survival outcome, increased metastatic potential and 
radioresistance and therefore inhibiting the EGFR pathway, through HSP90 inhibitors, may 
be particularly useful against SCCHN (29, 49, 50). Currently there is no published data 
regarding the use of HSP90 inhibitors in head and neck cancer possibly due to systemic 
toxicity of present HSP90 inhibitors. A new smaller synthetic inhibitor of HSP90 
AT13387 has been developed which has shown lower toxicity and better bioavailability 
(177, 178). This study investigates the use of HSP90 inhibitor AT13387 for the first time 
in UM-SCC laryngeal sqaumous cell carcinomas. 
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Initially cytotoxicity of AT13387 will be investigated in a panel of LSCC via MTT 
assay.  
 
Currently there are conflicting results as to whether HSP90 inhibitors can induce G1 or 
G2 arrest. In order to clarify how AT13387 may stop the proliferation of UM-SCC cells, 
cell cycle analysis via BrdU-PI flow cytometric analysis will be used. 
 
HSP90 inhibitors have been reported to be radiosensitising agents possibly as they lead 
to the degradation of EGFR (175). Through western blot analysis it will be seen whether 
AT13387 can also lead to the loss of EGFR in LSCC. Currently there is no published 
data demonstrating AT13387 as radiosensitiser. Therefore through clonogenic assay it 
will be explored whether AT13387 is also a radiosensitising agent 
 
HSP90 inhibitors have also been shown to act synergistically with cisplatin (161). Here 
it will be investigated whether similar results can be obtained with AT13387 via MTT 
assay. Furthermore as both AT13387 and EGF-SubA target different protein chaperones 
it will be seen if combining these two drugs will also lead to synergy.  
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Performing the above experiments should allow for a greater understanding of the 
potential for targeting heat shock protein HSP90 as a novel therapeutic target for head 
and neck cancers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
 
286 
 
7.4 Results: Investigating the cytotoxic effects of HSP90 
inhibitor AT13387 upon UM-SCC cells. 
 
7.4.1 AT13387 inhibits proliferation of UM-SCC laryngeal carcinoma 
cells 
 
Currently there are no studies which have reported the use of HSP90 inhibitors such as 
geldanamycin in head and neck cancers. As mentioned previously in section 7.2 HSP90 
is required for the stability and development of several oncoproteins including: EGFR, 
ErbB2, PKB/AKT, HIF-1α and telomerase (137). HSP90 inhibition leads to proteasomal 
degradation of such client proteins (137). Therefore HSP90 inhibitors provide a means 
of degrading several oncoproteins at once resulting in attenuation of angiogenesis, cell 
cycle arrest and apoptosis. In particular to head and neck cancers, EGFR is commonly 
over expressed in up to 50% of cases (6) Overexpression of EGFR has been correlated 
with increased metastatic potential and lower survival rates and because of this HSP90 
inhibitors may be an appropriate treatment option for head and neck cancer patients.  
 
Current HSP90 inhibitors such as geldanamycin have been shown to reduce tumour 
volume, attenuate angiogenesis and act as a radiosensitising agent in a variety of 
tumours including glioma, prostate, pancreas and cervix (177). However several HSP90 
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inhibitors such as geldanamycin are limited in their clinical use due to poor solubility, 
extensive metabolism, and hepatoxicity (177). A new smaller synthetic inhibitor of 
HSP90, AT13387, by drug company Astex Therapeutics, has been developed which has 
shown lower toxicity and better bioavailability (177, 178). Here the potential use of 
HSP90 inhibitor AT13387 on laryngeal squamous cell carcinoma was investigated in 
vitro for the first time. 
 
In order to establish what inhibitory effects AT13387 had upon the growth of UM-SCC 
cells an MTT assay was set up as described in Methods section 3.12. ATT1387 was first 
dissolved in DMSO to a concentration of 10 mM. Afterwards ATT1387 was serially 
diluted in PBS at the required concentrations. It was found in previous experiments that 
a final dilution of DMSO above 1% was in itself cytotoxic and therefore use of DMSO 
was limited to below this level. Previously Astex Therapeutics (the manufactures of 
AT13387) had tested this drug on ovarian, breast, melanoma and non small cell lung 
cancer cell lines and found the IC50 to range from 12 to 55nM (178). The time course of 
these experiments by Astex Therapeutics allowed for a greater or equal to three cell 
doubling times. Based on these previous experiments our study used concentrations of 
between 10nM to 3μM of AT13387. Typically UM-SCC cells double once every two 
days and therefore the duration of the experiment was for seven days. Fresh drugs and 
media were replaced daily. Each data point was repeated in quadruplicates. Typical dose 
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response curves can be seen in Figure 7.4.1 where increasing doses of AT13387 lead to 
a decreasing cell concentration. 
 
 IC50 values were calculated from data produced on day seven which allowed for at least 
three cell doubling times in the UM-SCC lines. IC50 curves were plotted as: percentage 
of MTT score the drug treated group as a proportion of the control group (y-axis) against 
the dose of the drug used on a log scale (x-axis). IC50 curves can be seen in Figure 7.4.2. 
IC50 values were between the 40nM to 1μM range for UM-SCC cells. 
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Figure 7.4.1 Dose response curves of LSCC treated with AT13387. 
 UM-SCC Cells were seeded in 96 well plates and allowed to adhere for 24 hours 
(shown as day 0). Cells were then treated with either AT13387 at concentrations of 
10nM, 30 nM, 100 nM, 300nM, 1μM, and 3μM or with drug vehicle control, for up to 
seven days. Both media and drugs were replaced every 24h. MTT assay was used to 
assess the viability/growth of cells. The absorbance was measured at an OD of 590 nm. 
Error bars represent the s.e.m. from four independent wells. 
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Figure 7.4.2 Figure 4.1.2 LSCC IC50 curves treated with AT13387. 
 IC50 data derived from day seven of UM-SCC cells being treated with either AT13387 at 
concentrations of 10nM, 30nM, 100nM, 300nM, 1μM, and 3μM or just drug vehicle 
control. IC50 curves are plotted as: percentage MTT score in the drug treated group as a 
proportion of the control group (y-axis) against the dose of the drug on a log scale (x-
axis). 
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7.4.2 AT13387 (HSP90 inhibitor) induces G2 cell cycle arrest.  
 
HSP90 inhibitors lead to the degradation of several HSP90 client protein which are 
responsible for progression of the cell cycle such as EGFR, Raf, AKT (169, 173). As a 
result there is suppression of cyclin D through the loss of the Raf pathway. As well as 
this the removal of AKT means that p21 can suppress the activity of the cyclin D-
CDK4/6 complexes. Astex Therapeutics have also shown reduced cyclin D levels upon 
treatment with AT13387 in vitro and reduced levels of AKT after 24h treatment with 
AT13387 at 1μM (178). Studies have also been performed on 17AAG showing G1 arrest 
in melanoma cells(173). 
 
At present there is no published data on the use of HSP90 inhibitors in head and neck 
cancer. In our study flow cytometry analysis is used in order to establish what effect 
AT13387 has upon the cell cycle of LSCC cell lines. 
 
 BrdU-PI double staining was performed simultaneously along side the conventional PI 
staining of fixed permeabilised cells alone in order to analyse cell cycle profiles. 
Transcription factor p53 is a tumour suppressor gene which can cause G1 cell cycle 
arrest under an array of stimuli such as DNA damage (149). Therefore, we examined a 
variety of UM-SCC cells of differing p53 status, to determine whether or not any impact 
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of AT13387 had upon the cell cycle was independent of p53 status (149). The cell lines 
studied were UM-SCC 17A which is wild-type for p53, UM-SCC 12 which is p53 null 
(homozygous Q104X), and UM-SCC 5 which has a single p53 mutation (heterozygous 
V157F) and retains a wild-type allele.  
 
Experiments were set up as explained in Methods sections 3.7 and 3.8. UM-SCC cells 
were first transferred to culture dishes and left to adhere for 24 hours. Cells were then 
treated with drugs or respective drug vehicle controls for two days with drugs and media 
being applied freshly on each day. As this study was the first to perform cell cycle 
analysis on UM-SCC cell lines with AT13387, relatively high drug doses above the IC50 
levels at 1μM was chosen, in order to ensure that an effect was observed. BD 
FACSCalibur flow cytometer machine was used and the data was analysed on CellQuest 
Pro Software. At all times doublet discrimination, as described in section 3.7, was 
performed in order to discriminate between signals produced from DNA content of 
single cells in G2 and doublets in G1. 
 
AT13387 was able to deplete the amount of cells in S phase in all three cell lines as well 
as cause G2 arrest. This effect appears to be independent of p53. The percentage 
decrease in S phase cell fraction after treatment with AT13387 as compared to controls 
in UM-SCC 17A, 12 and 5 were 8%, 4%, and 8% respectively, as analysed by PI 
staining of fixed permeabilised cells and 70%, 65% and 75% as deduced by BrdU-PI 
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double staining (see Figure 7.4.3 and Figure 7.4.4). The percentage increase in G2 cell 
fraction after treatment with AT13387 as compared to controls in UM-SCC 17A, 12 and 
5 were 20%, 10%, and 17% respectively, as analysed by PI staining of fixed 
permeabilised cells and 27%, 24% and 20% as deduced by BrdU-PI double staining.  
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Figure 7.4.3 AT13387 induces G2 cell cycle arrest regardless of p53 status.  
(A)UM-SCC cells were treated with either AT13387 at 1μM or drug vehicle control for 
48h . Cell cycle analysis was performed via BrdU-PI double staining. (B) Bar charts 
summarise cell fractions in treatment and control groups. Data was analysed on 
CellQuest Pro Software.  
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Figure 7.4.4 AT13387 induces G2 cell cycle arrest regardless of p53 status.  
(A)UM-SCC cells were treated with either AT13387 at 1μM or drug vehicle control for 
48h. Cell cycle analysis was performed via staining of fixed permeabilised cells with PI. 
(B) Bar charts summarise cell fractions in treatment and control groups. Data was 
analysed on CellQuest Pro Software. Note that in (A) the axes values are not the same. 
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7.4.3 AT13387 acts as a radiosensitising agent in three out of the four 
cell lines tested 
 
It is well known that HSP90 inhibitors lead to the degradation HSP90 client proteins 
such as EGFR. HSP90 suppresses the activity of transcription factor HSF. Upon HSP90 
inhibition there is both a decrease in EGFR levels and a concomitant increase in the 
transcription of genes such as HSP72 and HSP27 (161). Therefore we investigated 
whether or not HSP90 inhibitor AT13387 had similar effects on UM-SCC cell lines. A 
time course was established where cells were treated with AT13387 at 1μM at 4h, 8h, 
16h, 24h and 48h, or with drug vehicle control at 24h and 48h. Subsequent western blot 
analysis was performed on cells treated with AT13387 in order to view EGFR , HSP72 
and actin (loading controls) levels as shown in Figure 7.4.5 
 
As can be seen in Figure 7.4.5 there was a gradual increase in HSP72 induction from 4h 
to 48h and a concomitant decrease in EGFR levels when UM-SCC 17AS and 81B were 
treated AT13387 at 1μM.  
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Figure 7.4.5 AT13387 reduces EGFR levels and induces HSP72 on UM-SCC cells.  
Western blot analysis of UM-SCC 81B and 17AS treated with AT13387 at 1μM for 4h, 
8h, 16h, 24h and 48h or with drug vehicle control for 24 and 48h. All lanes were loaded 
with 35 μg protein. Blots were probed with anti EGFR antibody at 3 µg/ml, anti HSP72 
antibody at 50 ng/ml, and anti actin antibody at 3 µg/ml (protein loading control).  
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HSP90 inhibitors are known to be radiosensitising agents in a wide variety of tumours 
however currently there is no published data which has examined the use of HSP90 on 
head and neck cancers. Inhibition of HSP90 activity allows for a multi-target approach 
and down regulation of several client proteins that may be responsible for 
radioresistance. A study by Bull and colleagues found down regulation of ErbB2 and 
Raf-1, which are proteins which have been implicated in the regulation of 
radiosensitivity, upon cells pre-treated with 17-DMAG (179). The study also found a 
significant enhancement in radiosensitivity with 17-DMAG. 
 
As seen in Figure 7.4.5, AT13387 is capable of down regulating EGFR. EGFR and 
HSP90 client proteins are implicated in radioresistance. Furthermore cells in G2 are 
considerably more sensitive to radiation compared to cells in S phase (150). Therefore 
this drug could increase radiosensitisation by synchronising cells into the more 
radiosensitive phases of the cell cycle. This study therefore investigated whether pre-
treatment with AT13387 was able to radio-sensitise UM-SCC cells.  
 
Pilot studies were performed in order to establish the highest drug concentration that 
cells could tolerate for 24h without exposure to radiation that would provide survival 
fractions equal to that of drug omitted controls. Both UM-SCC 5 and UM-SCC 17A 
when treated with 100nM AT13387 without radiation had survival fractions below the 
controls and so cells were treated with a lower dose of AT13387 at 10nM. UM-SCC 12 
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and 81B were able to tolerate an AT13387 dose of 100nM without difference in survival 
fraction as compared to controls. UM-SCC cells were pre-incubated with either 10nM or 
100nM At13387, as indicated, or appropriate drug vehicle control for 24h before being 
irradiated with 0, 1, 2, or 4 Gy. Cells were then seeded in triplicate into six well plates, 
in normal growth media without drug and monitored for colony formation for 2-3 
weeks. 
 
AT13387 was able to radio-sensitise UM-SCC 12, 17A and 81B with significant 
decrease in SF2 compared to controls of between 13%-38% (p<0.05) as seen in Figure 
7.4.6. However no significant radiosensitising effect was observed in UM-SCC 5.  
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Figure 7.4.6 AT13387 was able to significantly radiosensitise three out four LSCC 
cell lines. 
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 (A,B,C,D) UM-SCC cells were pre-treated for 24h with AT13387 10-100nM or drug 
vehicle control and then exposed to γ-irradiation at 0, 1, 2, or 4 Gy as indicated. 
Clonogenic assays were established to allow for colony formation over a time period of 
two to three weeks. A colony was defined as equal to or more than 50 cells in order to 
allow for at least five cell doubling times. Crosses and squares indicate mean of three 
survival fractions for each data point with appropriate s.e.m. Survival curves were then 
fitted to the quadratic equation S(D)/S(0)= exp(- (αD + βD2)). (E) Bar charts showing 
survival fractions at 2 Gy with and without AT13387. Unpaired Student’s t test was used 
to calculate differences in SF2 between controls and treated cells.  
 
 
 
 
 
 
 
 
Appendix 
 
302 
 
7.4.4 AT13387 acts synergistic with cisplatin, but antagonistically with 
EGF-SubA 
HSP90 inhibitors such as geldanamycin in combination with cisplatin have been shown 
to enhance the cytotoxic effects when compared to using either of these drugs on their 
own. For example Bagatell and colleagues showed that the treatment of neurobalstoma 
and osteosarcoma cell lines with geldanamycin in combination with cisplatin resulted in 
greater than additive inhibition of survival and proliferation (174) 
 
  
HSP90 inhibitors may target the pathways which lead to known cisplatin resistance by 
the subsequent degradation of HSP90 client proteins such as ErbB2, AKT and mutant 
Raf (169, 173). Furthermore PI3K-AKT inhibitors have been shown to enhance the 
effect of cisplatin, in cisplatin resistant lines (180).  
 
HSP72 may also contribute to cisplatin resistance. In one study the use of siRNA against 
HSP72 made lung cancer cells more sensitive to cisplatin (161). Normally under HSP90 
inhibition, HSF induces transcription of genes such as HSP72 and HSP27 (161). 
However studies have shown that when cells were treated with geldanamycin and 
cisplatin there was no further rise in HSP72 levels as compared to controls as shown in 
Figure 7.2.2 (174). In a separate study it was demonstrated how cisplatin abrogated the 
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binding of HSF-1, upon treatment with geldanamycin, to chromatin therefore inhibiting 
the transcriptional activity of HSF-1 and subsequent induction of HSP72(161).  
Previous results in this thesis have established UM-SCC AT13387 IC50 and cisplatin 
IC50 via MTT assay after seven days of drug treatment as seen in Figure 7.4.2. and 
Figure 5.1.2 respectively. A range of values above and below the IC50 of both AT13387 
and cisplatin were combined in order to establish whether there was any synergy, 
additive or antagonistic effect. Cells were treated with each of the two drugs 
individually, in combination, or with carrying vehicle control in quadruplicate sets. 
Fresh media and drugs were replaced daily for a total of seven days. Cell 
viability/growth was assed at the end of day seven via MTT assay. For quantification of 
synergy or antagonism the combination index (CI) was used (156). 
 
From Figure 7.4.7 it can be seen that AT13387 combined with cisplatin produces a 
synergistic inhibitory effect against cell viability/growth in UM-SCC 81B where 
CI=0.875. 
 
 
 
 
 
Appendix 
 
304 
 
  
 
 
Figure 7.4.7 AT13387 in combination with cisplatin produces a synergistic effect in 
UM-SCC 81B cells. 
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 (A) UM-SCC 81B were seeded in 96 well plates and allowed to adhere for 24 hours. 
Cells were then treated at a range concentrations of either cisplatin at 0.6, 1.2, 2, 2.6μM 
alone or AT13387 at 30, 60, 90, 120nM alone, in combination, or with drug vehicle 
control. Both media and drugs were replaced every 24h for a total of seven days. MTT 
assay was used to assess the viability/growth of cells after day seven. The absorbance 
was measured at an OD of 590 nm. Bars represent the percentage MTT score of treated 
groups as a proportion of controls. Error bars show the s.e.m. from four independent 
wells. In the majority of cases there were statistically significant reductions in MTT 
score when MTT scores from cells treated with single agents were compared to MTT 
scores of cells treated with both cisplatin and AT13387 as deduced by unpaired 
Student’s t test (p<0.05). (B and C) IC50 values were calculated from log plots derived 
from data as shown in A for either cisplatin on its own, AT13387 on its own and any 
IC50 values established when cisplatin and AT13387 were used in combination. IC50 
curves were plotted as: percentage MTT score in the drug treated group as a proportion 
of the control group (y-axis) against the dose of the drug on a log scale (x-axis). (D) 
Isobologram showing a line joining the IC50 value of AT13387 at 80nM with the IC50 
value of cisplatin at 1.3μM. An IC50 value can also be seen when AT13387 at 30nM was 
combine with cisplatin at 0.65μM producing a combination index of 0.875. (CI) at IC50= 
(D)1/(Dx)1 + (D)2/(Dx)2. (Dx)1 and (Dx)2 is the dose of each of the drugs which, when used 
alone results in the IC50. (D)1 and (D)2 are the doses of each drug which when in 
combination result in the IC50. 
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Both AT13387 and EGF-SubA target different protein chaperones and therefore it was 
predicted that there might be at least some additive effect if these two drugs were 
combined together. However when EGF-SubA was combined with AT13387 there was 
a clear antagonistic effect as shown in Figure 7.4.8 upon UM-SCC 81B. AT13387 and 
EGF-SubA when used on their own have an IC50 value of 120nM and 20μM 
respectively. When both drugs were used in combination IC50 points were reached at: 
EGF-SubA at 10pM with AT13387 at 80nM producing a CI of 1.17, EGF-SubA at 
10pM with AT13387 at 100nM where CI is 1.33, EGF-SubA at 15pM with AT13387 at 
50nM resulting in a CI of 1.17, and EGF-SubA at 15pM with AT13387 at 100nM 
producing a CI of 1.58. One possible explanation for this antagonism may be due to the 
fact that EGFR is a client protein of HSP90. As shown by Backer and colleagues 2009, 
EGF-SubA is more potent in EGFR expressing cells compared to EGFR null cells (5). 
For example rat glioma EGFR +/+ cells had an IC50 of 20pM whilst rat glioma EGFR -/- 
cells had an EGF-SubA IC50 of 6nM which is a 30 fold increase. When HSP90 inhibitors 
are used such as AT13387 there is degradation and subsequent decrease in EGFR levels 
as shown in Figure 7.4.5, thus possibly reducing the cytoxicity of EGF-SubA. 
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EGF-SubA 10 pM, AT13387 80 nM. CI= (10/20)+(80/120)=   1.17
EGF-SubA 10 pM, AT13387 100 nM. CI= (10/20)+(100/120)=  1.33
EGF-SubA 15 pM, AT13387 50 nM. CI= (15/20)+(50/120)=  1.17
EGF-SubA 15 pM, AT13387 100 nM. CI = (15/20)+(100/120)=  1.58
 
 
 
Figure 7.4.8 AT13387 in combination with EGF-SubA produces an antagonistic 
effect in UM-SCC 81B treated cells.  
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(A) UM-SCC 81B cells were seeded in 96 well plates and allowed to adhere for 24 
hours. Cells were then treated at a range of concentrations of either EGF-SubA at 5, 10, 
15, 22.5pM alone or AT13387 at 30, 60, 90, 120nM alone, in combination, or with drug 
vehicle control. Both media and drugs were replaced every 24h for a total of seven days. 
MTT assay was used to assess the viability/growth of cells after day seven. The 
absorbance was measured at an OD of 590 nm. Bars represent the percentage MTT 
score of treated groups as a proportion of controls. Error bars show the s.e.m. from four 
independent wells. (B and C) New IC50 values were calculated from log plots derived 
from data as shown in Figure A for either EGF-SubA on its own, AT13387 on its own 
and any IC50 values established when EGF-SubA and AT13387 were used in 
combination. IC50 curves were plotted as: percentage MTT score in the drug treated 
group as a proportion of the control group (y-axis) against the dose of the drug on a log 
scale (x-axis). (D) Isobologram showing a line joining the IC50 value of AT13387 at 
120nM with the IC50 value of EGF-SubA at 20pM. When EGF-SubA was combined with 
AT13387 antagonistic effects were observed with combination (CI) indexes of above 1.1. 
(CI) at IC50= (D)1/(Dx)1 + (D)2/(Dx) 2. (Dx)1 and (Dx)2 is the dose of each of the drugs 
which, when used alone results in the IC50. (D)1 and (D)2 are the doses of each drug 
which when in combination result in the IC50. 
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8 Appendix: Trastuzumab in combination with 
cetuximab. 
8.1  Trastuzumab enhances the cytotoxic effects of cetuximab 
in UM-SCC 5, 12 and 81B but not in resistant cell line 
UM-SCC 17AS. 
 
EGFR is a member of the HER family of receptor tyrosine kinases which consists of 
EGFR, HER2, HER3 and HER4. HER family members share several downstream 
signalling cascades such as the MAPK and PI3K/AKT pathways, which can be initiated 
upon homo or hetero-dimerization between HER members (70). For example ligand-
EGFR binding stimulates homo-dimerization or hetero-dimerization with other HER 
family members leading to phosphorylation of tyrosine residues which can then activate 
downstream pathways. Other HER family members such as HER2 can hetero-dimerize 
with HER3 activating the same signalling pathways as EGFR. These signalling cascades 
are responsible for promoting cell proliferation, cell survival, angiogenesis and 
metastasis (181).  
 
A study by Wheeler and colleagues in 2008 cultured UM-SCC 1 cells in cetuximab for a 
total of six months thus obtaining a sub group of UM-SCC 1 cells which were resistant 
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to cetuximab (70). Upon comparison between parental UM-SCC 1 and resistant cells the 
study found that there were increased levels of phospho-EGFR, phospho-HER2 and 
phospho-HER3 in the resistant cells. Higher levels of phosphorylated forms of MAPK 
and AKT were also detected in the cetuximab resistant cells. 
  
It was also demonstrated through co-immunoprecipitation experiments that cetuximab 
resistant cells displayed increased EGFR binding with HER2 and HER3, thus suggesting 
that EGFR in cetuximab resistant cells have enhanced ability to hetero-dimerize with 
and transphosphorylate HER2 and HER3.  
 
To further investigate the role of HER2 and HER3 in cetuximab resistance the study 
used mAb 2C4 which binds and inhibits HER2 dimerization (70). As well as EGFR, 
HER2 can also hetero-dimerize with and promote the activity of HER3 (70). Treatment 
of cetuximab had little effect on HER2, HER3 and AKT activity whereas 2C4 treatment 
decreased the activity of these tyrosine kinases in the resistant cell lines. When 
cetuximab and 2C4 were combined together a potent suppression of phospho-HER3 and 
phospho-AKT was observed suggesting that HER3 activity which is dependent on 
EGFR and HER2 may promote survival in cetuximab resistant cells. Furthermore the 
use of siRNA against HER3 resulted in clones overcoming cetuximab resistance. 
Therefore HER3 through activation via hetero-dimerization with EGFR or HER2 may 
be a critical signal mediator in promoting cetuximab resistance (70). A similar study by 
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Kawaguchi and colleagues in 2007 used trastuzumab, a monoclonal antibody against 
HER2, in combination with cetuximab and found synergistic effects in vitro in 
oesophageal squamous carcinomas (182). Kawaguchi and colleagues used 68nM and 
0.68μM dilutions of trastuzumab in combination with cetuximab at 3.4nM and 34nM 
dilutions (182). 
 
In section 4.7.1 it was seen that cetuximab as a single agent had very little effect on 
inhibiting the viability/growth of UM-SCC cells. However, as discussed above, it is 
indicated by the study of Kawaguchi and colleagues that the resistance to cetuximab 
may be overcome by simultaneously targeting both EGFR and HER2. Therefore, the 
combined effects of cetuximab with trastuzumab on cell viability/growth in laryngeal 
and oral squamous cell carcinoma cell lines: UM-SCC 5, 12, 81B and 1 as well as the 
most resistant cell line which did not show any response to cetuximab alone UM-SCC 
17AS, were investigated. 
 
A preliminary MTT proliferation assay was set up in order to monitor the effects of 
trastuzumab at a high dose of 1μM on the viability/growth of UM-SCC cells. UM-SCC 
cell lines were seeded into 96 well plates and left for 24h. Cells were then treated with 
trastuzumab at 1µM or with drug vehicle control for a total of seven days. Due to a 
shortage of trastuzumab UM-SCC 1 cells were treated with a maximum dilution of 
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100nM trastuzumab for a period of five days. Fresh media and drugs were replaced 
daily. MTT analysis was performed as described in materials and methods section 3.12.  
 
As can be seen in Figure 8.1.1, trastuzumab had little effect on the viability/growth of 
UM-SCC cell lines. In two cases UM-SCC 12 and 81B no decrease in MTT score was 
observed as compared to controls. UM-SCC 11B was the most sensitive cell line with a 
decrease of 38% in MTT score after seven days treatment with trastuzumab.  
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UM-SCC 1 5 10A 11B 12 17A 17AS 81B 
Percentage decrease in MTT score 5% 21% 11% 38% 0% 9% 13% 0% 
 
Figure 8.1.1 1µM trastuzumab has little effect on the viability/growth of UM-SCC 
cells.  
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(A) UM-SCC laryngeal and oral squamous carcinoma cells were seeded in 96 well 
plates and allowed to adhere for 24 hours (shown as day 0). Laryngeal squamous cell 
carcinoma cell lines were treated with either trastuzumab at 1μM or with drug vehicle 
control. Oral squamous cell carcinoma cell line UM-SCC 1 was treated with only 
100nM trastuzumab due to a shortage of drug at the time of conducting the experiments. 
Both media and drugs were replaced every 24h. MTT assay was used to assess the 
quantity/viability of cells. Absorbance was measured at an OD of 590 nm. Error bars 
represent the s.e.m. from four independent wells. (B) Percentage decrease in MTT score 
of treated groups as a proportion of control groups after seven days of 1μM trastuzumab 
treatment for laryngeal squamous cell carcinoma cell lines or after five days of 100nM 
trastuzumab treatment for UM-SCC 1. 
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Next, the inhibitory effects on cell viability/growth of cetuximab in combination with 
trastuzumab were tested. UM-SCC 1, 5, 12, 17AS and 81B were seeded in 96 well plates 
and left to adhere for 24h. After which cells were treated with either trastuzumab at 
1nM, 10nM and 100nM alone; or cetuximab at 1nM, 10nM, 100nM and 1μM alone, or 
in combination, or with drug vehicle control. Fresh drugs and media were replaced daily 
for a total of five days. MTT analysis was performed as described in Methods section 
3.12, on the last day. Unpaired Student’s t test was used to assess if there was any 
significant difference in inhibitory effect between drug combination compared to 
cetuximab and trastuzumab being used as single agents. 
 
The majority of cetuximab and trastuzumab combinations in UM-SCC 1, 5, 12, and 81B 
produced significantly greater reductions (p<0.05) in viability/growth as compared to 
drugs when used as single agents as seen in Figure 8.1.2. Even at the lowest dilutions of 
1nM trastuzumab combined with 1nM cetuximab there were statistically significant 
(p<0.05) decreases in percentage viability/growth as measured by MTT, of 14% in UM-
SCC 1, 19% in UM-SCC 5, and 62% in UM-SCC 81B as compared to when cells were 
treated with single agents. However there was no additional inhibitory effect seen in 
UM-SCC 17AS when cetuximab at different concentrations were used in combination 
with trastuzumab at different concentrations. One exception was when 1nM cetuximab 
was combined with 10nM trastuzumab in UM-SCC 17AS (p<0.01) there appeared a 
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significant inhibitory effect compared to when cetuximab or trastuzumab at these 
concentrations were used as single agents. However this result may be a possible outlier. 
 In agreement with Kawaguchi and colleagues in 2007 which found enhanced effects of 
combining cetuximab with trastuzumab in oesophageal cancer cell lines, results 
presented in this thesis show that these mAbs produce an enhanced cytotoxic effect 
against cell viability/growth, when combined together, in laryngeal and oral squamous 
cell carcinoma cell lines.  
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Figure 8.1.2 Cytotoxic effects of either cetuximab alone or trastuzumab alone 
(herceptin) or in combination on UM-SCC cells. 
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UM-SCC 5 cells were seeded in 96 well plates and allowed to adhere for 24 hours. Cells 
were treated with either trastuzumab at 1nM, 10nM and 100nM alone; or cetuximab at 
1nM, 10nM, 100nM and 1μM alone, or both drugs in combination, or with drug vehicle 
control. Both media and drugs were replaced every 24h for a total of five days. MTT 
assay was used to assess the viability/growth of cells after day five. Absorbance was 
measured at an OD of 590 nm. Bars represent the percentage MTT score of treated 
groups compared to controls. Error bars show the s.e.m. from four independent wells. 
Unpaired Student’s t test was used to calculate statistical significance in drug 
combinations 
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8.2 Investigating trastuzumab and cetuximab as 
radiosensitising agents. 
 
Few studies have commented upon the use of trastuzumab as a radiosensitising agent. 
HER2 inhibition may act as a radiosensitising agent by blocking downstream signalling 
pathway PI3K/AKT which is known to mediate radioresistance in cancers (181). A 
study by Linag and colleagues in 2003, which pre-incubated breast cancer cells for 1 
hour with 20nM trastuzumab found trastuzumab to act as a radiosensitising agent (181). 
Furthermore a study by Uno and colleagues in 2001, found trastuzumab to have 
radiosensitising effects on laryngeal cell line HEp-2. Hep-2 cells were pre-incubated for 
four days with trastuzumab at concentration of 0.64nM, 6.4nM and 64nM. At all 
concentrations a significant radiosensitising effect was found. 
 
Previous results in this thesis (see Figure 8.1.2) have shown that cetuximab in 
combination with trastuzumab was found to have a greater cytotoxic effect than when 
both drugs were used as single agents, in four out of the five cell lines tested. Therefore 
it was investigated whether or not cetuximab in combination with trastuzumab could 
enhance the effects of radiation even further than when trastuzumab and cetuximab were 
used as single agents. 
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Pilot studies were performed in order to establish the highest drug combinatorial 
concentrations that cells could tolerate for 24h without exposure to radiation that would 
provide survival fractions equal to that of drug omitted controls. UM-SCC cells were 
pre-incubated with either 1nM trastuzumab alone, 1nM cetuximab alone, or both drugs 
in combination, or with drug vehicle control for 24h before being irradiated with 0, 1, 2, 
or 4 Gy. Cells were then seeded in triplicate into six well plates, in normal growth media 
without drugs and monitored for colony formation for 2-3 weeks. 
 
Colonies were counted using a light microscope. The mean number of colonies were 
recorded for each set of triplicate samples. Survival fractions were calculated and 
radiation survival curves were fitted according to the linear-quadratic model 
S(D)/S(0)=exp (-(αD + βD2)), where D is the irradiation dose in Gy; α is the cell kill per 
Gy of the initial linear component and β is the cell kill per Gy2 of the quadratic 
component of the survival curve. SPSS PASW statistics package version 18 was used to 
find values of α and β and survival curves were plotted as seen in  
Unpaired Student’s t test was used to evaluate whether there were significant differences 
in SF2 between controls and cells pre-treated with trastuzumab at 1nM, or cetuximab at 
1nM, or drugs combined together. However no radiosensitising effects were observed as 
shown in Figure 8.2.1. These results suggest that cetuximab and trastuzumab, in vitro, 
are not effective radiosensitising agents in laryngeal squamous cell carcinoma cell lines. 
The only exception being when UM-SCC 81B cells were treated with trastuzumab at 
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1nM there was a significant reduction in survival fraction by 28% as compared to 
controls (p=0.019). 
 
 
Figure 8.2.1 No enhancement in radiosensitivity was observed at 1nM cetuximab, 
or 1nM trastuzumab (herceptin), or when both drugs were combined, as compared 
to controls.  
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UM-SCC 5, 12, 17A and 81B cells were pre-treated for 24h with 1nM cetuximab, or 
1nM trastuzumab, or in combination, or with drug vehicle control and then exposed to γ-
irradiation at 0, 1, 2, or 4 Gy as indicated. Clonogenic assays were established to allow 
for colony formation over a time period of two to three weeks. A colony was defined as 
equal to or more than 50 cells in order to allow for at least five cell doubling times. 
Diamonds and triangles indicate mean of three survival fractions for each data point 
with appropriate s.e.m. Cell survival curves were then fitted to the quadratic equation 
S(D)/S(0)= exp (-(αD + βD2)). Unpaired Student’s t test was used to evaluate whether 
there were significant differences in SF2 between controls and treated cells. No 
significant differences in SF2 between treated and untreated cells were observed with 
the exception of UM-SCC 81B when cells were treated with trastuzumab 1nM (D) where 
SF2 decreased by 28% compared to controls (p=0.019).  
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9 Appendix: TNM classification for head and neck 
cancers 
9.1 TNM classification 
 
 
This test box is where the original thesis contained the table showing 
‘TNM staging for head and neck tumours’ which was reproduced 
from reference (22).  
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This test box is where the original thesis contained the table showing ‘TNM 
staging for head and neck tumours’ which was reproduced from reference 
(22).  
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Figure 9.1.1 Staging of head and neck tumours 
Tables reproduced from reference (22) 
 
This test box is where the original thesis contained the table showing ‘TNM 
staging for head and neck tumours’ which was reproduced from reference 
(22).  
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